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Abstract 
This thesis consists ten chapters and presents the findings from four research projects in 
eight areas of interest concerning the epidemiology and non-invasive assessment of non-
alcoholic fatty liver disease (NAFLD). In a cross-sectional study of 399 patients with 
diabetes mellitus in the Diabetic Clinic, University of Malaya Medical Centre, the 
prevalence of NAFLD was 49.6% and was highest among the Malays and the Indians 
compared to the Chinese. Further analysis revealed that low level of physical activity and 
high percentage calorie intake from fat, high cholesterol food and high saturated fatty acid 
food was associated with NAFLD in centrally obese but not in lean patients with diabetes 
mellitus. In addition, NAFLD was not found to be associated with ischemic heart disease 
in patients with diabetes mellitus. In a separate study on 35 NAFLD patients with paired 
liver biopsy over a mean interval of 6.4 years, it was found that patients can undergo 
significant disease progression, and fibrosis is irreversible without specific interventions. 
From the studies on non-invasive assessment of NAFLD, controlled attenuation 
parameter was found to be excellent for the detection of significant hepatic steatosis but 
less useful for distinguishing the different grades of significant hepatic steatosis, while 
plasma M30 was found to be less useful for the diagnosis of non-alcoholic steatohepatitis 
among NAFLD patients. The use of liver stiffness measurement for patients with 
indeterminate and high NAFLD fibrosis scores allowed accurate prediction of advanced 
fibrosis and reduced the number of patients requiring a liver biopsy. In the study on 472 
students at the Faculty of Medicine, University of Malaya, the prevalence of NAFLD was 
8.1% and was again highest among the Indians and the Malays compared to the Chinese. 
This study confirmed that differences in the prevalence of NAFLD among the different 
ethnic groups in Malaysia can be observed as early as young adulthood.   
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Abstrak 
Tesis ini mengandungi sepuluh bab dan memaparkan hasil-hasil kajian daripada empat 
projek penyelidikan dalam lapan aspek penting berkenaan epidemiologi and penilaian 
secara tidak invasif penyakit hati berlemak yang bukan disebabkan alkohol (non-
alcoholic fatty liver disease, NAFLD). Dalam kajian 399 pesakit kencing manis di Pusat 
Perubatan Universiti Malaya, kekerapan penyakit NAFLD adalah 49.6% dan adalah 
paling tinggi di kalangan Melayu dan India berbanding dengan Cina. Analisa juga 
menunjukkan bahawa tahap activiti fizikal yang rendah dengan peratus kalori tinggi 
daripada lemak, makanan tinggi kolesterol dan makanan tinggi asid lemak tepu adalah 
berkaitan dengan penyakit NAFLD di kalangan pesakit kencing manis yang obes tetapi 
bukan di kalangan pesakit kencing manis yang tidak obes. Penyakit NAFLD juga didapati 
tidak berkaitan dengan penyakit jantung di kalangan pesakit kencing manis. Dalam kajian 
berasingan ke atas 35 pesakit NAFLD dengan biopsi hati berkembar pada purata jangka 
masa 6.4 tahun, didapati penyakit hati boleh melarat dan fibrosis hati tidak akan 
bertambah baik tanpa rawatan khusus. Melalui kajian-kajian penilaian secara tidak 
invasif, didapati controlled attenuation parameter sangat baik untuk mengesan lemak 
dalam hati tetapi kurang baik untuk membezakan tahap-tahap hati berlemak, manakala 
M30 plasma tidak begitu berguna untuk diagnosa penyakit hati berlemak dan radang 
bukan disebabkan alkohol (non-alcoholic steatohepatitis) di kalangan pesakit NAFLD. 
Pengukuran ketegangan hati untuk pesakit dengan skor fibrosis NAFLD yang tidak tentu 
dan tinggi membolehkan penentuan tahap fibrosis serius dengan tepat dan mengurangkan 
pesakit yang memerlukan biopsi hati. Dalam kajian 472 pelajar di Fakulti Perubatan, 
Universiti Malaya, kekerapan penyakit NAFLD adalah 8.1% dan juga adalah paling 
tinggi di kalangan India dan Melayu berbanding dengan Cina. Kajian ini mengesahkan 
bahawa perbezaan kekerapan penyakit NAFLD di kalangan kaum berbeza boleh dilihat 
pada tahap awal dewasa lagi.            
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Chapter 1 
Introduction and objectives 
Non-alcoholic fatty liver disease (NAFLD) has rapidly increased over the years 
along with obesity and metabolic syndrome and has become one of the most common 
causes of chronic liver disease worldwide. It is now recognized that the condition is not 
as benign as previously thought. Patients with NAFLD can progress to cirrhosis and liver 
cancer. In addition, metabolic syndrome, which is closely related to NAFLD, predisposes 
patients with NAFLD to cardiovascular diseases. Overall, patients with NAFLD have 
increased mortality and morbidity compared to the general population. Unfortunately, 
patients diagnosed with NAFLD have limited options for treatment. Although lifestyle 
interventions have been shown to be effective, many patients find difficulty in following 
them. Despite much research, safe and effective treatment for NAFLD is still very limited.     
In Malaysia, the prevalence of obesity and metabolic syndrome has increased 
drastically over the years. The prevalence of NAFLD is expected to be high as well. 
However, there are limited studies on NAFLD in our local population. Specifically, the 
prevalence of NAFLD among our patients with diabetes mellitus has never been studied 
before. Some of the objectives of this thesis are, to determine the prevalence of NAFLD 
and associated factors, to study the role of diet and physical activity in NAFLD, and to 
determine if NAFLD is associated with ischemic heart disease, among patients with 
diabetes mellitus. In addition, there has not been any longitudinal study on NAFLD 
patients in the local setting. The prevalence of NAFLD among our younger population is 
also unknown. Other objectives of this thesis are, to elucidate the natural history of 
NAFLD, and to determine the prevalence of NAFLD and associated factors among our 
young adults.  
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Furthermore, at the time that research work for this thesis began, non-invasive methods 
for assessment of NAFLD were gaining popularity. Hence, another objective of this thesis 
is to evaluate some of the non-invasive methods for assessment of NAFLD. These 
objectives were determined to bridge the knowledge gaps in the local setting and to form 
the foundation for future NAFLD research that could enrich the literature in a more global 
context.       
The outline of this thesis is as follows: 
Chapter 2 provides an overview of NAFLD. The content of this chapter includes 
historical aspects of NAFLD and a description of the disease and its pathogenesis. The 
relationship between NAFLD and metabolic syndrome, and how the condition may be 
diagnosed are also described here.      
Chapter 3 reports the review of literature on epidemiology of NAFLD in the 
Asian-Pacific. This review formed the foundation for several of the studies presented in 
the following chapters of this thesis. 
Chapter 4 reports the findings from a cross-sectional study on prevalence of 
NAFLD among patients with diabetes mellitus at the University of Malaya Medical 
Centre, Kuala Lumpur. Independent factors associated with NAFLD were determined 
using multiple logistic regression analysis. The multiethnic composition of the study 
population has allowed analysis of data according to the different ethnic groups which 
has helped shed some light into ethnic differences in NAFLD. 
Diet and physical activity play important roles in NAFLD. In Chapter 5, 
interesting findings from a detailed analysis of dietary intake and level of physical activity 
of diabetic patients with and without NAFLD are presented and discussed.  
NAFLD has been associated with cardiovascular disease. The results of a cross-
sectional study to determine if ultrasonography-diagnosed NAFLD is associated with 
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prevalent ischemic heart disease among patients with diabetes mellitus are presented and 
discussed in Chapter 6.    
In Chapter 7, the findings from a follow-up study on NAFLD patients using paired 
liver biopsy are presented. 
Histopathological examination of a liver biopsy specimen is the current best 
standard for evaluation of NAFLD. However, a liver biopsy is invasive. Chapter 8 focuses 
on non-invasive methods to evaluate each of the histological components of NAFLD. 
Findings from studies on the accuracy of some of these non-invasive methods are 
presented here. 
The prevalence of NAFLD in younger populations will reflect the brunt of the 
disease in the future. Chapter 9 reports the findings of a cross-sectional study on the 
prevalence of NAFLD among young adults pursuing their tertiary education at the Faculty 
of Medicine, University of Malaya, Kuala Lumpur. Independent factors associated with 
NAFLD were determined using multiple logistic regression analysis. The multiethnic 
composition of the study population has also allowed analysis of data according to the 
different ethnic groups.      
In Chapter 10, the thesis is summarized and conclusions are made.        
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Chapter 2  
Overview of non-alcoholic fatty liver disease 
2.1 Historical aspects 
In 1980, Ludwig and colleagues described a series of 20 patients with chronic 
liver disease that had histological findings similar to patients with alcoholic liver disease 
although the patients denied alcohol intake (Ludwig et al., 1980). The term non-alcoholic 
steatohepatitis was coined to refer to this condition, the cause of which was unknown 
then. However, one important observation was that all but one of the patients were 
overweight or obese. Over the next 3 decades, research has led us to a better 
understanding of the condition which is now termed non-alcoholic fatty liver disease 
(NAFLD) and is recognized as the most common cause of chronic liver disease 
worldwide (Younossi et al., 2011).  
2.2 The definition and spectrum of NAFLD 
NAFLD encompasses a spectrum of liver conditions that occur in individuals who 
do not consume alcohol or who consume alcohol but in amounts regarded as insufficient 
to cause liver damage. Histologically, it is indistinguishable from alcoholic fatty liver 
disease. At one end of this spectrum is accumulation of fat in the liver or simple steatosis. 
This is followed by the more severe form of the disease, non-alcoholic steatohepatitis 
(NASH) which is characterized by the presence of inflammation. While simple steatosis 
is generally considered benign, NASH may lead to fibrosis and eventually cirrhosis with 
increased risk of liver-related death and hepatocellular carcinoma (Ekstedt et al., 2006; 
Sanyal et al., 2006) (Figure 2.1). 
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Figure 2.1 The spectrum of NAFLD 
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2.3  Pathogenesis of NAFLD 
Sources of free fatty acids (FFAs) in the liver are serum non-esterified fatty acids 
(NEFAs) from triglyceride breakdown in adipose tissue, de novo lipogenesis (DNL) and diet. 
Besides being esterified to triglycerides and stored in the liver, FFAs may undergo β-
oxidation or be exported as very low density lipoprotein. Any imbalance that results in excess 
FFAs in the liver would lead to accumulation of fat in the liver. 
NAFLD is the result of a two-hit mechanism (Figure 2.2). The first hit is insulin 
resistance. Insulin resistance results in impaired insulin-mediated suppression of triglyceride 
breakdown in adipose tissue. This leads to increased serum NEFAs. Insulin resistance also 
results in impaired insulin-mediated glucose uptake in adipose tissue and skeletal muscle. 
The resultant increase in blood glucose concentration leads to increased glucose uptake in 
the liver, a process which is insulin-independent. This promotes DNL. Therefore patients 
with insulin resistance have excess FFAs in the liver from increased serum NEFAs and DNL 
and are at risk of NAFLD. In patients with NAFLD, serum NEFAs and FFAs from DNL are 
main sources of accumulated fat in the liver (Donnelly et al., 2005). In contrast, DNL 
contributes to less than 5 % of liver fat in healthy individuals (Hudgins et al., 2000; Parks, 
2002).   
The second hit is oxidative stress. Excessive amounts of FFAs in the liver 
overwhelms the β-oxidation process within the mitochondria of liver cells. This leads to 
accumulation of reactive oxygen species that causes mitochondrial damage and activation of 
inflammatory pathways. Liver inflammation and fibrosis ensues. A detailed description of 
the two hits can be found elsewhere (Dowman et al., 2010).  
The discovery of various other factors in the pathogenesis of NASH subsequently led 
to the proposal of a more comprehensive multiple parallel hits hypothesis (Tilg et al., 2010). 
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For example, the gut microbiota is increasingly recognized to play a role in the pathogenesis 
of NAFLD. High fat diet has been shown to induce changes in the gut microbiota leading to 
bacterial overgrowth, disruption of intercellular tight junctions, increased intestinal 
permeability, and increased bacterial DNA and lipopolysaccharide in the portal circulation. 
This leads to activation of toll-like receptors on Kupffer cells and hepatic stellate cells, 
generation of inflammatory cytokines, fat accumulation in liver cells, cell death, and 
fibrogenesis (Wree et al., 2013). Another example is genetic polymorphism in the patatin-
like phospholipase domain containing 3 (PNPLA3) or adiponutrin gene which has been 
associated with increased hepatic fat and inflammation (Romeo et al., 2008). A study on a 
multi-ethnic population found that the PNPLA3 gene polymorphism is associated with 
susceptibility to NASH, NASH severity and presence of fibrosis. Interestingly, the study also 
found that the effect of the gene polymorphism appears to be greater in the Indians followed 
by the Malays and the Chinese (Zain et al., 2012).       
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Figure 2.2 The two-hit mechanism of NAFLD  
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2.4  NAFLD and the metabolic syndrome 
The metabolic syndrome is a constellation of closely related cardiovascular risk 
factors. The International Diabetes Federation defines metabolic syndrome as the presence 
of central obesity based on ethnic specific cut-off for waist circumference, plus two or more 
of the following: raised triglycerides, reduced serum high-density lipoprotein (HDL) 
cholesterol, raised blood pressure and raised fasting plasma glucose (Alberti et al., 2005). 
Insulin resistance is an important feature of metabolic syndrome. As elucidated in the earlier 
section, insulin resistance also serves as the first of the two hits in the pathogenesis of 
NAFLD. Hence, NAFLD is closely related to the metabolic syndrome. In fact, NAFLD has 
been considered as the liver manifestation of the metabolic syndrome (Kim et al., 2008). The 
prevalence of NAFLD is high in those with metabolic syndrome and the presence of 
metabolic syndrome in patients with NAFLD is associated with more severe liver disease 
(Marchesini et al., 2003).    
2.5 Diagnosis of NAFLD 
Most patients with NAFLD are asymptomatic. Some may have non-specific 
symptoms e.g. fatigue. The diagnosis of NAFLD is often suspected from elevated serum 
aminotransferase level in patients with metabolic syndrome. The diagnosis can be confirmed 
with ultrasonography and following exclusion of significant alcohol intake and other causes 
of chronic liver disease e.g. viral hepatitis B and C. NAFLD is also often incidentally 
diagnosed when patients undergo ultrasonography for unrelated indications. Patients with 
cirrhosis due to NAFLD present when they decompensate and in ways similar to patients 
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with decompensated cirrhosis due to other causes of chronic liver disease. Presentations 
include jaundice, ascites, ankle swelling, bleeding from esophageal varices, hepatic 
encephalopathy and hepatocellular carcinoma.  
Elevated serum aminotransferase level is neither sensitive nor specific for diagnosis 
of NAFLD. For example, Mofrad and colleagues showed that the entire spectrum of NAFLD 
can be seen in patients with normal serum alanine aminotransferase (ALT) level (Mofrad et 
al., 2003). At the same time, elevated serum ALT could be the result of many other liver 
conditions other than NAFLD.  
Ultrasonography is by far the most common method used to diagnose fatty liver in 
clinical practice and in epidemiological studies. Fatty liver is recognized on ultrasonography 
based on the following features: increased echogenicity, posterior attenuation and loss of 
intra-hepatic architectural details (Joy et al., 2003) (Figures 2.3a and 2.3b). In a study using 
a scoring system for ultrasonographic findings of NAFLD, Hamaguchi and colleagues 
reported excellent sensitivity (91.7 %) and specificity (100 %) of ultrasonography for 
diagnosis of NAFLD (Hamaguchi et al., 2007). However, a separate study by Saadeh and 
colleagues showed that ultrasonography is accurate only when fatty liver is moderate to 
severe (Saadeh et al., 2002). Moreover, ultrasonography is not able to distinguish NASH 
from simple steatosis and to assess the severity of fibrosis. Both factors carry important 
prognostic implications in NAFLD patients.  
Histopathological examination of a liver biopsy specimen is the current best standard 
for assessment of NAFLD. It confirms the diagnosis and helps exclude other causes of liver 
disease in some cases. It also distinguishes NASH from simple steatosis and allows 
assessment of the severity of fibrosis. The NASH Clinical Research Network (NASH CRN) 
scoring system provides a standardized manner for reporting of histopathological findings of 
NAFLD (Kleiner et al., 2005). The scoring system is elaborated in Chapter 8. Although 
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histopathological examination of a liver biopsy specimen could provide useful information, 
its use is limited as a liver biopsy is invasive and associated with a small risk of 
complications. Moreover, technical expertise is required, from obtaining a good specimen to 
processing and accurately interpreting the result. Histopathological examination of liver 
biopsy specimen may be further limited by sampling variability (Ratziu et al., 2005) and 
intra- and inter-observer variability (Younossi et al., 1998). Hence, there is a need for non-
invasive tests that can be easily performed to estimate histological severity of NAFLD. These 
are discussed in Chapter 8.      
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Figure 2.3a Normal liver on ultrasonography 
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Figure 2.3b Fatty liver on ultrasonography 
Fatty liver is characterized by increased echogenicity, posterior attenuation and loss of 
intra-hepatic architectural details on ultrasonography. 
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Chapter 3 
Review of literature: epidemiology of NAFLD in the Asian-Pacific 
3.1 Introduction 
At the beginning of my work on non-alcoholic fatty liver disease (NAFLD), I 
reviewed the literature to get an overview of the epidemiology of the disease, specifically in 
the Asian-Pacific. The findings are presented in this chapter. The knowledge acquired during 
the process served as the foundation for some of my subsequent work on NAFLD which are 
presented in the following chapters of this thesis.   
3.2 Method 
A search was made on PubMed using the MeSH terms (“Non-Alcoholic Fatty Liver 
Disease” OR “Fatty Liver”) AND (“Epidemiology” OR “Prevalence”) in November 2011. 
The search yielded 495 articles. Out of these, 139 articles were from the Asian-Pacific. The 
abstracts of the articles were examined and where doubt existed as to the relevance of an 
article to the review, the full paper was examined. In total, 63 articles were deemed relevant 
and were included in the review.     
3.3  Results and discussion 
Prevalence of NAFLD in the general population 
Prevalence of ultrasonography-diagnosed NAFLD in the general population in 
different regions across the Asian-Pacific is shown in Figure 3.1 and Table 3.1. Large studies 
from China have estimated the prevalence of NAFLD to be in the range of 11.8 % to 24.4 % 
(Chen et al., 2008; Gao et al., 2008; Hou et al., 2011; Li et al., 2009; Zhou et al., 2007). Only 
15 
 
a study from southwest China demonstrated a remarkably lower prevalence of NAFLD at 6.3 
% for which the author attributed to regional differences in age stratification, economic 
conditions, and dietary habits (Li et al., 2009). As expected, studies on fatty liver disease in 
general without distinction between alcoholic and non-alcoholic reported higher prevalence 
rates of between 17.3 % and 40.0 % (Dai et al., 2009; Fan et al., 2005; Kang et al., 2009).  
Two retrospective studies from China reported increasing prevalence of fatty liver 
disease over time. Fan and colleagues reviewed the medical records of employees of a factory 
in Shanghai and reported that the prevalence of fatty liver disease had increased from 3.9 % 
between 1995 and 1996 to 14.0 % between 2001 and 2002 (Fan et al., 2007). All the 
components of metabolic syndrome recorded significant increase during the same period of 
time while the proportion of subjects with habitual drinking remained unchanged. In a study 
of subjects who went for health check-up, Wang and colleagues found that the prevalence of 
fatty liver disease had almost doubled from 12.5 % in 1995 to 24.5 % between 2003 and 2004 
(Wang et al., 2007). Although these studies did not make a distinction between alcoholic and 
non-alcoholic fatty liver disease, the figures probably reflected an increasing prevalence of 
NAFLD.  
In Japan, recent studies on subjects attending health check-up estimated the 
prevalence of NAFLD to be close to 30 % (Jimba et al., 2005; Oya et al., 2010). This is a 
remarkable increase as similar studies in the late 1980s reported the prevalence of fatty liver 
disease in general to be just around 13 % (Kojima et al., 2003; Saito et al., 1989). In a large 
study of subjects who visited a hospital for health check-up, Kojima and colleagues reported 
a substantial increase in the prevalence of fatty liver disease, from 12.6 % in 1989 to 30.3 % 
in 1998 (Kojima et al., 2003). Among the 35 519 subjects who had examinations during the 
two time points, 14.3 % developed fatty liver while fatty liver resolved in 3.5 %. The 
development of fatty liver was associated with increase in body mass index (BMI) while 
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resolution was associated with a decrease in BMI. In a study of elderly subjects of a health 
check-up program in Nagasaki, the prevalence of NAFLD was estimated to be between 3 % 
and 4 % among non-obese subjects and between 18 % and 22 % among obese subjects 
(Akahoshi et al., 2001).   
In Korea, a population-based study estimated the prevalence of NAFLD to be 16.1 % 
(Park et al., 2006). Two other studies on subjects attending health check-up estimated much 
higher prevalence although one of the studies excluded diabetic patients (Bae et al., 2010) 
while the other excluded obese and diabetic patients (Kim et al., 2004). Studies from Taiwan 
have estimated the prevalence of NAFLD to be around 11.5 % (Chen et al., 2006; Kuo et al., 
2010). One relatively smaller hospital-based study that focused on metabolic syndrome 
recorded an unusually high prevalence of NAFLD at 42.6 % (Tsai et al., 2008). As expected, 
studies that looked at fatty liver disease in general reported higher prevalence of between 
29.5 % and 57.8 % (Hsiao et al., 2007; Lai et al., 2002; Lin et al., 2005; Lu et al., 1990).  
Studies from India reported high prevalence of NAFLD, between 16.6 % and 32.0 % 
(Amarapurkar et al., 2007; Mohan et al., 2009; Singh et al., 2004). One study recorded a 
relatively lower prevalence at 8.7 %, but it is interesting to note that the study was conducted 
in a rural population where the majority of subjects were young, physically active, less 
affluent and non-obese. The prevalence is considerably high given the profile of the study 
population and raised concern that NAFLD will become a significant health burden even in 
less affluent populations. This study also reported that 12 % of subjects with NAFLD had a 
BMI of less than 18.5 kg/m2. The author used the term “third-world non-alcoholic fatty liver” 
to describe this phenotype where instead of overt obesity, subtle measures of increased 
adiposity predisposed to NAFLD (Das et al., 2010).  
There were limited published studies on prevalence of NAFLD in the general 
population from other countries in the Asian-Pacific. Population-based studies from Sri 
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Lanka and Israel estimated NAFLD to be present in approximately 30 % (Dassanayake et al., 
2009; Zelber-Sagi et al., 2006). A study on subjects who received health check-up from 
Thailand reported fatty liver disease in general to be present in 35.9 % (Rungsinaporn  et al., 
2008). A study on a multi-ethnic health check-up population in Malaysia found the 
prevalence of NAFLD to be 22.7 % (Goh et al., 2013). Interestingly, the prevalence of 
NAFLD was remarkably higher among the Indians and Malays compared to the Chinese in 
this study. This corresponded with the risk of diabetes mellitus and cardiovascular diseases 
among the different ethnic groups. The observed racial predilection was attributed to 
differences in genetic and environmental factors, especially the difference in the diet of the 
different ethnic groups.  
Overall, the prevalence of NAFLD in the Asian-Pacific has increased rapidly over 
the years and is now comparable to that in Western countries, which has been estimated to 
be between 20 % and 33 % in large population-based studies (Bedogni et al., 2005; Caballeria 
et al., 2010). If this trend continues, NAFLD will become the most common cause of chronic 
liver disease in the Asian-Pacific, as is already the case in Western countries.   
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Figure 3.1 Prevalence of ultrasonography-diagnosed NAFLD in the general population in different regions across the Asian-Pacific 
All studies were population-based or on subjects attending health check-up, except the studies in Ningbo and Coastal Eastern India. The 
former was on employees of a company while the latter was on healthy individuals accompanying patients to a Gastroenterology Clinic. 
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Table 3.1 Description of the studies on the prevalence of ultrasonography-diagnosed NAFLD in the general population in different regions 
across the Asian-Pacific  
Author, Year Population Studied n Prevalence 
of NAFLD, 
% 
China 
Zhou et al., 2007  
Gao et al., 2008 
Chen et al., 2008 
Li et al., 2009 
Li et al., 2009  
Hou et al., 2011 
 
 
Randomized, multi-stage stratified sampling of subjects over 7 years old in Guangdong  
Randomized, multi-stage stratified sampling of civil servants in Chongqing  
Adults who received health check-up in a hospital in Hangzhou 
Employees of a company in Ningbo 
Adults who received health check-up in a hospital in Chengdu  
Randomized, multi-stage stratified sampling of adults in Shanghai  
 
3543 
2176 
26527 
8925 
9094 
2226 
 
15.0 
20.9 
24.4 
11.8 
6.3 
23.3 
Japan  
Jimba et al., 2005 
Oya et al., 2010  
 
 
Adults who received health check-up in a hospital in Saitama  
Adults who received health check-up in a hospital in Saitama 
 
1950 
796 
 
29.0 
27.9 
Korea  
Kim et al., 2004 
Park et al., 2006  
Bae et al., 2010  
 
 
Non-obese non-diabetic adults who received health check-up in Seoul  
Adults who received health check-up in a hospital in Seoul  
Non-diabetic adults who received health check-up in a hospital in Seoul  
 
768 
6648 
99969 
 
23.4 
16.1 
28.1 
Taiwan  
Chen et al., 2006  
Tsai et al., 2008  
Kuo et al., 2010 
 
 
Randomized sampling of adults in a rural area in central Taiwan  
Adults who received health check-up in a hospital in Taichung  
Adults who received health check-up in a hospital in Taoyuan 
 
3245 
876 
54325 
 
11.5 
42.6 
11.3 
India  
Amarapurkar et al., 2007 
  
 
Residents of two railway colonies in Mumbai  
 
 
541 
 
 
16.6 
 
20 
 
Mohan et al., 2009 
Singh et al., 2004  
Das et al., 2010 
 
Subsample of the Chennai Urban Rural Epidemiology Study  
Healthy individuals accompanying patients to a Gastroenterology Clinic in East India 
Adults in a rural administrative unit in West Bengal 
159 
1168 
1911 
32.0 
24.5 
8.7 
Other Countries  
Goh et al., 2013  
 
Dassanayake et al., 2009  
Zelber-Sagi et al., 2006 
 
 
Multi-racial suburban population who received health check-up in a medical centre in 
Petaling Jaya, Malaysia  
Randomized stratified sampling of an urban Sri Lankan population  
Subsample of national health survey in Israel 
 
1621 
 
2985 
326 
 
22.7 
 
32.6 
30.0 
 
n = number of subjects  
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Prevalence of NAFLD in children and adolescents 
The prevalence of NAFLD among children has been reported to be between 2.1 % 
and 4.5 % (Tominaga et al., 1995; Tsuruta et al., 2010; Wan et al., 2007). In one of the largest 
study on children from two elementary schools in Shanghai, the overall prevalence of 
NAFLD was estimated to be 2.1 % and was closely associated with body mass index (BMI). 
Prevalence of NAFLD increased from normal to overweight to obese children at 0.6 %, 2.9 
%, and 13.8 %, respectively (Wan et al., 2007). In a study from Japan, Tsuruta and colleagues 
found reduced daily physical activity to be associated with NAFLD in children, independent 
of obesity (Tsuruta et al., 2010). In studies that included adolescents, higher prevalence of 
NAFLD was observed ranging from 7.1 % to 16.9 % (Adibi et al., 2009; Alavian et al., 2009). 
In a large study of randomly selected children and adolescents from schools in Isfahan, the 
overall prevalence of NAFLD was 16.9 % and increased from normal to overweight to obese 
subjects at 1 %, 10.5 % and 54.4 %, respectively (Adibi et al., 2009). In hospital-based 
studies, the prevalence of NAFLD among overweight or obese children is much higher, 
ranging from 60.3 % to 80.5 % (Fu et al., 2006; Sagi et al., 2007; Shi et al., 2009). As in 
adults, NAFLD was found to be closely associated with insulin resistance and features of 
metabolic syndrome (Shi et al., 2009). Worryingly, fibrosis is common in children with 
NASH, and cirrhosis due to NASH have been reported in children as young as 10 years old 
(Molleston et l., 2002). 
NAFLD – effect of gender  
In younger populations, NAFLD has been consistently shown to be more prevalent 
among men than women (Amarapurkar et al., 2007; Chen et al., 2006; Fan et al., 2007; Singh 
et al., 2004; Zelber-Sagi et al., 2006), but such trend was no longer observed in older 
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populations (Fang et al., 2005; Kang et al., 2009; Zhou et al., 2007), suggesting the potential 
influence of sex hormones in the development of the disease. For example, in a study of non-
diabetic subjects, no significant difference in prevalence of NAFLD was observed in men 
below and above 50 years old. However, the risk for NAFLD was 3.5 times higher in women 
above 50 years old (Bae et al., 2010). NAFLD may also have different impact depending on 
the gender. For example, in an Australian population-based cross-sectional study of 1170 
adolescents, male with NAFLD had greater visceral adipose tissue thickness and lower 
adiponectin levels, and significantly worse metabolic features (higher glucose levels, higher 
systolic blood pressure, lower high-density lipoprotein cholesterol levels) compared to their 
female counterparts (Ayonrinde et al., 2011). 
NAFLD and serum ALT levels 
NAFLD is one of the most common causes of elevated serum alanine 
aminotransferase (ALT) levels. A cross-sectional study in a rural village of Taiwan identified 
NAFLD as the single most common cause of elevated serum ALT levels (Chen et al., 2007). 
NAFLD was also found to be the most common cause of persistently elevated serum ALT 
levels among the general population in Iran (Jamali et al., 2008). However, not all patients 
with NAFLD have raised serum ALT levels. In fact, patients across the spectrum of NAFLD 
may have normal serum ALT levels. Therefore, the use of serum ALT level as a surrogate 
marker for NAFLD underestimates the prevalence of NAFLD (Zelber-Sagi et al., 2006). In 
patients with NAFLD, serum ALT levels were found to be significantly higher in those with 
metabolic syndrome and the mean serum ALT levels increased significantly with increasing 
number of components of metabolic syndrome (Chen et al., 2008). In another study, raised 
serum ALT levels in non-NAFLD patients were associated with hypertriglyceridemia while 
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in NAFLD patients were associated with both hypertriglyceridemia and hyperglycemia (Hou 
et al., 2011).      
NAFLD and metabolic syndrome – new insight 
NAFLD has been considered the liver manifestation of metabolic syndrome and is 
closely related to other features of metabolic syndrome. Recent studies have shown that 
presence of NAFLD itself increases the risk of developing diabetes mellitus independent of 
other features of metabolic syndrome. In a retrospective longitudinal study, Yamada and 
colleagues found that significantly more subjects had newly diagnosed impaired fasting 
glucose and diabetes mellitus over a 5-year period if they had fatty liver, and fatty liver 
remained an independent factor after adjusting for other risk factors (Yamada et al., 2010). 
In an observational cohort study of Japanese male workers over 40 years old, NAFLD was 
found to be associated with significant increase in the risk of developing diabetes mellitus 
(Shibata et al., 2007). In an interesting study from Korea, NAFLD was found to be closely 
associated with metabolic syndrome even in non-obese, non-diabetic subjects, and can be 
considered an early predictor of metabolic disorders, particularly in the normal-weight 
population (Kim et al., 2004). Findings in these studies suggest that NAFLD may be a 
mediator of metabolic syndrome rather than just a manifestation of it. 
NAFLD may contribute to insulin resistance and thus metabolic syndrome the way 
visceral adiposity does. In a large cross-sectional study of non-diabetic subjects, Bae and 
colleagues found that presence of NAFLD was associated with higher levels of insulin 
resistance independent of other features of metabolic syndrome including obesity, a well-
known determinant of insulin resistance. Furthermore, even subjects in the lowest quartile of 
HbA1c in the group with NAFLD had significantly higher insulin resistance compared to 
subjects in the highest quartile of HbA1c in the group without NAFLD. Another interesting 
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finding was insulin resistance increased with increasing HbA1c levels in the group with 
NAFLD but not in the group without NAFLD suggesting that HbA1c levels have different 
meaning on insulin resistance by NAFLD status in non-diabetic subjects (Bae et al., 2010).  
In a study of healthy subjects in a health check-up program, the prevalence of NAFLD 
increased with increasing fasting plasma glucose level: 27% in the subgroup with normal 
fasting plasma glucose, 43% in the subgroup with impaired fasting glucose and 62% in the 
subgroup with newly diagnosed diabetes mellitus (Jimba et al., 2005). In a population-based 
study, Mohan and colleagues demonstrated increasing prevalence of NAFLD with increasing 
severity of glucose intolerance. NAFLD was diagnosed in 22.5% of subjects with normal 
glucose tolerance, 33% of subjects with either impaired fasting glucose or impaired glucose 
tolerance, and 54.5% of subjects with frank diabetes mellitus (Mohan et al., 2009). The 
reported prevalence of NAFLD among patients with diabetes mellitus is consistent with that 
of another Indian study which estimated the figure to be 57.2% (Agarwal et al., 2011). 
Another study on NAFLD in patients with diabetes mellitus from China estimated the 
prevalence to be 42.1% (J. Zhou et al., 2007).  
An interesting study from Hong Kong demonstrated high prevalence of undiagnosed 
diabetes mellitus and impaired glucose tolerance among patients with NAFLD. This study 
also showed that nearly half the patients with diabetes mellitus or impaired glucose tolerance 
had normal fasting glucose and highlighted the importance of oral glucose tolerance test 
among NAFLD patients with normal fasting glucose (Wong et al., 2006). The reason some 
diabetic patients have NAFLD but others do not, and the reason some NAFLD patients have 
diabetes mellitus but others do not remains unclear.  
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NAFLD – the liver and beyond 
NAFLD can progress to liver cirrhosis and patients with liver cirrhosis due to NAFLD 
are at increased risk of hepatocellular carcinoma. Besides liver-related complications, 
NAFLD has been associated with several other extra-hepatic conditions, the most important 
being cardiovascular complications. Progression to significant liver disease occurs over a 
long period of time, and cardiovascular complications may overshadow liver-related 
complications in causing morbidity and mortality in patients with NAFLD.      
In a cross-sectional study of 124 patients with type 2 diabetes mellitus, NAFLD was 
identified as an independent predictor of coronary artery disease along with hypertension, 
elevated LDL cholesterol and microalbuminuria (Agarwal et al., 2011). In other studies, 
NAFLD was independently associated with ischemic changes on electrocardiography (Lin et 
al., 2005), significant coronary artery stenosis on computed tomography coronary 
angiography (Assy et al., 2010), impaired left ventricular systolic and diastolic function 
(Fotbolcu et al., 2010), and increased carotid artery intima-media thickness (Aygun et al., 
2008).   
NAFLD has also been associated with hyperuricemia and gout. In a large cross-
sectional study of employees of a company in China, Li and colleagues found that the 
prevalence of NAFLD was significantly higher among patients with hyperuricemia, and that 
the prevalence increased with increasing level of serum uric acid level, independent of other 
features of metabolic syndrome (Li et al., 2009). In a large study of subjects attending health 
check-up in Taiwan, Kuo and colleagues found that the prevalence of NAFLD was 
significantly higher among patients with gout, independent of other features of metabolic 
syndrome, and also reported a dose-response relationship between serum uric acid level and 
the presence of NAFLD (Kuo et al., 2010). Other studies found an association between 
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NAFLD and chronic kidney disease (Yasui et al., 2011), gallstone disease (Chen et al., 2006), 
colorectal adenomatous polyps (Hwang et al., 2010), and polycystic ovarian syndrome 
(Brzozowska et al., 2009). 
NAFLD and viral hepatitis 
Asia-Pacific carries the major burden of viral hepatitis B and C in the world. NAFLD 
can affect the progression of other chronic liver diseases and its increasing prevalence may 
impact on the many patients with chronic liver disease due to viral hepatitis B and C in this 
region. Several studies from the Asia-Pacific have looked into the association of NAFLD and 
viral hepatitis B and C with interesting findings.  
In a study of liver biopsies of 1915 patients with chronic hepatitis B, it was found that 
presence of NAFLD was independently associated with metabolic features, namely body 
mass index, serum triglyceride, serum uric acid and fasting blood glucose. There was no 
significant difference in HBeAg status and viral load between patients with and without 
NAFLD. Fibrosis was associated with increasing age and inflammatory grade, the latter 
associated with viral load (Shi et al., 2008). In another study of liver biopsies of 86 young 
male patients with chronic hepatitis B, NAFLD was again independently associated with 
metabolic features, namely insulin resistance and serum triglyceride, but not with significant 
fibrosis. Significant fibrosis was associated with necro-inflammatory activity and elevated 
serum gamma-glutamyl transpeptidase (Yun et al., 2009).  
Hepatic steatosis is seen in a significant proportion of patients with chronic hepatitis 
C and substantial evidences support viral hepatitis C, especially genotype 3 as a cause of 
hepatic steatosis. Term such as “metabolic steatosis” and “viral steatosis” have been used to 
distinguish the cause of hepatic steatosis in patients with viral hepatitis C, the former referring 
to patients with features of metabolic syndrome when the hepatic steatosis is attributed to 
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NAFLD. However, it may be difficult to separate the two causes which may together 
contribute to hepatic steatosis in the same patient.  
In a study of 106 non-diabetic and non-alcoholic patients with chronic hepatitis C, 
Hwang et al found over half the patients to have hepatic steatosis, and the presence of hepatic 
steatosis was associated with obesity, but not HCV RNA levels and HCV genotypes. 
Majority were genotype 1 or 2.  Hepatic steatosis was also related to more severe hepatic 
fibrosis (Hwang et al., 2001). One study with genotype 1 or 2 patients (Liu et al., 2005) and 
another study (Ahmed et al., 2011) also reported association of hepatic steatosis with features 
of metabolic syndrome and more severe hepatic fibrosis. The former also reported a trend 
towards lower response to antiviral therapy in the presence of hepatic steatosis although this 
was not statistically significant. In another study with large proportion of genotype 3 patients, 
although metabolic features such as BMI and serum levels of cholesterol, triglyceride and 
glucose were found to be associated with hepatic steatosis, these were not significant on 
multivariate analysis. On multivariate analysis, only genotype 3 and viral load were 
significantly associated with hepatic steatosis. The presence of hepatic steatosis was again 
associated with significantly higher stage of fibrosis (Minakari et al., 2008).  
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3.4 Conclusion 
The prevalence of NAFLD has been rapidly increasing in the Asia-Pacific. Its 
prevalence increases with increasing age and is more common in men than women although 
this trend fades with increasing age. Patients newly diagnosed with NAFLD should undergo 
a thorough metabolic evaluation and the presence of any features of metabolic syndrome 
should be addressed accordingly. Patients with NAFLD should be advised for intensified 
lifestyle modification effort even if non-obese and non-diabetic. Besides liver complications, 
NAFLD is associated with a wide range of diseases. In patients with chronic hepatitis B, 
NAFLD seems to be related to host metabolic factors rather than viral factors and does not 
seem to affect severity of the liver disease. On the other hand, hepatic steatosis may be related 
to both host metabolic and viral factors in patients with chronic hepatitis C and seems to have 
adverse impacts in terms of severity of liver disease and possibly response to antiviral 
therapy.  
 
 
 
 
 
 
 
 
 
Note: The full article of this literature review has been published in Hepatology International 
(Chan et al., 2013) 
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Chapter 4 
NAFLD in diabetics – prevalence and associated factors in a multi-racial 
hospital clinic population in Malaysia 
4.1 Introduction 
 As elucidated in the earlier chapter, non-alcoholic fatty liver disease (NAFLD) has 
been rapidly increasing in the Asian-Pacific and is estimated to affect up to 30 % of the 
general population (Chan et al., 2013). In the only published study on prevalence of NAFLD 
in the general population in Malaysia, Goh and colleagues reported a prevalence of 22.7 % 
among individuals attending a health-check in a suburban medical facility (Goh et al., 2013). 
The study reported an inordinately high prevalence of NAFLD among the Malays and Indians 
compared to the Chinese.  
NAFLD is closely associated with diabetes mellitus and obesity. The prevalence of 
NAFLD is higher in patients with diabetes mellitus and has been estimated to be between 55 
% and 70 % in previous studies from other parts of the world (Leite et al., 2009; Merat et al., 
2009; Targher et al., 2006). The prevalence of NAFLD is even higher among the morbidly 
obese and has been reported to be over 90 % (Machado et al., 2006). In Malaysia, the 
prevalence of diabetes mellitus and obesity has reached epidemic proportions over the years. 
The Third National Health and Morbidity Survey (NHMS III) estimated the prevalence of 
diabetes mellitus among adults aged 30 years old and above to have almost doubled from 8.3 
% in 1996 to 14.9 % in 2006 (Institute for Public Health, 2008). Yet to be published, the 
Fourth National Health and Morbidity Survey found that this figure has increased to 20 % in 
2011. The NHMS III also reported that 43.1 % of adults were overweight or obese in 2006, 
almost double that reported ten years earlier. Moreover, the reports followed the World 
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Health Organization criteria, which have higher body mass index (BMI) cut-offs for 
definition of overweight and obese compared to the Western Pacific Regional Office criteria 
for Asians leading to an underestimation of the true weight of the problem (Anuurad et al., 
2003).  
This study was carried out to determine the local prevalence of NAFLD and 
associated factors among patients with diabetes mellitus. There were no published study on 
this in Malaysia. We also aimed to compare the prevalence of NAFLD among diabetics from 
the three major ethnic groups in Malaysia, namely the Malays, Chinese and Indians. There 
were no published study comparing the prevalence of NAFLD among diabetic patients of 
different ethnicity in the Asian-Pacific.  
4.2  Patients and methods 
The study was a cross-sectional study on consecutive patients seen at the diabetic 
clinic of University of Malaya Medical Centre between November 2011 and April 2012. 
Patients who have been included but returned for follow-up during the study period were 
identified and not included a second time. Patients with known chronic liver disease other 
than fatty liver and patients who did not agree to participate were excluded. The study was 
approved by the University of Malaya Medical Centre’s Medical Ethics Committee and 
informed consent was obtained from all included patients.  
Demographic and anthropometric data and relevant clinical and laboratory data were 
obtained using a standard protocol. Alcohol intake was estimated using the quantity-
frequency method (Goddard, 2007). Alcohol intake was estimated based on patient’s self-
reported frequency and quantity of intake of each of the 3 main types of alcoholic beverages 
i.e. beer, wine and spirit. Frequency of intake was divided into 7 categories i.e. almost every 
day, 5 or 6 days a week, 3 or 4 days a week, once or twice a week, once or twice a month, 
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once every couple of months and once or twice a year. Each of these categories provided a 
multiplying factor for calculation of alcohol intake per week. Information on average intake 
during each drinking session was captured using common serving measurements and this 
was translated into units of alcohol based on the volume consumed and the alcohol by volume 
for each of the types of alcoholic beverages. Units of alcohol consumed in a week in the form 
of beer, wine and spirit was calculated separately and summed up to give an estimate of 
alcohol intake per week for each patient. Significant alcohol intake was defined as more than 
21 units per week for men and more than 14 units per week for women (Chalasani et al., 
2012).    
The Global Physical Activity Questionnaire (GPAQ) was used to measure physical 
activity (World Health Organization, 2005). The GPAQ categorizes level of physical activity 
into low, moderate and high according to reported frequency and duration of physical activity 
in three domains: work, travel and leisure. A semi-quantitative food-frequency questionnaire 
(FFQ) comprising 200 common Malaysian food items was used to assess dietary intake 
(Mohd Razif Shahril et al., 2008). This FFQ had similar estimates of dietary intakes when 
compared to three days 24-hour dietary recall and is an adequate tool for estimation of dietary 
intakes for epidemiological studies in Malaysia. A copy of the GPAQ and FFQ is enclosed 
in the Appendix. The dietary composition of each food items was based on a standard 
reference (Tee et al., 1997). Daily calorie intake, intake of carbohydrate, protein and fat, and 
percentage calorie intake from carbohydrate, protein and fat were estimated. Some patients 
who participated in the study did not wish to complete the FFQ as the process required 
substantial time.     
Weight and height were measured using standardized equipment. Body mass index 
(BMI) was calculated by dividing weight in kilogram by the square of height in meters. 
Patients were categorized as underweight (BMI < 18.5 kg per m2), normal (18.5 kg per m2 ≤ 
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BMI < 23.0 kg per m2), overweight (23.0 kg per m2 ≤ BMI < 25.0 kg per m2) or obese (BMI 
≥ 25.0 kg per m2) (Anuurad et al., 2003). Waist circumference (WC) was measured at the 
mid-point between the lowest margin of the least palpable rib and the top of the iliac crest in 
the standing position. Central obesity was defined as WC > 90 cm for men and > 80 cm for 
women (Alberti et al., 2005). Blood pressure was measured in the sitting position using 
standardized equipment.  A patient was considered hypertensive if there was a self-reported 
history of hypertension, if the patient was on anti-hypertensive medication(s), if the systolic 
blood pressure (SBP) was ≥ 130 mmHg, or if the diastolic blood pressure (DBP) was ≥ 85 
mmHg.  
All patients had venous blood drawn after an overnight fast for blood sugar, glycated 
hemoglobin (HbA1c), lipid profile and liver function test as routine before their appointment 
at the Diabetic Clinic. Biochemical measurements were performed using standard laboratory 
procedures.  HbA1c ≥ 7.0 % was considered to be reflective of overall suboptimal blood 
sugar control. A patient was considered to have dyslipidemia if there was a self-reported 
history of dyslipidemia, if the patient was on lipid-lowering medication(s), if the serum total 
cholesterol (TC) was ≥ 5.2 mmol/L, if the serum triglyceride (TG) was ≥ 1.7 mmol/L, if the 
serum high-density lipoprotein (HDL) was < 1.0 mmol/L for men or < 1.3 mmol/L for 
women, or if the serum low-density lipoprotein (LDL) was ≥ 3.4 mmol/L. A patient was 
considered to have metabolic syndrome if two or more of the following were present: central 
obesity, hypertension, hypertriglyceridemia and low serum HDL (according to the 
aforementioned cut-offs) (Alberti et al., 2009). Our laboratory’s upper limit of normal for 
liver enzymes were as follow: alkaline phosphatase (ALP) 136 IU/L, aspartate 
aminotransferase (AST) 37 IU/L, alanine aminotransferase (ALT) 65 IU/L and gamma-
glutamyl transpeptidase (GGT) 55 IU/L.  Serum ALP, AST, ALT and GGT above these 
levels were considered as elevated. In addition, a more stringent cut-off of 30 IU/L for men 
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and 19 IU/L for women was used for serum ALT level during data analysis. Additional 
venous blood was drawn on the day of study for viral hepatitis B and C serology. The Elecsys 
HBsAg II assay and the Elecsys Anti-HCV II assay (Roche, Mannheim, Germany) were used 
to test for viral hepatitis B and C infection, respectively. 
Diagnosis of NAFLD was by trans-abdominal ultrasonography and following 
exclusion of significant alcohol intake, use of medications known to cause fatty liver and 
other causes of chronic liver disease. The following criteria were used for ultrasonographic 
diagnosis of fatty liver: increased echogenicity, posterior attenuation and loss of intra-hepatic 
architectural details (Joy et al., 2003). Investigators involved in other parts of the study were 
blinded to the ultrasonography findings, vice versa.     
Statistical analysis 
  With an estimated prevalence of 65 % based on the average of previous studies (Leite 
et al., 2009; Merat et al., 2009; Targher et al., 2006), a sample size of 350 patients was needed 
to estimate the prevalence with 95 % confidence and 5 % precision. Data were analyzed using 
SPSS 15.0. Continuous variables were expressed as mean ± standard deviation or median 
(inter-quartile range), and analyzed using student’s t-test or Mann-Whitney U test where 
appropriate. Categorical variables were expressed as percentage and analyzed using chi-
square test or Fisher’s exact test where appropriate. Independent factors associated with 
NAFLD were identified using multiple logistic regression analysis. Significance was 
assumed at p < 0.05. 
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4.3  Results   
Patient characteristics 
Three hundred and ninety nine patients were included in the analysis (Figure 4.1). 
The mean age of the study population was 62.3 ± 10.5 years old comprising of 43.1 % men. 
The racial distribution was as follows: Chinese 43.6 %, Indian 33.1 %, Malay 22.3 %, others 
1.0 %. Most patients (82.7 %) had at least lower secondary education with a median income 
of RM 1050 (RM 667 – RM 2000) per household person per month. Mean duration since 
diagnosis of diabetes mellitus was 16.1 ± 9.7 years. Most patients had co-existing 
hypertension (91.2 %) and dyslipidemia (97.2 %) while around two thirds (66.4 %) were 
obese. Central obesity was seen in 73.2 % of the study population and was more prevalent 
among women than men (79.3 % vs. 65.1 %, p = 0.002). Most patients (95.2 %) had the 
metabolic syndrome. 
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Figure 4.1 Flow chart illustrating the details of patients included/excluded in the analysis 
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Prevalence of NAFLD and associated factors 
The prevalence of NAFLD was 49.6% (198/399). Characteristics of patients with and 
without NAFLD are summarized in Table 4.1. Patients with NAFLD were “younger” with 
higher BMI and WC, higher DBP, and higher serum TG, HbA1c, AST, ALT and GGT levels 
compared to patients without NAFLD. The proportion of patients with NAFLD declined with 
increasing age (Figure 4.2). Overall, there was no significant difference in the prevalence of 
NAFLD between genders. However, there was a trend towards lower prevalence of NAFLD 
in women compared to men below the age of 50 years old (Figure 4.3). This was despite a 
significantly higher prevalence of central obesity among women compared to men in this age 
group (92.9 % vs. 42.9 %, p < 0.001).  
Patients with low level of physical activity were more likely to have NAFLD 
compared to patients with moderate level of physical activity (OR = 1.67, 95 % CI = 1.06 – 
2.63, p = 0.020). Daily calorie intake and intake of carbohydrate, protein and fat were not 
significantly different between patients with and without NAFLD. NAFLD was not 
associated with duration of diabetes mellitus but was associated with suboptimal control of 
blood sugar level as reflected by HbA1c level ≥ 7.0 %.   
Patients with NAFLD had a significantly higher mean serum ALT level (37 ± 18 vs. 
28 ± 11, p < 0.001). However, only 3.8 % of the study population had elevated serum ALT 
level using the 65 IU/L cut-off. When the more stringent cut-off of 30 IU/L for men and 19 
IU/L for women was used, 71.5 % of the study population had elevated serum ALT level. 
Patients with elevated serum ALT level using this more stringent cut-off were more likely to 
have NAFLD (OR = 2.34, 95 % CI = 1.45 – 3.79, p < 0.001). However, the sensitivity and 
specificity of serum ALT level using this more stringent cut-off for the prediction of NAFLD 
was only 80.0 % and 36.9 %, respectively.     
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Univariate and multivariate analyses of factors associated with NAFLD 
On univariate analysis, factors that were significantly associated with NAFLD were 
as follows: age < 65 years old, race, obesity, central obesity, HbA1c ≥ 7.0 %, elevated ALT 
using the more stringent cut-off and elevated GGT. These factors were included in multiple 
logistic regression analysis. As central obesity is closely related to obesity, a second model 
of multiple logistic regression analysis was performed without the inclusion of obesity. 
Independent factors associated with NAFLD were central obesity and elevated ALT in both 
models. As expected, the effect of central obesity was attenuated in the model that included 
obesity (Table 4.2).  
Prevalence of NAFLD according to the different ethnic groups and its 
association with obesity, central obesity, physical activity and dietary 
intake 
The prevalence of NAFLD was highest among the Malays followed by the Indians 
and lowest among the Chinese. This paralleled the prevalence of obesity and central obesity 
in the different ethnic groups. There was no significant difference in daily calorie intake and 
level of physical activity between the different ethnic groups. However, some differences 
were seen in the calorie source between the different ethnic groups. The Chinese had 
significantly higher protein intake compared to the Malays and Indians. Percentage calorie 
intake from fat was highest among the Malays followed by the Indians and lowest among the 
Chinese (Table 4.3). 
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Table 4.1 Characteristics of patients with and without NAFLD 
 NAFLD p 
Yes 
n =198 
No 
n = 201 
Age, years 60.7 ± 11.2 64.8 ± 9.3 < 0.001 
Age < 65 years old 63.1 % 49.8 % 0.007 
Male 44.9 % 41.3 % 0.461 
Race 
Malay 
Chinese 
Indian 
Others 
 
27.3 % 
36.9 % 
34.3 % 
1.5 % 
 
17.4 % 
50.3 % 
31.8 % 
0.5 % 
 
0.022 
Education level 
None 
Primary 
Secondary 
Tertiary 
 
5.6 % 
8.6 % 
54.5 % 
31.3 % 
 
10.4 % 
10.0 % 
52.7 % 
26.9 % 
 
0.271 
Income per household person per month, RM 1000 (667 – 2000) 1067 (645 – 2000) 0.984 
Smoking 5.6 % 2.0 % 0.073 
Duration of diabetes mellitus, years 15.5 ± 9.4 16.9 ± 9.9 0.146 
Hypertension 89.9 % 92.5 % 0.352 
Dyslipidemia 97.0 % 97.5 % 0.741 
Body mass index, kg per m2 29.7 ± 7.9 26.3 ± 5.5 < 0.001 
Obesity 75.8 % 57.2 % < 0.001 
Waist circumference, cm 96.0 ± 11.7 89.1 ± 12.6 < 0.001 
Central obesity 82.8 % 63.7 % < 0.001 
Systolic blood pressure (SBP), mmHg 135 ± 19 134 ± 21 0.529 
SBP ≥ 130 mmHg 67.2 % 62.7 % 0.348 
Diastolic blood pressure (DBP), mmHg 75 ± 10 73 ± 11 0.019 
DBP ≥ 85 mmHg 14.1 % 14.4 % 0.935 
39 
 
 NAFLD p 
Yes 
n =198 
No 
n = 201 
Metformin 81.8 % 77.1 % 0.245 
Sulphonylurea 43.9 % 39.8 % 0.402 
Insulin 46.5 % 44.3 % 0.661 
Statin 85.4 % 85.1 % 0.937 
Fibrate 13.1 % 17.4 % 0.235 
Fasting blood sugar, mmol/L 8.2 ± 3.0 8.0 ± 3.5  0.530 
HbA1c, % 8.31 ± 1.74 7.83 ± 1.79 0.007 
HbA1c ≥ 7.0 % 83.0 % 69.0 % 0.001 
Total cholesterol (TC), mmol/L 4.25 ± 1.06 4.25 ± 0.94 0.972 
TC ≥ 5.2 mmol/L 14.4 % 17.1 % 0.471 
High-density lipoprotein (HDL), mmol/L 1.20 ± 0.37 1.28 ± 0.41 0.428 
HDL < 1.0 for men and < 1.29 for women  44.3 % 38.7 % 0.257 
Low-density lipoprotein (LDL), mmol/L 2.12 (1.74 – 2.60) 2.15 (1.77 – 2.76) 0.506 
LDL ≥ 3.4 mmol/L 10.4 % 7.6 % 0.326 
Triglyceride (TG), mmol/L 1.50 (1.20 – 2.13) 1.30 (1.00 – 1.80) 0.001 
TG ≥ 1.7 mmol/L 37.6 % 33.7 % 0.412 
Alkaline phosphatase (ALP), IU/L 68 ± 26 65 ± 22 0.154 
ALP ≥ 136 IU/L 2.1 % 0.5 % 0.372 
Aspartate aminotransferase (AST), IU/L 23 ± 12 19 ± 9 0.002 
AST ≥ 37 IU/L 7.7 % 5.2 % 0.307 
Alanine aminotransferase (ALT), IU/L 37 ± 18 28 (11) < 0.001 
Elevated ALT ≥ 65 IU/L 5.1 % 2.6 % 0.188 
Elevated ALT ≥ 30 IU/L for men and ≥ 19 IU/L for women 80.0 % 63.1 % < 0.001 
Gamma glutamyl transpeptidase (GGT), IU/L 36 (25 – 57) 25 (17 – 43) < 0.001 
GGT ≥ 55 IU/L 27.3 % 14.4 % 0.002 
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Figure 4.2 Prevalence of NAFLD according to age group 
There was a significant decrease in the proportion of patients with NAFLD with increasing 
age group (p = 0.031). 
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Figure 4.3 Prevalence of NAFLD according to age and gender 
There was a trend towards lower prevalence of NAFLD in women compared to men among 
patients below the age of 50 years old but no such difference was observed among patients 
50 years old and above.
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Table 4.2 Univariate and multivariate analyses of factors associated with NAFLD 
 Univariate analysis Multivariate analysis 
Model 1 
Multivariate analysis 
Model 2 
OR 95 % CI p OR 95 % CI p OR 95 % CI p 
Age < 65 years 1.73 1.14 – 2.63 0.007 1.48 0.95 – 2.29 0.084 1.52 0.98 – 2.35 0.061 
Race 
Chinese 
Indian 
Malay 
 
1 
1.47 
2.13 
 
– 
0.91 – 2.38 
1.23 – 3.72 
 
– 
0.097 
0.004 
 
1 
1.36 
1.49 
 
– 
0.82 – 2.27 
0.83 – 2.68 
 
– 
0.240 
0.187 
 
1 
1.39 
1.55 
 
– 
0.84 – 2.31 
0.87 – 2.78 
 
– 
0.205 
0.140 
Obesity 2.34 1.49 – 3.67 0.000 1.38 0.79 – 2.40 0.262 – – – 
Central obesity 2.75 1.68 – 4.52 0.000 1.86 1.01 – 3.42 0.045 2.20 1.29 – 3.75 0.004 
HbA1c ≥ 7.0 % 2.19 1.32 – 3.64 0.001 1.55 0.91 – 2.62 0.104 1.59 0.94 – 2.68 0.083 
Elevated ALT  2.34 1.45 – 3.79 0.000 2.04 1.24 – 3.36 0.005 1.98 1.21 – 3.25 0.007 
Elevated GGT  2.23 1.30 – 3.83 0.002 1.69 0.97 – 2.95 0.063 1.73 0.99 – 3.00 0.053 
 
All categorical variables which were significant on univariate analysis were included in multivariate analysis in Model 1.  
In Model 2, only central obesity (and not obesity) was included in the multivariate analysis. 
ALT = alanine aminotransferase, GGT = gamma glutamyl transpeptidase  
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Table 4.3 NAFLD prevalence according to different ethnic groups and association with central obesity, physical activity and dietary intake  
 Chinese Malay Indian 
 p*  p* 
NAFLD 42.0 % 60.7 % 0.004 51.5 % 0.097 
Central obesity 60.3 % 84.3 % 0.000 82.6 % 0.000 
Low physical activity 51.5 % 59.6 % 0.196 53.8 % 0.647 
†Calorie intake, kcal/kg/day  19.8 (14.7 – 25.7) 17.0 (13.1 – 24.0) 0.069 18.1 (13.3 – 24.7) 0.231 
†Carbohydrate intake, g/kg/day 2.65 (1.97 – 3.33) 2.26 (1.68 – 3.06) 0.064 2.68 (1.80 – 3.44) 0.831 
†Protein intake, g/kg/day 0.84 (0.63 – 1.18) 0.76 (0.51 – 0.98) 0.034 0.68 (0.52 – 0.92) 0.003 
†Fat intake, g/kg/day 0.56 (0.39 – 0.84) 0.56 (0.37 – 0.81) 0.758 0.57 (0.38 – 0.72) 0.928 
†Calorie source, % 
Carbohydrate 
Protein 
Fat 
 
54.1 ± 9.7 
17.1 ± 3.5 
26.4 ± 6.7 
 
54.0 ± 9.4 
17.2 ± 2.9 
28.9 ± 7.7 
 
0.955 
0.372 
0.018 
 
56.1 ± 9.5 
15.8 ± 3.1 
28.5 ± 7.6 
 
0.110 
0.000 
0.072 
 
*p-values were from comparing Malay vs. Chinese, and Indian vs. Chinese, respectively 
†For dietary data, n = 140, 61 and 97 for Chinese, Malays and Indians, respectively
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4.4     Discussion 
Half of the study population has NAFLD. While the prevalence is lower than the 
reported 55 % – 70 % in previous studies from other parts of the world (Leite et al., 2009; 
Merat et al., 2009; Targher et al., 2006), NAFLD is poised to be a significant cause of chronic 
liver disease in Malaysia given the huge and increasing burden of diabetes mellitus in the 
country. NAFLD should not to be taken lightly as it is not an entirely benign condition 
(Ekstedt et al., 2006). NAFLD has been recognized as an important cause of cryptogenic 
cirrhosis (Maheshwari et al., 2006) and is associated with increased risk of hepatocellular 
carcinoma, even in patients without cirrhosis (Page et al., 2009). In a study on etiology of 
cirrhosis and association with hepatocellular carcinoma in our center, cryptogenic cause, 
which is believed to be due to NAFLD contributed to 15.4 % of cases of cirrhosis and was 
an independent predictor of hepatocellular carcinoma (Qua et al., 2011). NAFLD is also 
associated with cardiovascular diseases (Bhatia et al., 2012). The implications of NAFLD 
will be discussed further in Chapter 6 and Chapter 7.    
As elucidated in Chapter 3, population-based studies have shown that the prevalence 
of NAFLD increases with increasing age. Conversely and interestingly, we found that 
NAFLD is seen less commonly with increasing age in this study population. We hypothesize 
that NAFLD may be associated with increased co-morbidities in aging diabetic patients and 
this could have limited their survival and attendance to the clinic and hence their lower 
representation in the study population. The prevalence of NAFLD was higher among men 
compared to women below the age of 50 years old despite a significantly higher prevalence 
of central obesity among women compared to men in this age group. The protective effect 
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against NAFLD in women of reproductive age has been reported in population-based studies, 
and seems to apply to diabetic patients as well based on findings from this study.   
A recently published study on multiracial health-check subjects from Malaysia 
reported an inordinately high prevalence of NAFLD among the Malays and Indians 
compared to the Chinese. Similarly, in our study on diabetic patients, we found that the 
prevalence of NAFLD was higher among the Malays and Indians compared to the Chinese. 
The Chinese were significantly less obese (both overall and centrally) compared to their 
Malay and Indian counterparts. We did not find any differences in the daily calorie intake 
and the level of physical activity between the different ethnic groups. Obesity is the result of 
energy intake in excess of expenditure over time and the contribution of differences in dietary 
intake and level of physical activity to obesity and NAFLD is difficult to demonstrate in cross 
sectional studies. Nevertheless, we did show that the Malays and Indians had higher 
percentage of calorie intake from fat compared to the Chinese. Although there is an overlap 
in the food consumed by the different ethnic groups in Malaysia, there are some distinct 
differences in the regular choice of food. The Malays and Indians generally consume more 
curry and deep-fried food while the Chinese often consume stir-fried, steamed or soup-based 
food. A more detailed analysis of dietary intake and physical activity of diabetic patients with 
and without NAFLD is presented in the next chapter. Genetic differences between the ethnic 
groups may also play a role. A study on a multi-ethnic Malaysian population found that the 
PNPLA3 gene polymorphism is associated with susceptibility to NASH, NASH severity and 
presence of fibrosis, and that the effect of the gene polymorphism appears to be greater in 
the Indians followed by the Malays and the Chinese (Zain et al., 2012).       
In view of the high prevalence of NAFLD among diabetic patients, it would seem 
appropriate to look for the condition in diabetic patients. There are currently differing views 
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on this in the American and European guidelines (Chalasani et al., 2012; Ratziu et al., 2010). 
Our study echoes previously published studies that serum ALT level is not useful to identify 
NAFLD patients (see Chapters 2 and 3). Ultrasonography is a simple, non-invasive and 
relatively inexpensive test for the diagnosis of NAFLD and should be considered in all 
diabetic patients. The real challenge is to identify diabetic patients with NAFLD who has 
non-alcoholic steatohepatitis (NASH) or advanced fibrosis. Liver biopsy is invasive and does 
not seem to be the appropriate test for all diabetic patients with NAFLD. Moreover, it is 
limited by sampling variability (Ratziu et al., 2005) and inter-observer variability (Younossi 
et al., 1998). Measurement of cytokeratin-18 fragment levels in the blood has been shown to 
predict histological NASH (Feldstein et al., 2009). The NAFLD fibrosis score utilizes readily 
available parameters to identify NAFLD patients with and without advanced fibrosis and 
limits the need for liver biopsy to only those with indeterminate scores (Angulo et al., 2007). 
Measurement of liver stiffness using transient elastography has been shown to have high 
negative predictive value for advanced fibrosis (Wong et al., 2010). All these methods are 
promising and deserve further studies for use in diabetic patients, not only for initial 
assessment but also for follow-up purpose. These non-invasive tests are further discussed in 
Chapter 8.       
 Despite our effort, this study has several limitations. First, the diagnosis of fatty liver 
was based on ultrasonography and not histopathological examination of liver biopsy 
specimen. While the latter is more accurate to diagnose fatty liver, a liver biopsy is invasive 
and is not feasible in a study of this nature. As discussed in Chapter 2, ultrasonography is by 
far the most common method to diagnose fatty liver in clinical practice and in 
epidemiological studies. It has good sensitivity and specificity in moderate and severe fatty 
liver. However, it lacks sensitivity when fatty liver is mild. Hence, the true prevalence of 
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NAFLD could have been underestimated as cases of mild fatty liver could have been missed 
on ultrasonography. Second, measurement of dietary intake (including alcohol intake) and 
physical activity were self-reported. Strict and continuous measurement of dietary intake and 
physical activity over time would not be practical in cross-sectional studies involving fairly 
large number of patients like this and has its own inherent way of causing bias. We did use 
previously validated questionnaires to capture information on dietary intake and physical 
activity. To the best of our knowledge, this is the only study from the Asian-Pacific on 
prevalence of NAFLD among diabetic patients and associated factors that provided 
information on different ethnic groups and included data on dietary intake and physical 
activity. 
4.5 Conclusion 
 NAFLD was seen in half of a cohort of diabetic patients and was independently 
associated with central obesity and elevated serum ALT level. The prevalence of NAFLD 
was higher among the Malays and Indians compared to the Chinese consistent with higher 
prevalence of central obesity and higher percentage calorie intake from fat in the former 
groups of patients.  
Note: The findings from this study was presented at the Malaysian Society of 
Gastroenterology and Hepatology Annual Scientific Meeting in 2012 and won the Best Paper 
Award. A poster on the findings from this study was also presented at the Asia-Pacific 
Digestive Week 2012 in Bangkok, Thailand, and the abstract was published in a 
supplementary issue of the Journal of Gastroenterology and Hepatology (Chan et al., 2012). 
The full article has been published in the Journal of Gastroenterology and Hepatology (Chan 
et al., 2013).   
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Chapter 5 
Role of diet and physical activity in NAFLD in diabetics 
5.1  Introduction 
Diet and physical activity are important factors in non-alcoholic fatty liver disease 
(NAFLD). A case-control study identified increased fructose consumption as a risk factor for 
NAFLD (Ouyang et al., 2008). This is consistent with findings from a population-based 
cross-sectional study that found increased intake of soft drink (which contains fructose) as 
an independent predictor for NAFLD (Zelber-Sagi et al., 2007). Various other experimental 
and clinical studies on the role of fructose in the pathogenesis of metabolic syndrome and 
NAFLD have been reviewed by Yilmaz and colleagues (Yilmaz, 2012).  
Higher percentage calorie intake from fat has also been found to be an independent 
factor for NAFLD in a case-control study (Sathiaraj et al., 2011) and in a randomized study 
(Westerbacka et al., 2005). Higher carbohydrate intake (Solga et al., 2004), particularly 
simple carbohydrates (Toshimitsu et al., 2007), and higher fat intake, particularly excessive 
amount of n-6 polyunsaturated fatty acids (PUFAs) (Cortez-Pinto et al., 2006) have been 
implicated in non-alcoholic steatohepatitis (NASH), the more severe form of NAFLD.  
The importance of diet and physical activity in NAFLD is also reflected by the many 
interventional trials that have looked at energy restrictions, with and without increased 
physical activity to reduce liver fat (Cortez-Pinto et al., 2006). We aimed to look specifically 
at the role of diet and physical activity in NAFLD in diabetics as there were no published 
data on this.  
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5.2 Patients and methods 
We performed further detailed analysis on diet and physical activity for patients from 
the study presented in Chapter 4. Only patients who completed the food-frequency 
questionnaire (FFQ) in that study were included in this analysis.  
Food items were further categorized as high sugar, high cholesterol and/or high 
saturated fatty acid (SFA) where applicable (Table 5.1). Percentage calorie intake from high 
sugar food, high cholesterol food and high SFA food were estimated for each patient. 
Percentage calorie intake from macronutrients (i.e. carbohydrate, protein and fat), and 
percentage calorie intake from high sugar food, high cholesterol food and high SFA food 
were stratified into quartiles. Prevalence of NAFLD was compared across quartiles and 
between the highest quartile and lower quartiles for each of the variables. Percentage calorie 
intake from macronutrients, and percentage calorie intake from high sugar food, high 
cholesterol food and high SFA food were analyzed individually with level of physical activity 
to look for any association with prevalence of NAFLD. Further analysis was performed for 
patients who were and were not centrally obese.    
Statistical analysis 
Data were analyzed using SPSS 15.0. Continuous variables were expressed as mean 
± standard deviation or median (inter-quartile range), and analyzed using student’s t-test or 
Mann-Whitney U test where appropriate. Categorical variables were expressed as percentage 
and analyzed using chi-square test or Fisher’s exact test where appropriate. Significance was 
assumed at p < 0.05.    
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Table 5.1 List of high sugar food, high cholesterol food and high SFA food 
High sugar food 
Sweetened condensed milk, sugar, kaya (coconut jam), fruit jam, chocolate cereal, syrup 
drink, bandung (syrup-flavored milk), lemonade, iced lemon tea, carbonated drink, 
doughnut,  various types of sweet kuih (bite-sized snack), various types of cake, muffin, 
chocolate, ice-cream, chocolate biscuits, sweets.     
High cholesterol food 
Full cream milk powder, cheese, sambal (chili-based sauce), deep-fried beef lung, deep-
fried chicken liver, other offal, sambal ikan bilis (chili-based sauce with anchovies), squid, 
prawn, crab, fried egg, boiled egg, salted egg, full cream yogurt, ice-cream. 
High SFA food 
Roti canai (flatbread), roti telur (flatbread with egg), sambal, nasi lemak (rice cooked in 
coconut milk), fried rice, nasi minyak (ghee rice), biryani rice, chicken rice, fried chicken, 
curry with coconut milk, kuah masak lemak (creamy coconut sauce), kurma sauce, kuah 
rendang (a spicy sauce made from coconut milk and mixture of ground spices), deep-fried 
fish, deep-fried meat, deep-fried beef lung, deep-fried anchovies, sambal ikan bilis, 
chicken burger, beef burger, sausage/frankfurter, nuggets, French fries, cekodok pisang 
(bite-sized snack made from banana), banana fritter, shrimp fritter, curry puff, fried spring 
roll, mung bean fritter, vadai kacang dhal (fritter-type snack made from pulses), various 
types of cakes, chocolate, ice-cream, chocolate biscuits. 
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5.3 Results 
Patient characteristics 
Data for 299 patients were analyzed (Figure 5.1). Mean age of the study population 
was 63.3 ± 10.5 years old with 41.1 % male. Majority (81.9 %) completed at least lower 
secondary education with median income of RM 1000 (RM 667 – RM 2000) per household 
person per month. Mean duration since diagnosis of diabetes mellitus was 16.6 ± 9.7 years. 
Most patients had hypertension (90.3 %) and dyslipidemia (97.7 %). Central obesity was 
seen in 71.9 %. Majority (95.7 %) had metabolic syndrome. The prevalence of NAFLD was 
49.2 %.  
The characteristics of patients with and without NAFLD are shown in Table 5.1. 
Similar to the entire cohort of 399 patients presented in Chapter 4, independent factors 
associated with NAFLD were central obesity and raised serum ALT level (data not shown). 
Central obesity was associated with NAFLD on multivariate analysis while obesity was not. 
Hence, central obesity instead of obesity was used during further analysis on dietary intake 
and physical activity.     
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Figure 5.1 Flow chart illustrating the details of patients included/excluded in the analysis 
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Table 5.2 Characteristics of patients with and without NAFLD  
 NAFLD p 
Yes 
n = 147 
No 
n = 152 
Age, years 61.5 ± 11.4 65.0 ± 9.3  0.004 
Male 42.2 % 40.1 % 0.719 
Race 
Malay 
Chinese 
Indian 
Others 
 
25.9 % 
42.2 % 
31.3 % 
0.7 % 
 
15.1 % 
51.3 % 
33.6 % 
0 % 
 
0.082 
Education level 
None or primary 
Secondary and above 
 
17.0 % 
83.0 % 
 
19.1 % 
80.9 % 
 
0.641 
Income per household person, RM 1000 (667 – 2000) 1000 (635 – 1969) 0.880 
Duration of diabetes mellitus, years 16.1 ± 9.8 16.9 ± 9.6 0.540 
Hypertension 88.4 % 92.1 % 0.284 
Dyslipidemia 98.0 % 97.4 % 1.000 
Body mass index, kg per m2 28.8 ± 6.3 26.0 ± 5.1 < 0.001 
Obesity 72.1 % 54.6 % 0.002 
Waist circumference, cm 94.7 ± 11.5 88.8 ± 12.8 < 0.001 
Central obesity 81.0 % 63.2 % 0.001 
Metabolic syndrome 95.9 % 95.4 % 0.824 
Metformin 81.0 % 75.0 % 0.215 
Sulphonylurea 46.9 % 44.1 % 0.620 
Insulin 45.6 % 44.7 % 0.884 
Statin 85.0 % 84.9 % 0.968 
Fibrate 10.2 % 17.8 % 0.060 
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 NAFLD p 
Yes 
n = 147 
No 
n = 152 
Fasting blood sugar, mmol/L 7.5 (6.2 – 9.6) 7.3 (5.9 – 9.0) 0.387 
HbA1c, % 7.90 (7.03 – 9.08) 7.60 (6.80 – 8.50) 0.018 
Total cholesterol, mmol/L 4.2 ± 1.0 4.2 ± 1.0 0.966 
High-density lipoprotein, mmol/L 1.2 ± 0.4 1.3 ± 0.4 0.274 
Low-density lipoprotein, mmol/L 2.2 ± 0.8 2.3 ± 0.8 0.802 
Triglyceride, mmol/L 1.5 (1.2 – 1.9) 1.3 (1.0 – 1.8) 0.011 
Alkaline phosphatase, IU/L 65 (54 – 81) 61 (50 – 77) 0.134 
Alanine aminotransferase, IU/L 33 (23 – 45) 25 (21 – 34) < 0.001 
Aspartate aminotransferase, IU/L 20 (16 – 28) 18 (15 – 23) 0.010 
Gamma glutamyl transpeptidase, IU/L 36 (26 – 58)   26 (18 – 43) < 0.001 
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Detailed analysis of level of physical activity, dietary intake and NAFLD 
More than half (53.8 %) of patients had low level of physical activity. Percentage of 
patients with moderate and high level of physical activity was 34.1 % and 12.0 %, 
respectively. Patients with low level of physical activity were more likely to have NAFLD 
compared to patients with moderate level of physical activity (OR = 1.75, 95 % CI = 1.03 – 
2.99, p = 0.029). There was no significant difference in calorie intake, intake of 
macronutrient, percentage calorie intake from each macronutrient, and percentage calorie 
intake from high sugar food, high cholesterol food and high SFA food between patients with 
and without NAFLD (Table 5.3).  
When percentage calorie intake from each macronutrient and percentage calorie 
intake from high sugar food, high cholesterol food and high SFA food was stratified 
according to quartiles, no significant difference in prevalence of NAFLD was seen across 
quartiles and between the highest and lower quartiles (Table 5.4). The findings were similar 
when analysis was performed separately for patients who were and were not centrally obese 
(data not shown). 
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Table 5.3 Level of physical activity, calorie intake, intake of macronutrients, percentage calorie intake from each macronutrient, and 
percentage calorie from high sugar food, high cholesterol food and high SFA food in patients with and without NAFLD 
 NAFLD No NAFLD OR 95 % CI p 
Level of physical activity 
Low 
Moderate 
High 
 
59.2 % 
27.9 % 
12.9 % 
 
48.7 % 
40.1 % 
11.2 % 
 
1.75 
1 
1.66 
 
1.03 – 2.99 
– 
0.72 – 3.83 
 
0.029 
– 
0.190 
Calorie intake, kcal/day  1272 (946 – 1600) 1242 (1001 – 1631) – – 0.775 
Carbohydrate intake, g/day 170.6 (126.7 – 223.9) 165.4 (135.8 – 226.1) – – 0.957 
Protein intake, g/day 52.0 (39.7 – 70.5) 53.1 (39.9 – 70.5) – – 0.883 
Fat intake, g/day 37.4 (27.0 – 51.7) 37.4 (27.6 – 54.4) – – 0.492 
Calorie source, % 
Carbohydrate 
Protein 
Fat 
 
55.0 ± 9.6 
17.1 ± 3.7 
27.2 ± 6.8 
 
54.6 ± 9.4 
16.8 ± 3.0 
27.5 ± 7.2 
 
– 
– 
– 
 
– 
– 
– 
 
0.722 
0.481 
0.690 
Percentage calorie from high sugar food, % 2.5 (0.3 – 7.0) 2.8 (0.5 – 5.6) – – 0.951 
Percentage calorie from high cholesterol food, % 3.0 (0.9 – 7.9) 2.4 (0.8 – 5.9) – – 0.317 
Percentage calorie from high SFA food, % 12.7 (5.7 -23.5) 11.7 (4.9 – 18.4) – – 0.154 
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Table 5.4 Prevalence of NAFLD across quartiles and between highest and lower quartiles of percentage calorie intake from each macronutrient, 
and percentage calorie intake from high sugar food, high cholesterol food and high SFA food  
 NAFLD No NAFLD OR 95 % CI p 
Percentage calorie from carbohydrate 
< 48.2 % 
48.2 % – 55.3 % 
55.3 % – 61.0 % 
≥ 61.0 % 
 
< 61.0 % 
≥ 61.0 % 
 
 
26.5 % 
24.5 % 
23.1 % 
25.9 % 
 
74.1 % 
25.9 % 
 
23.0 % 
26.3 % 
27.0 % 
23.7 % 
 
76.3 % 
23.7 % 
 
1 
0.81 
0.74 
0.95 
 
1 
1.12 
 
– 
0.40 – 1.61 
0.37 – 1.49 
0.47 – 1.90 
 
– 
0.64 – 1.96 
 
– 
0.514 
0.368 
0.869 
 
– 
0.664 
Percentage calorie from protein 
< 14.6 % 
14.6 % – 16.9 % 
16.9 % – 19.1 % 
≥ 19.1 % 
 
< 19.1 % 
≥ 19.1 % 
 
 
25.2 % 
23.1 % 
26.5 % 
25.2 % 
 
74.8 % 
25.2 % 
 
23.7 % 
27.0 % 
25.7 % 
23.7 % 
 
76.3 % 
23.7 % 
 
1 
0.81 
0.97 
1.00 
 
1 
1.08 
 
– 
0.40 – 1.62 
0.49 – 1.94 
0.50 – 2.02 
 
– 
0.62 – 1.90 
 
– 
0.515 
0.933 
1.000 
 
– 
0.765 
Percentage calorie from fat 
< 22.5 % 
22.5 % – 27.5 % 
27.5 % – 31.5 % 
≥ 31.5 % 
 
< 31.5 % 
≥ 31.5 % 
 
25.2 % 
25.2 % 
24.5 % 
25.2 % 
 
74.8 % 
25.2 % 
 
25.0 % 
23.7 % 
26.3 % 
25.0 % 
 
75.0 % 
25.0 % 
 
1 
1.06 
0.92 
1 
 
1 
1.01 
 
– 
0.53 – 2.12 
0.46 – 1.84 
0.50 – 2.00 
 
– 
0.58 – 1.76 
 
– 
0.869 
0.809 
1.000 
 
– 
0.973 
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 NAFLD No NAFLD OR 95 % CI p 
Percentage calorie from high sugar food 
< 0.44 % 
0.44 % – 2.68 % 
2.68 % – 6.22 % 
≥ 6.22% 
 
< 6.22 % 
≥ 6.22 % 
 
 
26.5 % 
25.2 % 
22.4 % 
25.9 % 
 
74.1 % 
25.9 % 
 
23.7 % 
24.3 % 
33.6 % 
18.4 % 
 
81.6 % 
18.4 % 
 
1 
0.92 
0.60 
1.25 
 
1 
1.54 
 
– 
0.46 – 1.85 
0.30 – 1.18 
0.61 – 2.58 
 
– 
0.86 – 2.78 
 
– 
0.807 
0.108 
0.507 
 
– 
0.122 
Percentage calorie from high cholesterol food 
< 0.91 % 
0.91 % – 2.68 % 
2.68 % – 6.74 % 
≥ 6.74 % 
 
< 6.74 % 
≥ 6.74 % 
 
 
23.8 % 
23.8 % 
22.4 % 
29.9 % 
 
70.1 % 
29.9 % 
 
25.7 % 
26.3 % 
27.6 % 
20.4 % 
 
79.6 % 
20.4 % 
 
1 
0.98 
0.88 
1.58 
 
1 
1.67 
 
– 
0.49 – 1.95 
0.44 – 1.76 
0.79 – 3.19 
 
– 
0.95 – 2.93 
 
– 
0.939 
0.686 
0.164 
 
– 
0.058 
Percentage calorie from high SFA food 
< 5.27 % 
5.27 % – 11.84 % 
11.84 % – 20.23 % 
≥ 20.23 % 
 
< 20.23 % 
≥ 20.23 % 
 
 
 23.1 % 
23.8 % 
23.8 % 
29.3 % 
 
70.7 % 
29.3 % 
 
26.3 % 
26.3 % 
26.3 % 
21.1 % 
 
78.9 % 
21.1 % 
 
1 
1.03 
1.03 
1.58 
 
1 
1.55 
 
– 
0.51 – 2.06 
0.51 – 2.06 
0.79 – 3.18 
 
– 
0.89 – 2.72 
 
– 
0.930 
0.930 
0.164 
 
– 
0.102 
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Among centrally obese patients, patients with low level of physical activity and in the 
highest quartile of percentage calorie intake from fat were the most likely to have NAFLD 
(OR = 4.03, 95 % CI = 1.12 – 14.99, p = 0.015).  Among patients who were not centrally 
obese, level of physical activity and percentage calorie intake from fat was not associated 
with NAFLD (Table 5.5). Among centrally obese patients, patients with low level of physical 
activity and in the highest quartile of percentage calorie intake from high cholesterol food 
(OR = 3.61, 95 % CI = 1.37 – 9.72, p = 0.004) and high SFA food (OR = 2.67, 95 % CI = 
1.08 – 6.67, p = 0.019) were most likely to have NAFLD. Among patients who were not 
centrally obese, level of physical activity and percentage calorie intake from high cholesterol 
food and high SFA food was again not associated with NAFLD (Table 5.6). These findings 
were not affected when adjusted for age and gender, and other components of metabolic 
syndrome (data not shown).  
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Table 5.5 Level of physical activity and percentage calorie intake from each macronutrient in patients with and without central obesity and 
the prevalence of NAFLD 
 NAFLD No NAFLD OR 95 % CI p 
a) Carbohydrate      
All patients 
A1 
A2 
B1 
B2 
 
12.9 % 
46.9 % 
12.9 % 
27.2 % 
 
12.5 % 
35.5 % 
11.2 % 
40.8 % 
 
0.78 
1 
0.87 
0.50 
 
0.35 – 1.72 
– 
0.39 – 1.97  
0.29 – 0.89 
 
0.509 
– 
0.725 
0.012 
Patients with central obesity 
A1 
A2 
B1 
B2 
 
14.3 % 
49.6 % 
13.4 % 
22.7 % 
  
14.6 % 
31.2 % 
12.5 % 
41.7 % 
 
0.62 
1 
0.68 
0.34 
 
0.25 – 1.54 
– 
0.26 – 1.76  
0.17 – 0.70 
 
0.254 
– 
0.379 
0.001 
Patients without central obesity 
A1 
A2 
B1 
B2 
 
7.1 % 
35.7 % 
10.7 % 
46.4 % 
 
8.9 % 
42.9 % 
8.9 % 
39.3 % 
 
0.96 
1 
1.44 
1.42 
 
0.11 – 7.28 
– 
0.22 – 9.13  
0.46 – 4.39 
 
1.000 
– 
0.686 
0.496 
b) Protein      
All patients 
A1 
A2 
B1 
B2 
 
15.6 % 
44.2 % 
9.5 % 
30.6 % 
 
10.5 % 
37.5 % 
13.2 % 
38.8 %  
 
1.88 
1.50 
0.92 
1 
 
0.84 – 4.26 
0.85 – 2.62 
 0.39 – 2.16  
– 
 
0.094 
0.133 
0.830 
– 
Patients with central obesity 
A1 
A2 
B1 
 
18.5 % 
45.4 % 
9.2 % 
 
11.5 % 
34.4 % 
13.5 % 
 
2.44 
1.99 
1.03 
 
0.95 – 6.33 
1.00 – 3.97 
0.37 – 2.88  
 
0.040 
0.033 
0.948 
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 NAFLD No NAFLD OR 95 % CI p 
B2 26.9 % 40.6 % 1 – – 
Patients without central obesity 
A1 
A2 
B1 
B2 
 
3.6 % 
39.3 % 
10.7 % 
46.4 % 
 
8.9 % 
42.9 % 
12.5 % 
35.7 % 
 
0.31 
0.71 
0.66 
1 
 
0.01 – 3.37 
0.23 – 2.14 
0.11 – 3.66 
– 
 
0.391 
 0.492 
0.719 
– 
c) Fat      
All patients 
A1 
A2 
B1 
B2 
 
18.4 % 
41.5 % 
 6.8 % 
33.3 % 
 
11.8 % 
36.2 % 
13.2 % 
38.8 % 
 
3.00 
2.22 
1 
1.66 
 
1.03 – 8.88 
0.89 – 5.61 
–  
0.66 – 4.23 
 
0.024 
0.060 
– 
0.238 
Patients with central obesity 
A1 
A2 
B1 
B2 
 
19.3 % 
44.5 % 
 6.7 % 
29.4 % 
 
10.4 % 
35.4 % 
14.6 % 
39.6 %  
 
4.03 
2.73 
1 
1.61 
 
1.12 – 14.99 
0.94 – 8.05 
– 
0.55 – 4.83 
 
0.015 
0.038 
– 
0.339 
Patients without central obesity 
A1 
A2 
B1 
B2 
 
14.3 % 
28.6 % 
7.1 % 
50.0 % 
 
14.3 % 
37.5 % 
10.7 % 
37.5 %  
 
1.50 
1.14 
1 
2.00 
 
0.14 – 17.50 
0.15 – 10.30 
–  
0.29 – 16.87 
 
1.000 
1.000 
– 
0.688 
 
A1 = low level of physical activity and highest quartile of percentage calorie intake from corresponding macronutrient 
A2 = low level of physical activity and lower quartiles of percentage calorie intake from corresponding macronutrient 
B1 = moderate or high level of physical activity and highest quartile of percentage calorie intake from corresponding macronutrient  
B2 = moderate or high level of physical activity and lower quartiles of percentage calorie intake from corresponding macronutrient  
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Table 5.6 Level of physical activity and percentage calorie intake from high sugar, high cholesterol and high SFA food in patients with and 
without central obesity and the prevalence of NAFLD 
 NAFLD No NAFLD OR 95 % CI p 
a) High sugar food      
All patients 
A1 
A2 
B1 
B2 
 
15.0 % 
44.9 % 
10.9 % 
29.3 % 
 
11.2 % 
36.8 % 
7.2 % 
44.7 % 
 
2.05 
1.86 
2.30 
1 
 
0.92 – 4.58 
1.07 – 3.25 
0.90 – 5.91  
– 
 
0.055 
0.019 
0.053 
– 
Patients with central obesity 
A1 
A2 
B1 
B2 
 
16.8 % 
47.1 % 
10.1 % 
26.1 % 
 
9.4 % 
36.5 % 
7.3 % 
46.9 % 
 
3.23 
2.32 
2.49 
1 
 
1.19 – 8.89 
1.19 – 4.55 
0.79 – 7.99  
– 
 
0.010 
0.008 
0.080 
– 
Patients without central obesity 
A1 
A2 
B1 
B2 
 
7.1 % 
35.7 % 
14.3 % 
42.9 % 
 
14.3 % 
37.5 % 
7.1 % 
41.1 % 
 
0.48 
0.91 
1.92 
1 
 
0.06 – 3.12 
0.29 – 2.87 
0.32 – 11.59  
– 
 
0.469 
0.862 
0.443 
– 
b) High cholesterol food      
All patients 
A1 
A2 
B1 
B2 
 
21.1 % 
38.8 % 
8.8 % 
31.3 % 
 
9.9 % 
38.2 % 
8.8 % 
31.3 % 
 
2.83 
1.35 
1.11 
1 
 
1.30 – 6.24 
0.77 – 2.36 
0.45 – 2.74  
– 
 
0.004 
0.269 
0.799 
– 
Patients with central obesity 
A1 
A2 
B1 
 
21.8 % 
42.0 % 
9.2 % 
 
9.4 % 
36.5 % 
12.5 % 
 
3.61 
1.79 
1.15 
 
1.37 – 9.72 
 0.90 – 3.54 
0.40 – 3.24  
 
0.004 
0.072 
0.777 
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 NAFLD No NAFLD OR 95 % CI p 
B2 26.9 % 41.7 % 1 – – 
Patients without central obesity 
A1 
A2 
B1 
B2 
 
17.9 % 
25.0 % 
7.1 % 
50.0 % 
 
10.7 % 
41.1 % 
7.1 % 
41.1 % 
 
1.37 
0.50 
0.82 
1 
 
0.29 – 6.48 
0.15 – 1.65  
0.09 – 6.39  
– 
 
0.732 
0.203 
1.000 
– 
c) High SFA food      
All patients 
A1 
A2 
B1 
B2 
 
19.7 % 
40.1 % 
9.5 % 
30.6 % 
 
12.5 % 
35.5 % 
8.6 % 
43.4 %  
 
2.24 
1.60 
1.58 
1 
 
1.06 – 4.74 
0.91 – 2.82 
0.63 – 3.99  
– 
 
0.021 
0.080 
0.287 
– 
Patients with central obesity 
A1 
A2 
B1 
B2 
 
21.0 % 
42.9 % 
9.2 % 
26.9 % 
 
12.5 % 
33.3 % 
11.5 % 
42.7 %  
 
2.67 
2.04 
1.28 
1 
 
1.08 – 6.67 
1.03 – 4.08 
0.45 – 3.69 
– 
 
0.019 
0.028 
0.611 
– 
Patients without central obesity 
A1 
A2 
B1 
B2 
 
14.3 % 
28.6 % 
10.7 % 
46.4 % 
 
12.5 % 
39.3 % 
3.6 % 
44.6 % 
 
1.10 
0.70 
2.88 
1 
 
0.22 – 5.37 
0.21 – 2.25 
0.33 – 29.05  
– 
 
1.000 
0.504 
0.344 
– 
 
A1 = low level of physical activity and highest quartile of percentage calorie intake from corresponding food type 
A2 = low level of physical activity and lower quartiles of percentage calorie intake from corresponding food type 
B1 = moderate or high level of physical activity and highest quartile of percentage calorie intake from corresponding food type 
B2 = moderate or high level of physical activity and lower quartiles of percentage calorie intake from corresponding food type  
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5.4 Discussion 
Obesity is the result of energy intake in excess of expenditure over time. Given 
sufficient time, even a relatively small imbalance between energy intake and expenditure can 
lead to obesity. Moreover, such imbalance and the resultant weight change may occur at 
some time but not others (Roberts et al., 1998). Consequently, detecting and linking 
differences in dietary intake and physical activity to the development of obesity and its 
associated conditions such as NAFLD is difficult even under the best circumstances. Hence, 
it came as no surprise that we did not detect any significant differences in the calorie intake, 
the intake of macronutrients, and the percentage of calorie intake from each macronutrient 
and the percentage of calorie intake from high sugar food, high cholesterol food and high 
SFA food in our cross-sectional study of diabetic patients with and without NAFLD.  
In a retrospective analysis of data from a large population-based cross-sectional study 
that used physical activity monitors, Gerber and colleagues showed that average physical 
activity and moderate/vigorous physical activity was significantly lower in patients with 
NAFLD or diabetes mellitus compared to those without either conditions. Average physical 
activity and moderate/vigorous physical activity were lowest among patients with coexisting 
NAFLD and diabetes mellitus (Gerber et al., 2012). This is consistent with our findings, that 
diabetic patients with NAFLD were more likely to have low level of physical activity 
compared to diabetic patients without NAFLD. Whether low level of physical activity is the 
cause or effect of NAFLD is unclear. Reduced energy expenditure due to low level of 
physical activity can theoretically contribute to energy excess, weight gain, obesity and 
NAFLD. On the other hand, obese patients have lower cardio-respiratory fitness and lower 
level of physical activity. These associations can potentially form a self-perpetuating vicious 
cycle that promotes NAFLD. 
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We also found that low level of physical activity and high percentage calorie intake 
from fat, high cholesterol food and high SFA food was associated with NAFLD in centrally 
obese but not in lean diabetic patients. Obese patients have increased insulin resistance. As 
elucidated in Chapter 2, insulin resistance results in impaired insulin-mediated glucose 
uptake in adipose tissue and skeletal muscle. The resultant increase in blood glucose 
concentration leads to increased glucose uptake in the liver, a process which is insulin-
independent. This leads to increase de novo lipogenesis (DNL). In patients with NAFLD, 
free fatty acids from DNL are a significant source of accumulated fat in the liver (Donnelly 
et al., 2005). Insulin resistance also results in impaired insulin-mediated suppression of 
triglyceride hydrolysis in adipose tissue leading to increased non-esterified fatty acids 
(Donnelly et al., 2005; Finelli et al., 2012).  Low level of physical activity aggravates insulin 
resistance (Mayer-Davis et al., 1998). This, along with increased dietary fat makes obese 
diabetic patients more susceptible to NAFLD compared to their non-obese counterparts. 
Dietary cholesterol has been shown to exacerbate hepatic steatosis and inflammation in 
animal model (Subramanian et al., 2011). In a study comparing non-obese and obese NAFLD 
patients, dietary cholesterol was superabundant in non-obese NAFLD patients suggesting an 
important role in development of NAFLD. Accumulation of SFA in the liver also plays an 
important role in the pathogenesis of NAFLD and has been shown to exacerbate liver 
inflammation and injury in various studies at the cellular and molecular level (Gentile et al., 
2011).  
Findings from this study are novel and complement that from other previous studies. 
However, as the study population consisted of diabetic patients only, the findings may not be 
generalized to non-diabetic patients. Further studies should be performed to see if similar 
findings are observed in other populations. Despite our effort, there were several other 
limitations in our study. Dietary intake and physical activity were self-reported and could be 
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subjected to bias. However, strict and continuous measurement of dietary intake and physical 
activity over time would not be practical in cross-sectional studies involving fairly large 
number of patients like this and has its own inherent way of causing bias too. We did use 
previously validated questionnaires to capture information on dietary intake and physical 
activity. Dietary composition for many Malaysian food items was incomplete so we were not 
able to look at the sugar, cholesterol and SFA content of each individual food items. Instead, 
we categorized food items into high sugar food, high cholesterol food and high SFA food for 
analysis. Similarly, we were also not able to look at the role of dietary n-3 and n-6 PUFAs 
and trans fatty acids in our patients. Lastly, diagnosis of fatty liver was based on ultrasound 
and not histopathological examination of liver biopsy specimen. While the latter is more 
accurate to diagnose fatty liver, it is invasive and not feasible in our study. Ultrasonography 
is by far the most common method to diagnose fatty liver in clinical practice and in 
epidemiological studies with good sensitivity and specificity in moderate and severe fatty 
liver.   
5.5  Conclusion  
Based on findings from this study, we conclude that low level of physical activity and 
high percentage calorie intake from fat, high cholesterol food and high SFA food is associated 
with NAFLD in centrally obese but not in lean diabetic patients. We are not implying that 
there should be different lifestyle recommendations for centrally obese and lean diabetic 
patients in regards to NAFLD, but are simply putting forward direct evidence from a cross-
sectional study that low level of physical activity and poor dietary habits have different 
impact on NAFLD in diabetic patients with and without central obesity.  
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Note: A poster on the findings from this study was presented at The 3rd Asian-Pacific Topic 
Conference in Tokyo, Japan in 2012. A poster on the findings from this study was also 
presented at the Malaysian Society of Gastroenterology and Hepatology Annual Scientific 
Meeting in 2013. The full article has been accepted for publication in the Asian Pacific 
Journal of Clinical Nutrition (Chan et al., 2014).  
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Chapter 6 
NAFLD and ischemic heart disease in diabetics 
6.1 Introduction 
As discussed in Chapter 2, non-alcoholic fatty liver disease (NAFLD) is considered 
the liver manifestation of metabolic syndrome, which is a constellation of closely related 
cardiovascular risk factors. Hence, it is not surprising that studies have shown that NAFLD 
is associated with increased risk of cardiovascular disease. However, there is substantial 
heterogeneity in the design of published studies on this matter. Some studies utilized serum 
alanine aminotransferase (ALT) or gamma glutamyl transpeptidase (GGT) levels as a 
surrogate marker of NAFLD (Lee et al., 2006; Ruttmann et al., 2005; Schindhelm et al., 2007; 
Wannamethee et al., 1995; Yun et al., 2009). These studies reported NAFLD to be associated 
with cardiovascular disease independent of traditional risk factors. However, it is known that 
these enzymes lack sensitivity and specificity for diagnosis of NAFLD. On the other hand, 
some studies were on patients with liver biopsy. These studies reported increased mortality 
in patients with NAFLD compared to the general population with cardiovascular disease as 
a leading cause of death (Ekstedt et al., 2006; Soderberg et al., 2010). However, patients with 
NAFLD who are subjected to a liver biopsy may arguably have more severe liver disease and 
findings from studies on these patients may not be generalized to all patients with NAFLD. 
Ultrasonography is by far the most widely used modality for diagnosis of NAFLD as it is 
widely available and relatively inexpensive. Studies utilizing ultrasonography similarly 
reported association of NAFLD with cardiovascular disease (Adams et al., 2005; Hamaguchi 
et al., 2007; Targher et al., 2006; Targher et al, 2012; Wong et al., 2011).  
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While most of the studies mentioned above were population-based (Adams et al., 
2005; Hamaguchi, et al., 2007; Lee et al., 2006; Ruttmann et al., 2005; Schindhelm et al., 
2007; Wannamethee et al., 1995; Yun et al., 2009), some were hospital-based (Ekstedt et al., 
2006; Soderberg et al., 2010) or included exclusive populations e.g. patients with diabetes 
mellitus (Targher et al., 2006; Targher et al., 2012), patients undergoing coronary 
angiography (Wong et al., 2011). Targher and colleagues have made tremendous 
contributions in the study of the association of NAFLD with cardiovascular diseases in 
patients with diabetes mellitus (Targher et al., 2006; Targher et al., 2007; Targher et al., 
2012). However, there were no published studies from other centers on this matter. NAFLD 
and cardiovascular diseases are both common among patients with diabetes mellitus and we 
found it difficult to appreciate that NAFLD is associated with increased risk for 
cardiovascular diseases independent of the other traditional risk factors. Hence, we embarked 
on this study to determine if ultrasonography-diagnosed NAFLD is associated with ischemic 
heart disease (IHD) in our hospital clinic patients with diabetes mellitus.  
6.2  Patients and methods 
All patients who were included in the study described in Chapter 4 were assessed for 
IHD at the same setting by their attending endocrinologists. The medical record for each of 
the patients was carefully reviewed for documented IHD. Documented IHD was defined as 
previous admission for acute coronary syndrome (i.e. ST segment elevation myocardial 
infarction, non-ST segment elevation myocardial infarction or unstable angina), previous 
coronary intervention (i.e. coronary angioplasty with/without stent placement or coronary 
artery by-pass grafting), previous coronary angiography showing coronary artery disease, or 
under follow-up and medical treatment for IHD. Patients without documented IHD were 
interviewed by their attending endocrinologists for any symptoms suggestive of IHD and 
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sent for an electrocardiography. History of chest pain or discomfort that was precipitated by 
exertion and relieved by rest was considered suggestive of IHD. Pathological Q wave, ST 
segment depression and/or deep T wave inversion were considered suggestive of IHD. 
Patients with symptoms and/or electrocardiographic changes suggestive of IHD were 
referred to a cardiologist for further evaluation. The endocrinologists who assessed patients 
for IHD were blinded to ultrasonography findings, and the operator who performed 
ultrasonography was blinded to the endocrinologists’ assessment for IHD. 
Statistical analysis 
Data were analyzed using SPSS 15.0. Continuous variables were expressed as mean 
± standard deviation or median (inter-quartile range), and analyzed using student’s t-test or 
Mann-Whitney U test where appropriate. Categorical variables were expressed as percentage 
and analyzed using chi-square test or Fisher’s exact test where appropriate. All variables 
which were significant on univariate analysis were entered into multivariate logistic 
regression analysis to identify independent factors associated with IHD. Significance was 
assumed at p-value < 0.05. 
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6.3 Results 
Patient characteristics 
Data for 399 patients were analyzed. Mean age of the study population was 62.8 ± 
10.5 years and consisted of 43.1 % male. Mean duration of diabetes mellitus was 16.2 ± 9.7 
years and mean serum glycated hemoglobin (HbA1c) level was 8.1 ± 1.8 %. The prevalence 
of NAFLD was 49.6 %. Ninety-two patients had documented IHD while six patients were 
newly diagnosed to have IHD (Figure 6.1). Eight patients who had history and/or ECG 
changes suggestive of IHD but missed their cardiology appointment were assumed to have 
IHD for the analysis. The results of analyses were similar whether these patients were 
completely excluded or assumed to have or not to have IHD.  
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Figure 6.1 Flow chart illustrating cases of IHD in the study population 
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Characteristics of patients with and without IHD 
Characteristics of patients with and without IHD are as shown in Table 6.1. The 
prevalence of IHD was highest among the Indians (34.1 %) followed by the Malays (29.2 %) 
and the Chinese (20.1 %). Patients with IHD were older, less active physically and more 
likely to have metabolic syndrome. They were diagnosed with diabetes mellitus for a longer 
duration and seemed to have poorer control as reflected by a higher HbA1c level. They also 
had greater body mass index (BMI), waist circumference (WC) and systolic blood pressure 
(SBP) compared to those without IHD. Patients with IHD were less likely to be on metformin 
but more likely to be on anti-platelet, beta-blocker and angiotensin converting enzyme 
inhibitor (ACE-i) or angiotensin receptor blocker (ARB).  
Patients with ultrasound-diagnosed NAFLD were not more likely to have IHD. 
Elevated serum alanine aminotransferase (ALT) level was not associated with IHD 
regardless of whether the laboratory or a more stringent cut-off was used. Elevated serum 
gamma glutamyl transpeptidase (GGT) level was also not associated with IHD. No 
association was found between ultrasonography-diagnosed NAFLD and IHD, and between 
elevated serum ALT and GGT levels and IHD, even when analyzed according to the different 
ethnic groups (Table 6.2).  
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Table 6.1 Characteristics of patients with and without IHD 
 IHD p 
Yes 
n = 106 
No 
n = 293 
Age, years 66.4 ± 8.9 61.5 ± 10.7 0.000 
Male 50.0 % 40.6 % 0.095 
Race 
Malay 
Chinese 
Indian 
Others 
 
24.5 % 
33.0 % 
42.5 % 
0.0 % 
 
21.5 % 
47.4% 
29.7 % 
1.4 % 
 
0.025 
Education – secondary and above 79.2 % 84.0 % 0.271 
Income/household person/month, RM 1000 (625 – 1813) 1176 (667 – 2000) 0.117 
Smoking 2.8 % 4.1 % 0.768 
Calorie intake†, kcal per day 1296 (932 – 1609) 1247 (1002 – 1618) 0.590 
Physical activity 
Low 
Moderate 
High 
 
61.3 % 
35.8 % 
2.8 % 
 
51.2 % 
34.1 % 
14.7 % 
 
0.004 
 
NAFLD  46.2 % 50.9 % 0.414 
Metabolic syndrome 100.0 % 93.5 % 0.007 
Duration of diabetes mellitus, years 19.0 ± 9.6  15.1 ± 9.5 0.001 
Fasting blood sugar, mmol/L 8.2 ± 3.7 8.0 ± 3.1 0.671 
HbA1c, % 8.4 ± 2.1 7.9 ± 1.6 0.024 
Hypertension 99.1% 88.4 % 0.000 
Systolic blood pressure ≥130 mmHg 75.5 % 61.1 % 0.008 
Diastolic blood pressure ≥80 mmHg 46.2 % 41.3 % 0.379 
Dyslipidemia‡ 100.0 % 96.2 % 0.042 
Body mass index, kg per m2 29.3 ± 8.3  27.6 ± 6.4 0.031 
Waist circumference, cm 95.8 ± 11.4 91.4 ± 12.9 0.002 
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 IHD p 
Yes 
n = 106 
No 
n = 293 
Medications§ 
Metformin  
ACE-i or ARB 
Beta-blocker 
Aspirin 
 
72.6 % 
85.8 % 
42.5 % 
59.4 % 
 
81.9 % 
67.6 % 
21.5 % 
47.8 % 
 
0.043 
0.000 
0.000 
0.040 
Elevated serum alanine aminotransferase (lab cut-off) 1.0 % 4.9 % 0.080 
Elevated serum alanine aminotransferase (stringent cut-off) 69.5 % 72.3 % 0.593 
Elevated serum gamma glutamyl transpeptidase 24.8 % 19.4 % 0.251 
 
†No significant difference in intake of carbohydrate, protein and fat and percentage calorie intake from these macronutrients between patients 
with and without IHD 
‡No significant difference in total cholesterol, low- and high-density lipoprotein, and triglyceride between patients with and without IHD 
§No significant difference in use of other medications – sulphonylurea, insulin, calcium channel blocker, hydrochlorothiazide, statin and fibrate 
between patients with and without IHD 
IHD =ischemic heart disease, ACE-i = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker 
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Table 6.2 No association was found between ultrasonography-diagnosed NAFLD and IHD, and between elevated serum ALT and GGT levels 
and IHD when analyzed according to the different ethnic groups 
 Malay, n = 88 Chinese, n = 168 Indian, n = 45 
 IHD No IHD p IHD No IHD p IHD No IHD p 
NAFLD 46.2 % 66.7 % 0.072 37.1 % 43.2 % 0.519 53.3 % 50.6 % 0.764 
Elevated serum ALT 
(laboratory cut-off) 
3.8 % 4.8 % 1.000 0 % 6.0 % 0.207 0 % 3.5 % 0.550 
Elevated serum ALT 
(stringent cut-off) 
69.2 % 72.6 % 0.751 77.1 % 76.7 % 0.955 63.6 % 66.3 % 0.764 
Elevated serum GGT 38.5 % 30.6 % 0.477 25.7 % 19.8 % 0.450 15.9 % 11.6 % 0.493 
 
IHD = ischemic heart disease, ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma glutamyl transpeptidase  
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Univariate and multivariate analyses of factors associated with IHD 
The results of univariate and multivariate analyses of factors associated with IHD are 
shown in Table 6.3. The number of subjects of other races, without metabolic syndrome and 
without dyslipidemia were small, and there were no patients with IHD in these groups of 
patients. Hence, these variables were not included in univariate and multivariate analyses. 
BMI and WC were not entered together in multivariate analysis as there parameters are 
closely associated with each other. On multivariate analysis, independent factors associated 
with IHD were older age, lower levels of physical activity, greater WC and higher HbA1c 
levels.  
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Table 6.3 Univariate and multivariate analyses on factors associated with IHD 
 
IHD = ischemic heart disease 
 
 Univariate analysis Multivariate analysis 
OR (95 % CI) p OR (95 % CI) p 
Age 1.05 (1.03 – 1.08) 0.000 1.05 (1.01 – 1.08) 0.004 
Race 
Malay 
Chinese 
Indian 
 
1.64 (0.91 – 2.95) 
1 
2.05 (1.23– 3.44) 
 
0.098 
– 
0.006 
 
1.42 (0.72 – 2.79) 
1 
1.70 (0.96 – 3.00) 
 
0.309 
– 
0.071 
Physical activity 
Low 
Moderate 
High 
 
6.15 (1.84 – 20.56) 
5.37 (1.57 – 18.38) 
1 
 
0.001 
0.003 
– 
 
4.13 (1.18 – 14.42) 
3.66 (1.01 – 13.23) 
1 
 
0.026 
0.048 
– 
Duration of diabetes mellitus 1.04 (1.02 – 1.06) 0.001 1.02 (0.99 – 1.04) 0.277 
Diagnosis of non-alcoholic fatty liver disease 1.19 (0.76 – 1.86) 0.450 – – 
Body mass index 1.03 (1.00 – 1.07) 0.038 – – 
Waist circumference 1.03 (1.01 – 1.05) 0.002 1.03 (1.00 – 1.05) 0.021 
Systolic blood pressure ≥130 mmHg 2.00 (1.21 – 3.31) 0.008 1.50 (0.86 – 2.60) 0.150 
HbA1c 1.16 (1.02 – 1.31) 0.026 1.17 (1.02 – 1.35) 0.028 
Serum alanine aminotransferase level 0.98 (0.97 – 1.00) 0.054 0.99 (0.97 – 1.00) 0.112 
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6.4 Discussion 
In this cross-sectional study of diabetic patients in our hospital clinic, 
ultrasonography-diagnosed NAFLD was not found to be associated with IHD. In a cross-
sectional study of diabetic patients, Targher et al found ultrasonography-diagnosed NAFLD 
to be associated with prevalent cardiovascular disease independent of classical risk factors, 
glycemic control, medications and metabolic syndrome features (Targher et al., 2006). We 
believe the explanation for this contrasting finding lies in important differences in the study 
populations. Although both study populations consisted of patients of similar age, patients in 
our study population had diabetes mellitus for longer durations (16.2 years vs. 11.1 years) 
with poorer control as reflected by higher serum HbA1c levels (8.1 % vs. 7.2 %) and possibly 
more advanced NAFLD. Patients with more advanced NAFLD may have increased co-
morbidities that could have limited their survival and/or attendance to clinic. This could have 
in turn resulted in their lower representation in our study population. Moreover, hepatic 
steatosis decreases as NAFLD progresses (Adams et al., 2005). Ultrasonography is good to 
detect moderate to severe but not milder hepatic steatosis (Saadeh et al., 2002). Therefore, 
NAFLD patients with more advanced disease/fibrosis may be missed on ultrasonography. 
Both of these factors would explain the lower prevalence of ultrasonography-diagnosed 
NAFLD in our study population as compared with that of Targher et al (49.6 % vs. 69.5 %) 
and the decreasing prevalence of NAFLD with advancing age in our study population (see 
Chapter 4).  
Histology-based studies have suggested that cardiovascular disease is mainly 
associated with more severe forms of NAFLD (Ekstedt et al., 2006; Soderberg et al., 2010). 
NASH is associated with a more severe inflammatory and insulin-resistant state that 
promotes atherosclerosis (Bhatia et al., 2012). On the other hand, advanced fibrosis is the 
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result of long-standing non-alcoholic steatohepatitis (NASH) and may indirectly reflect 
exposure to risk factors for cardiovascular disease. The current gold standard for assessing 
severity of NAFLD is by histopathological examination of a liver biopsy specimen. However, 
performing a liver biopsy in NAFLD patients for risk stratification of cardiovascular disease 
is not justified. A recently published study that characterized severity of NAFLD patients 
using non-invasive methods i.e. the NAFLD fibrosis score, the aspartate aminotransferase to 
platelet ratio index and FIB-4 score clearly demonstrated that those with higher probability 
of advanced fibrosis based on these scores had a significantly higher mortality that was 
almost entirely from cardiovascular causes. NAFLD as a whole was not associated with 
higher mortality (Kim et al., 2013). Controlled attenuation parameter has been shown to 
correlate well with degree of hepatic steatosis (Sasso et al., 2010) while measurement of liver 
stiffness using transient elastography has been shown to have high negative predictive value 
for advanced fibrosis (Wong et al., 2010). On the other hand, measurement of cytokeratin-
18 fragment levels in the blood has been shown to predict histological NASH (Feldstein et 
al., 2009). Use of these non-invasive methods to better characterize NAFLD patients may 
allow more accurate risk stratification for cardiovascular disease and deserves further study. 
These are further discussed in Chapter 8. 
To the best of our knowledge, there were no published study on ultrasonography-
diagnosed NAFLD and IHD among patients with diabetes mellitus from the Asian-Pacific 
region at the time that this thesis was written. There were only two studies looking at 
ultrasonography-diagnosed NAFLD and cardiovascular disease from the Asian-Pacific 
region. In a cohort study of healthy subjects, Hamaguchi et al found NAFLD to be an 
independent factor associated with incident cardiovascular disease (Hamaguchi et al., 2007). 
In a study on patients undergoing coronary angiography, Wong et al reported that NAFLD 
was associated with coronary artery disease independent of other metabolic factors (Wong et 
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al., 2011). None of the patients in the former study and only 32 % of patients in the latter 
study had diabetes mellitus. We were also able to compare data from the three major ethnic 
groups in Malaysia, namely the Malays, Indians and Chinese. The prevalence of IHD was 
found to be highest among Indians followed by Malays and Chinese, similar to previously 
reported in other studies (Danaraj et al., 1959; Lee et al., 2001). In our study, the absence of 
association between ultrasonography-diagnosed NAFLD and IHD was consistent across the 
different ethnic groups. We were also able to look at dietary intake and level of physical 
activity between diabetic patients with and without IHD. We found lower level of physical 
activity to be an independent factor associated with IHD among diabetic patients but could 
not determine causality due to cross-sectional nature of our study.   
Despite our best effort, this study has several limitations. We could not subject all 
patients without documented IHD to coronary angiography for objective assessment of IHD 
due to ethical reason. Nevertheless, we did interview and perform electrocardiography for 
each of these patients and refer those suspected to have IHD to a cardiologist for further 
evaluation so that the diagnosis of IHD would be reflective of that in real clinical practice. 
The IHD status could not be determined for 8 patients who did not attend their cardiology 
appointment. Nevertheless, subsequent analyses were found to be unaffected whether these 
patients were completely excluded or assumed to have or not to have IHD. NAFLD may 
precede by years the clinical diagnosis of ischemic heart disease. A follow-up study of our 
cohort of patients would elucidate whether ultrasonography-diagnosed NAFLD is associated 
with increased coronary event in diabetic patients with and without IHD at baseline. 
Secondly, diagnosis of fatty liver was based on ultrasonography and not histopathological 
examination of liver biopsy specimen. While the latter is more accurate to diagnose fatty 
liver, it is invasive and not feasible in our study. Retrospectively, it would have been better 
if we have used a non-invasive method e.g. transient elastography, NAFLD fibrosis score 
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etc. to detect patients with more advanced NAFLD and to see if this correlated well with 
cardiovascular disease. Lastly, dietary intake and physical activity were self-reported and 
could be subjected to bias. Nevertheless, we did use previously validated methods to capture 
the information.  
6.5 Conclusion 
Ultrasonography-diagnosed NAFLD was not found to be associated with IHD among 
long-standing poorly-controlled diabetics in a hospital clinic setting. Independent factors 
associated with IHD identified in this study were older age, lower levels of physical activity, 
greater WC and higher HbA1c levels. Better characterization of patients using non-invasive 
methods may allow more accurate risk stratification for cardiovascular disease and deserves 
further studies.  
 
 
 
 
 
 
 
Note: A poster on the findings from this study was presented at the Malaysian Society of 
Gastroenterology and Hepatology Annual Scientific Meeting in 2013. A poster on the 
findings from this study was also presented at the World Congress of Gastroenterology 2013 
in Shanghai, China, and the abstract was published in a supplementary issue of the Journal 
of Gastroenterology and Hepatology (Chan et al., 2013). The full article has been published 
in Clinics and Research in Hepatology and Gastroenterology (Chan et al., 2014).     
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Chapter 7 
Progression of liver disease in NAFLD 
7.1 Introduction 
As elucidated in Chapter 3, non-alcoholic fatty liver disease (NAFLD) has rapidly 
increased over the years and is estimated to affect up to 30 % of the general population in the 
Asian-Pacific region (Chan et al., 2013). In Malaysia, the prevalence of NAFLD in the 
general population has been estimated to be 22.7 % based on a study on individuals attending 
a health-check in a suburban medical facility (Goh et al., 2012). The prevalence of NAFLD 
among diabetics is higher and has been estimated to be 49.6 % based on a separate study on 
a hospital clinic population (Chan et al., 2013) (as presented in Chapter 4).  
NAFLD is not entirely benign. It encompasses a spectrum of liver conditions ranging 
from simple steatosis to its more severe form known as non-alcoholic steatohepatitis (NASH) 
which can lead to fibrosis and cirrhosis. In fact, NASH has been recognized as an important 
cause of cryptogenic cirrhosis (Maheshwari et al., 2006) and is associated with increased risk 
of hepatocellular carcinoma, even in patients without cirrhosis (Page et al., 2009). In a study 
on etiology of cirrhosis and association with hepatocellular carcinoma in our center, 
cryptogenic cause which is believed to be due to NASH, contributed to 15.4 % of cases of 
cirrhosis and was an independent predictor of hepatocellular carcinoma (Qua et al., 2011). 
While there have been quite a number of studies on the natural history of NAFLD, 
few utilized paired liver biopsy for evaluation of disease status. Apart from being invasive 
and is associated with a small risk of complications, liver biopsy requires technical expertise, 
from obtaining a good specimen to processing and accurately interpreting the result. 
Nevertheless, histopathological examination of liver biopsy specimen is the current best 
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standard for evaluation of NAFLD. The use of a standardized scoring system such as that by 
the NASH Clinical Research Network (NASH CRN) enables objective quantification of all 
the important components of NAFLD i.e. steatosis, lobular inflammation, hepatocyte 
ballooning and fibrosis.  
A descriptive study on a cohort of biopsy-proven NAFLD patients was conducted at 
our center between June 2003 and May 2005(Malik et al., 2007). We performed a follow-up 
study on this cohort of patients to elucidate the natural history of NAFLD and to determine 
factors associated with disease progression.  
7.2  Patients and methods 
Seventy-five NAFLD patients from the previous study were considered for inclusion 
into the current study. The patients were contacted by phone and if unsuccessful, by post, 
using information available in the hospital registry and in their medical records. When these 
measures have failed, a check was made at the National Registration Department for patient’s 
status and address. Another letter was sent if the address was different from that earlier 
available. Patients who agreed for a repeat liver biopsy were included into the current study. 
For patients who have died, the cause of death was ascertained at the National Registration 
Department. The study was approved by the University of Malaya Medical Centre’s Medical 
Ethics Committee and all patients who participated provided informed consent. 
Demographic and anthropometric data and relevant clinical and laboratory data at 
baseline were retrieved from the database of the earlier study. The follow-up study was 
conducted between October 2009 and June 2010. Corresponding data were obtained using a 
standard protocol during the follow-up study. Alcohol intake was estimated using the 
quantity-frequency method (Goddard, 2007). Significant alcohol intake was defined as more 
than 21 units per week for men and more than 14 units per week for women (Chalasani et al., 
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2012). Weight and height were measured using standardized equipment. Body mass index 
(BMI) was calculated by dividing weight in kilogram by the square of height in meters. 
Patients with BMI ≥ 25.0 kg per m2 were considered obese (Anuurad et al., 2003). Waist 
circumference (WC) was measured at the mid-point between the lowest margin of the least 
palpable rib and the top of the iliac crest in the standing position. Central obesity was defined 
as WC > 90 cm for men and > 80 cm for women (Alberti et al., 2005). Blood pressure was 
measured in the sitting position using standardized equipment.  A patient was considered 
hypertensive if there was a self-reported history of hypertension, if the patient was on anti-
hypertensive medication(s), if the systolic blood pressure was ≥ 130 mmHg, or if the diastolic 
blood pressure was ≥ 85 mmHg.  
All patients had venous blood drawn after an overnight fast for blood sugar, glycated 
hemoglobin (HbA1c), lipid profile, liver profile and tests for viral hepatitis B and C infection. 
Biochemical measurements were performed using standard laboratory procedures. A patient 
was considered to have diabetes mellitus if there was a self-reported history of diabetes 
mellitus or if the patient was on anti-diabetic medication(s). Patients who were not known to 
have diabetes mellitus were subjected to an oral glucose tolerance test. Patients were 
diagnosed to have diabetes mellitus if the fasting blood sugar was ≥ 7.0 mmol/L or if the 2-
hour post-glucose challenge blood sugar was ≥ 11.1 mmol/L. Impaired fasting glucose was 
defined as fasting blood sugar ≥ 6.1 mmol/L but < 7.0 mmol/L while impaired glucose 
tolerance was defined as 2-hour post-glucose challenge ≥ 7.8 mmol/L but < 11.1 mmol/L. A 
patient was considered to have dyslipidemia if there was a self-reported history of 
dyslipidemia, if the patient was on lipid-lowering medication(s), if the serum total cholesterol 
(TC) was ≥ 5.2 mmol/L, if the serum triglyceride (TG) was ≥ 1.7 mmol/L, if the serum high-
density lipoprotein (HDL) was < 1.0 mmol/L for men or < 1.3 mmol/L for women, or if the 
serum low-density lipoprotein (LDL) was ≥ 3.4 mmol/L. A patient was considered to have 
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metabolic syndrome if three or more of the following were present: impaired fasting 
glucose/impaired glucose tolerance/diabetes mellitus, central obesity, hypertension, 
hypertriglyceridemia and low serum HDL (according to the aforementioned cut-offs) 
(Alberti et al., 2009). Our laboratory’s upper limit of normal for liver enzymes were as 
follows: alkaline phosphatase (ALP) 136 IU/L, aspartate aminotransferase (AST) 37 IU/L, 
alanine aminotransferase (ALT) 65 IU/L and gamma-glutamyl transpeptidase (GGT) 55 
IU/L.  Serum ALP, AST, ALT and GGT above these levels were considered as elevated. The 
Elecsys HBsAg II assay and the Elecsys Anti-HCV II assay (Roche, Mannheim, Germany) 
were used to test for viral hepatitis B and C infection, respectively.  
Liver biopsy and histopathological assessment 
Liver biopsies were performed using 18 G Terumo liver biopsy needle. Liver biopsy 
specimens were processed using standard laboratory procedures. Liver biopsy slides were 
stained with hematoxylin and eosin stain and masson trichrome stain. Paired liver biopsy 
slides were examined by an experienced histopathologist (PLC) who was blinded to clinical 
data and order of liver biopsy slides. Histopathological findings were reported according to 
the NASH CRN scoring system (Kleiner et al., 2005). The NAFLD activity score (NAS) is 
the sum of scores for hepatic steatosis (0 – 3), lobular inflammation (0 – 3) and hepatocyte 
ballooning (0 – 2). NAS 0 – 2 is not diagnostic of NASH, 3 – 4 is borderline NASH and 5 – 
8 is definite NASH. Fibrosis was staged 0 – 4 (0 = no fibrosis, 1 = mild fibrosis, 2 = moderate 
fibrosis, 3 = severe fibrosis, 4 = cirrhosis). Typical histological findings are shown in Figures 
7.1a and 7.1b. 
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Figure 7.1a Hematoxylin and eosin staining shows a constellation of steatosis, 
inflammation and ballooning in a case of NAFLD 
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Figure 7.1b Masson trichrome highlighting the fibrosis  
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Statistical analysis 
Data were analyzed using SPSS 15.0. Continuous variables were expressed as mean 
± standard deviation or median (inter-quartile range), and analyzed using unpaired student’s 
t-test or Mann-Whitney U test, as appropriate. Changes in continuous variables were 
analyzed using paired student’s t-test or Wilcoxon rank-sum test, as appropriate. Categorical 
variables were expressed as percentage and analyzed using chi-square test or Fisher exact 
test, as appropriate. Univariate and multivariate analyses were performed to identify factors 
associated with worsened NAS and fibrosis. Significance was assumed when p < 0.05. 
7.3 Results 
Patient characteristics 
Thirty-nine patients agreed for repeat liver biopsy (Figure 7.2). However, slides for 
the initial liver biopsy were missing for 4 patients. Hence, paired liver biopsies were available 
for 35 patients and data for these patients were analyzed. Mean age of the patients at baseline 
was 47.5 ± 10.9 years old and consisted of 40.0 % male. None of the patients had significant 
alcohol intake. At baseline, 62.9 % of patients had metabolic syndrome. Obesity and central 
obesity was present in 74.3 % and 85.7 %, respectively. Dyslipidemia, diabetes mellitus and 
hypertension was present in 97.1 %, 54.3 % and 31.4 %, respectively. At follow-up, 94.3 % 
of patients had metabolic syndrome. One patient developed obesity but the prevalence of 
central obesity remained unchanged. The prevalence of diabetes mellitus and hypertension 
increased to 80.0 % and 68.6 %, respectively, while the prevalence of dyslipidemia remained 
unchanged. Mean interval between the paired liver biopsies was 6.4 ± 0.8 years. Mean 
number of portal tracts for the initial and repeat liver biopsy was 8.6 ± 4.4 and 6.6 ± 4.6, 
respectively. 
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Figure 7.2 Flow chart detailing patients from the original cohort who were included/excluded from the current study 
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Changes in NAS and associated factors 
At baseline, 1 patient had simple steatosis, 11 patients had probable NASH while 23 
patients had definite NASH. At follow-up, 12 patients had probable NASH while 23 patients 
had definite NASH. NAS worsened in 13 patients, remained unchanged in 9 patients and 
improved in 13 patients. Distribution of NAS at baseline and at follow-up is shown in Table 
7.1. Characteristics of patients with worsened, and unchanged or improved NAS are shown 
in Table 7.2. Although patients with worsened NAS had significantly lower BMI and WC at 
baseline and at follow-up, there was no significant change in BMI and WC between baseline 
and follow-up in both groups of patients. Metformin use was significantly higher among 
patients with unchanged or improved NAS. Patients with worsened NAS had significantly 
lower HbA1c at baseline but showed a significant increase in HbA1c so that there was no 
longer a significant difference in both groups during follow-up. Patients with unchanged or 
improved NAS had significant decrease in TC, TG, ALP, ALT, AST and GGT so that these 
variables were significantly lower at follow-up compared to patients with worsened NAS.  
Elevated serum ALT, AST and GGT levels was seen in 53.8 %, 69.2 % and 92.3 % 
of patients with worsened NAS at follow-up compared to only 13.6 %, 13.6 % and 31.8 % 
of patients with unchanged or improved NAS.  On univariate analysis, elevated serum ALT, 
AST and GGT levels at follow-up were associated with worsened NAS. On multivariate 
analysis, only elevated serum AST and GGT levels were associated with worsened NAS 
(Table 7.3).     
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Table 7.1 Distribution of NAS at baseline and at follow-up 
  NAS at follow-up 
0 – 2  3 – 4 5 – 8 Total 
NAS at 
baseline 
0 – 2 0 1 0 1 
3 – 4 0 3 8 11 
5 – 8 0 8 15 23 
Total 0 12 23 35 
 
NAS = non-alcoholic fatty liver disease activity score 
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Table 7.2 Characteristics of patients with worsened NAS and patients with unchanged or improved NAS 
 Patients with worsened NAS 
n = 13 
Patients with unchanged or improved NAS 
n = 22 
Baseline Follow-up p Baseline Follow-up p 
Age, years 44.1 ± 12.0  –  – 50.5 ± 12.0 – – 
Male 46.2 – – 36.4 – – 
Ethnicity 
Malay 
Chinese 
Indian 
 
69.2 
23.1 
7.7 
 
– 
– 
– 
 
– 
– 
– 
 
45.5 
27.3 
27.3 
 
– 
– 
– 
 
– 
– 
– 
Anthropometry 
BMI, kg per m2 †, ‡ 
WC, cm †, ‡ 
 
25.1 ± 3.6 
87.4 ± 8.5 
 
25.7 ± 5.1 
88.5 ± 11.9  
 
NS 
NS 
 
29.2 ± 4.6 
95.5 ± 10.4 
 
29.0 ± 3.9 
96.5 ± 9.3 
 
NS 
NS 
Glycemic profile 
FBS, mmol/L 
HbA1c, % † 
 
5.3 (5.0 – 6.0) 
5.47 (5.26 – 6.07) 
 
6.0 (5.1 – 7.8) 
7.12 (6.30 – 7.83) 
 
NS 
0.018 
 
5.9 (5.3 – 7.3) 
6.31 (5.94 – 7.46) 
 
6.6 (5.4 – 7.6) 
7.10 (6.08 – 8.35) 
 
NS 
NS 
Lipid profile 
TC, mmol/L ‡ 
HDL, mmol/L 
LDL, mmol/L  
TG, mmol/L ‡ 
 
5.9 (5.7 – 6.7) 
1.1 (1.0 – 1.4) 
3.9 (3.6 – 4.2) 
1.9 (1.2 – 2.9) 
 
5.0 (4.7 – 6.0) 
1.2 (1.0 – 1.6) 
3.0 (1.9 – 3.7) 
2.0 (1.4 – 2.7) 
 
NS 
NS 
NS 
NS 
 
5.7 (5.1 – 6.3) 
1.3 (1.1 – 1.6) 
3.3 (2.9 – 4.3) 
1.8 (1.2 – 2.4) 
 
4.4 (3.8 – 4.8) 
1.2 (1.1 – 1.5) 
2.4 (1.8 – 2.7) 
1.2 (1.0 – 1.7) 
 
< 0.001 
NS 
< 0.001 
0.049 
Liver profile 
ALP, IU/L ‡ 
ALT, IU/L § 
AST, IU/L § 
GGT, IU/L § 
 
83 (79 – 117) 
92 (79 – 115) 
44 (38 – 59) 
88 (72 – 275) 
 
86 (76 – 113) 
67 (41 – 208) 
45 (24 – 129) 
98 (61 – 320) 
 
NS 
NS 
NS 
NS 
 
84 (66 – 95) 
109 (71 – 132) 
50 (35 – 71) 
78 (50 – 158) 
 
56 (39 – 90) 
40 (31 – 52) 
26 (18 – 31) 
35 (28 – 95) 
 
0.014 
< 0.001 
< 0.001 
0.009 
Interval between paired 
liver biopsies, years 
– 6.3 ± 0.6 – – 6.5 ± 0.9 – 
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 Patients with worsened NAS 
n = 13 
Patients with unchanged or improved NAS 
n = 22 
Baseline Follow-up p Baseline Follow-up p 
Number of portal tracts 8.6 ± 4.8 7.3 ± 4.8 NS 8.6 ± 4.3 6.2 ± 4.5 NS 
 
† p < 0.05 comparing patients with worsened NAS and patients with unchanged or improved NAS at baseline  
‡ p < 0.05 comparing patients with worsened NAS and patients with unchanged or improved NAS at follow-up 
§ p < 0.01 comparing patients with worsened NAS and patients with unchanged or improved NAS at follow-up 
NAS = non-alcoholic fatty liver disease activity score, BMI = body mass index, WC = waist circumference, FBS = fasting blood sugar, TC = 
total cholesterol, TG = triglyceride, HDL = high-density lipoprotein, LDL = low-density lipoprotein, ALP = alkaline phosphatase, ALT = 
alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma glutamyl transpeptidase  
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Table 7.3 Univariate and multivariate analysis of factors associated with worsened NAS 
 OR (95 % CI) p OR (95 % CI) p 
Age 1.05 (0.98 – 1.12) 0.155 1.03 (0.93 – 1.13) 0.609 
Male gender 1.50 (0.37 – 6.05) 0.569 1.45 (0.16 – 12.85) 0.738 
Elevated serum ALT level at follow-up 7.39 (1.44 – 37.88) 0.016 0.83 (0.08 – 8.80) 0.876 
Elevated serum AST level at follow-up 14.25( 2.62 – 77.54) 0.002 10.74 (1.00 – 115.86) 0.050 
Elevated serum GGT at follow-up 25.71 (2.77 – 238.79) 0.004 16.10 (1.30 – 198.90) 0.030 
 
NAS = non-alcoholic fatty liver disease activity score, ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma 
glutamyl transpeptidase 
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Changes in fibrosis and associated factors 
Distribution of fibrosis stage at baseline and at follow-up is as shown in Table 7.4. 
Fibrosis stage worsened in 18 patients and remained unchanged in 17 patients. None of the 
patients had improvement in fibrosis stage. Nearly two thirds of patients without significant 
fibrosis (F0/F1) at baseline developed significant fibrosis (F ≥ 2) at follow-up. Two patients 
developed cirrhosis at follow-up. Characteristics of patients with worsened fibrosis and 
patients with unchanged fibrosis are shown in Table 7.5. Patients with worsened fibrosis had 
lower FBS and HbA1c compared to patients with unchanged fibrosis but the difference was 
only significant for FBS at baseline and HbA1c at follow-up. Both groups of patients had 
increase in FBS and HbA1c at follow-up but the increase was only significant for HbA1c for 
patients with worsened fibrosis. Both groups of patients had significant improvement in TC, 
LDL and ALT. However, there was no significant difference in these parameters between 
the groups at baseline and at follow-up. Overall, no plausible factors were found to be 
associated with worsened fibrosis. 
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Table 7.4 Distribution of fibrosis stage at baseline and at follow-up 
  Follow-up 
F0 F1 F2 F3 F4 Total 
Baseline F0 0 0 1 0 0 1 
F1 0 6 7 1 1 15 
F2 0 0 7 7 0 14 
F3 0 0 0 3 1 4 
F4 0 0 0 0 1 1 
Total 0 6 15 11 3 35 
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Table 7.5 Characteristics of patients with worsened fibrosis and patients with unchanged fibrosis  
 Patients with worsened fibrosis 
n = 13 
Patients with unchanged fibrosis 
n = 22 
Baseline Follow-up p Baseline Follow-up p 
Age, years 48.3 ± 11.8  –  – 46.7 ± 10.2 – – 
Male 38.9 – – 41.2 – – 
Ethnicity 
Malay 
Chinese 
Indian 
 
44.4 
27.8 
27.8 
 
– 
– 
– 
 
– 
– 
– 
 
64.7 
23.5 
11.8 
 
– 
– 
– 
 
– 
– 
– 
Anthropometry 
BMI, kg per m2  
WC, cm  
 
27.1 ± 3.1 
90.4 ± 7.3 
 
27.5 ± 4.2 
92.2 ± 10.5  
 
NS 
NS 
 
28.3 ± 5.9 
94.7 ± 12.7 
 
28.0 ± 5.1 
94.9 ± 11.4 
 
NS 
NS 
Glycemic profile 
FBS, mmol/L † 
HbA1c, % § 
 
5.5 (5.0 – 5.9) 
5.98 (5.60 – 6.34) 
 
5.8 (4.8 – 7.1) 
6.30 (6.00 – 7.11) 
 
NS 
0.028 
 
6.4 (5.2 – 8.6) 
6.24 (5.46 – 8.74) 
 
7.3 (5.7 – 8.2) 
7.40 (7.10 – 9.18) 
 
NS 
NS 
Lipid profile 
TC, mmol/L  
HDL, mmol/L 
LDL, mmol/L  
TG, mmol/L  
 
5.8 (5.1 – 6.3) 
1.3 (1.0 – 1.6) 
3.6 (3.0 – 4.1) 
2.0 (1.2 – 2.7) 
 
4.7 (3.8 – 5.2) 
1.2 (1.1 – 1.7) 
2.4 (1.9 – 2.8) 
1.6 (0.9 – 2.6) 
 
0.004 
NS 
0.003 
NS 
 
6.0 (5.3 – 7.0) 
1.2 (1.0 – 1.5) 
3.8 (3.3 – 4.7) 
1.7 (1.1 – 2.3) 
 
4.6 (3.9 – 4.9) 
1.2 (1.0 – 1.4) 
2.6 (1.8 – 3.1) 
1.6 (1.1 – 1.9) 
 
0.004 
NS 
0.004 
NS 
Liver profile 
ALP, IU/L  
ALT, IU/L  
AST, IU/L  
GGT, IU/L  
 
86 (79 – 102) 
94 (78 – 144) 
50 (38 – 70) 
85 (66 – 199) 
 
83 (56 – 90) 
45 (37 – 81) 
30 (23 – 40) 
69 (32 – 191) 
 
NS 
0.028 
NS 
NS 
 
83 (70 – 95) 
104 (74 – 118) 
45 (34 – 70) 
76 (51 – 142) 
 
76 (38 – 103) 
49 (33 – 69) 
27 (19 – 45) 
57 (31 – 93) 
 
NS 
0.018 
NS 
NS 
Interval between paired liver 
biopsies, years 
– 6.5 ± 0.8 – – 6.3 ± 0.9 – 
Number of portal tracts ‡  6.1 ± 2.9 7.2 ± 5.5 NS 11.3 ± 4.3 6.0 ± 3.4 0.001 
 
 99 
 
† p < 0.05 comparing patients with worsened fibrosis and patients with unchanged fibrosis at baseline  
‡ p < 0.01 comparing patients with worsened fibrosis and patients with unchanged fibrosis at baseline  
§ p < 0.05 comparing patients with worsened fibrosis and patients with unchanged fibrosis at follow-up 
NAS = non-alcoholic fatty liver disease activity score, BMI = body mass index, WC = waist circumference, FBS = fasting blood sugar, TC = 
total cholesterol, TG = triglyceride, HDL = high-density lipoprotein, LDL = low-density lipoprotein, ALP = alkaline phosphatase, ALT = 
alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma glutamyl transpeptidase  
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Baseline NAS and changes in NAS and overall histology 
The patient with simple steatosis at baseline developed probable NASH but had 
no change in fibrosis stage at follow-up. Of the 11 patients with probable NASH at 
baseline, 8 patients developed definite NASH while 3 patients continued to have probable 
NASH at follow-up. NAS worsened in 8 patients (72.7 %) and remained unchanged in 3 
patients (27.3 %). Fibrosis stage worsened in 6 patients (54.5 %), occurring in 5 patients 
(62.5 %) with worsened NAS and 1 patient (33.3 %) with unchanged NAS. Of the 23 
patients with definite NASH at baseline, 8 patients had probable NASH while 15 patients 
continued to have definite NASH at follow-up. NAS worsened in 4 patients (17.4 %), 
remained unchanged in 6 patients (26.1 %) and improved in 13 patients (56.5 %). Fibrosis 
stage worsened in 11 patients (47.8%), occurring in 2 patients with worsened NAS (50.0. 
%), 2 patients with unchanged NAS (33.3 %) and 7 patients with improved NAS (53.8 
%). Patients with borderline NASH at baseline were significantly more likely to have 
worsened NAS at follow-up compared to patients with definite NASH (OR = 12.67, 95 
% CI = 2.29 – 70.02, p = 0.004). However, both groups of patients had similar likelihood 
of having worsened fibrosis stage at follow-up.  
Three of the six patients who were found to have cirrhosis on histological 
examination of liver biopsy specimen in the previous study developed decompensated 
cirrhosis. All three patients had esophageal varices and ascites. Two of these patients had 
hepatic encephalopathy. Three other patients from the initial cohort have died due to 
carcinoma of colon, myocardial infarction and hepatocellular carcinoma, respectively.  
7.4 Discussion 
 The largest prospective longitudinal study of NAFLD patients with paired liver 
biopsy in the Asian-Pacific to date is that by Wong and colleagues (Wong et al., 2010). 
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Of the 52 patients in the study, 13 patients had simple steatosis, 22 patients had borderline 
NASH and 17 patients had NASH at baseline. After 3 years, fibrosis stage had worsened 
in 14 patients (27 %), remained unchanged in 25 patients (48 %) and improved in 13 
patients (25 %). In comparison, fibrosis stage had worsened in 18 patients (51.4 %) and 
remained unchanged in 17 patients (48.6 %) in our study. None of the patients in our 
study had improvement in fibrosis stage. This difference may be due to the substantial 
proportion of patients with simple steatosis and the shorter duration of follow-up in the 
study by Wong and colleagues. Moreover, none of the patients in our study were on 
specific interventions with nearly half of the patients lost to follow-up subsequent to the 
initial liver biopsy. Following the diagnosis of NASH, our patients were only given 
general advice on diet and encouraged to exercise and lose weight which was the standard 
of care at that time. In addition, nearly half of the patients were lost to follow-up 
subsequent to the initial liver biopsy. Longitudinal data for such patients would be 
increasingly rare with more and more intervention trials targeting these patients.  
The study by Hui and colleagues (Hui et al., 2005), which is the first and only 
other longitudinal study on NAFLD patients with paired liver biopsy in the Asian-Pacific 
till date, similarly found that none of their patients had improvement in fibrosis stage 
while 53 % had worsened fibrosis stage over a median follow-up of 6.1 years. Of the 17 
patients in the study, only 3 patients had steatosis alone while the remainder had 
necroinflammation at baseline. A systematic review summarized longitudinal studies of 
NAFLD patients with paired liver biopsy but most of these studies consisted of Caucasian 
patients and small number of subjects (Argo et al., 2009).      
Findings from our study of a cohort of mostly NASH patients show that a 
substantial proportion of NASH patients undergo significant progression and suggest that 
fibrosis is irreversible without specific interventions. Hence, it is important that all 
patients diagnosed with NASH be considered for specific interventions to prevent disease 
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progression. While many studies have shown lifestyle interventions i.e. dietary 
restrictions, exercise and weight loss to be effective in NASH (Thoma et al., 2012), these 
measures are difficult to implement in practice. Pioglitazone and vitamin E have been 
shown useful in NASH but specific concerns have limited their use (Sanyal et al., 2010). 
Until a safe and effective drug becomes available, NASH patients may be considered for 
interventional trials where these are available.         
 We found that greater baseline BMI and WC did not predict worsening of NAS. 
Although patients with worsened NAS had significantly lower BMI and WC at baseline, 
there was a trend towards increasing BMI and WC among these patients. On the other 
hand, patients with unchanged or improved NAS had a trend towards decreasing BMI. In 
their study, Wong and colleagues showed that reduction in BMI and WC was 
independently associated with non-progressive disease activity and fibrosis (Wong et al., 
2010). Therefore, NAFLD patients with greater BMI and WC should not be discouraged 
to undergo lifestyle interventions. Patients with worsened NAS had significant increase 
in serum HbA1c level at follow-up, reflecting poorer control of diabetes mellitus with 
increasing severity of liver disease. An excellent review on the intricate relationship 
between diabetes mellitus and liver disease can be found elsewhere (Moscatiello et al., 
2007). We also found that patients with unchanged or improved NAS have significant 
decrease and normalization of serum ALP, ALT, AST and GGT levels at follow-up. 
Patients with elevated serum AST and GGT at follow-up were more likely to have 
worsened NAS. Therefore, NAFLD patients with persistently elevated serum AST and 
GGT levels during follow-up should be suspected of having worsened NAS.  
Three of the six patients who were incidentally found to have cirrhosis on 
histology in the previous study have progressed to decompensated cirrhosis while 3 other 
patients have died due to carcinoma of colon, myocardial infarction and hepatocellular 
carcinoma, respectively. Patients with NAFLD have been shown to have lower survival 
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with higher rate of liver-related morbidity and mortality compared to the general 
population (Adams et al., 2005). Malignancy and cardiovascular diseases were shown to 
be the leading causes of death followed by liver-related complications in NAFLD 
patients. Although progressive disease is mainly associated with NASH, patients with 
simple steatosis should also be followed as they too may develop NASH and progressive 
disease as clearly reported by Wong and colleagues (Wong et al., 2010). 
This study had several limitations. First, we were not able to perform repeat liver 
biopsy for all patients from the original cohort as some patients were not contactable 
while others were not willing due to the invasive nature of the procedure. However, 
patients who had the repeat liver biopsy and who were included in our analysis were well 
characterized. Baseline and follow-up data were prospectively captured during the 
previous and current study, and were therefore complete and robust. Second, the analysis 
of factors associated with worsened NAS and fibrosis may be limited by the sample size. 
However, this is considered a fairly large number of subjects for a longitudinal study of 
NAFLD patients with paired liver biopsy. Moreover, we did identify some interesting 
associations in our analysis. Third, histopathological examination of liver biopsy 
specimen may be limited by sampling variability as the liver biopsy specimen only 
represents approximately 1 in 50000 of the total liver volume (Ratziu et al., 2005). 
However, until more accurate methods become available, histopathological examination 
of liver biopsy specimen remains the best standard for evaluation of NAFLD status.  
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7.5  Conclusion  
 NAFLD patients with persistently elevated serum AST and GGT levels during 
follow-up should be suspected of having worsened NAS. NASH patients can undergo 
significant disease progression over a relatively short period of time and fibrosis is 
irreversible without specific interventions. Hence, it is important that all patients 
diagnosed with NASH be considered for specific interventions to prevent disease 
progression. 
 
 
 
 
 
 
 
 
 
 
 
 
Note: A poster on the findings from this study was presented at the Asia-Pacific Digestive 
Week 2012 in Bangkok, Thailand, and the abstract was published in a supplementary 
issue of the Journal of Gastroenterology and Hepatology (Chan  et al., 2012). The findings 
from this study was also presented at the Malaysian Society of Gastroenterology and 
Hepatology Annual Scientific Meeting in 2013 and won the Best Paper Award. The full 
article has been published in the Journal of Digestive Diseases (Chan et al., 2014).        
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Chapter 8 
Non-Invasive Assessment of NAFLD 
8.1 Introduction 
The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased 
rapidly over the years parallel to the increase in metabolic syndrome and it is recognized 
as one of the most common causes of chronic liver disease worldwide (Chan et al., 2013). 
NAFLD encompasses a spectrum of liver conditions, ranging from benign steatosis to 
non-alcoholic steatohepatitis (NASH) to fibrosis and cirrhosis (Ekstedt et al., 2006). 
NASH has been recognized as an important cause of cryptogenic cirrhosis (Maheshwari 
et al., 2006) and is associated with an increased risk of hepatocellular carcinoma, even in 
patients without cirrhosis (Page et al., 2009). In a study on etiology of cirrhosis and 
association with hepatocellular carcinoma in our centre, cryptogenic cause which is 
believed to be due to NASH, contributed to 15.4 % of cases of cirrhosis and was an 
independent predictor of hepatocellular carcinoma (Qua et al., 2011).  
Ultrasonography is by far the most common method used to diagnose fatty liver 
in clinical practice and in epidemiological studies. However, ultrasonography is accurate 
only when fatty liver is moderate to severe (Saadeh et al., 2002). Moreover, 
ultrasonography is not able to distinguish NASH from simple steatosis and to assess the 
severity of fibrosis. Both factors carry important prognostic implications in NAFLD 
patients. Histopathological examination of a liver biopsy specimen is the current best 
standard for assessment of NAFLD. It confirms the diagnosis and helps exclude other 
causes of liver disease in some cases. It also distinguishes NASH from simple steatosis 
and allows assessment of the severity of fibrosis. However, liver biopsy is invasive and 
associated with a small risk of complications. It may also be limited by sampling 
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variability (Ratziu et al., 2005) and intra- and inter-observer variability (Younossi et al., 
1998).    
In this chapter, findings from studies on several non-invasive methods for 
assessment of NAFLD are presented and discussed, namely the use of controlled 
attenuation parameter (CAP) for the detection and quantification of hepatic steatosis, 
plasma cytokeratin-18 fragment level for the diagnosis of NASH, and NAFLD fibrosis 
score and liver stiffness measurement for the estimation of hepatic fibrosis.  
8.2 CAP for the detection and quantification of hepatic steatosis  
Recently, a novel technology called transient elastography has been used to 
estimate liver stiffness, which has been shown to correlate well with histopathological 
fibrosis stage. This has allowed non-invasive and accurate estimation of fibrosis stage in 
NAFLD patients (Yoneda et al., 2007). The decrease in amplitude of ultrasound as it is 
propagated through the liver tissue can be estimated using the same radio-frequency data 
that is used for estimation of liver stiffness using Fibroscan (Echosens, Paris, France), an 
ultrasound-based vibration-controlled transient elastography device. This is called 
controlled attenuation parameter (CAP) and it has been suggested to correlate well with 
hepatic steatosis (Sasso et al., 2010). Several publications have explored CAP for 
estimation of hepatic steatosis in patients with chronic liver disease (Chon et al., 2013; de 
Ledinghen et al., 2012; Kumar et al., 2013; Masaki et al., 2013; Myers et al., 2012; Sasso 
et al., 2012). All of these studies were on patients with chronic liver disease of various 
etiologies with limited number of NAFLD patients, except one study which consisted of 
a homogeneous cohort of chronic hepatitis C patients (Sasso et al., 2012). We conducted 
a prospective study to evaluate the diagnostic performance of CAP in estimation of 
hepatic steatosis specifically in NAFLD patients.  
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8.2.1 Methods 
Consecutive adult patients (aged ≥ 18 years) with NAFLD who were scheduled 
for a liver biopsy were prospectively recruited between November 2012 and October 
2013 for this study. The diagnosis of NAFLD was based on ultrasonography finding of 
fatty liver and exclusion of significant alcohol intake, use of medications that can cause 
fatty liver, viral hepatitis B and C infection, and other causes of chronic liver disease 
where indicated (Chalasani et al., 2012). An additional 60 subjects who did not have signs 
of fatty liver on ultrasonography were recruited as controls. Percutaneous liver biopsy 
was not performed for controls due to ethical considerations but all other relevant data 
were obtained. This study was approved by the University of Malaya Medical Centre’s 
Ethics Committee and all patients who participated provided informed consent. 
Demographic, anthropometric, relevant clinical and laboratory data were obtained 
using a standard protocol on the day of the liver biopsy procedure. Weight and height 
were measured using standard equipment. Body mass index (BMI) was calculated by 
dividing weight in kilogram by the square of height in meters. Subjects with BMI ≥ 25.0 
kg per m2 were considered obese (Anuurad et al., 2003). Waist circumference (WC) was 
measured at the mid-point between the lowest margin of the least palpable rib and the top 
of the iliac crest in the standing position. Central obesity was defined as WC > 90 cm for 
men and > 80 cm for women (Alberti et al., 2005). Blood pressure was measured in the 
sitting position using standardized equipment.  A subject was considered hypertensive if 
there was a self-reported history of hypertension, if the subject was on anti-hypertensive 
medication(s), if the systolic blood pressure was ≥ 130 mmHg, or if the diastolic blood 
pressure was ≥ 85 mmHg.  
All subjects had venous blood drawn after an overnight fast for complete blood 
count, blood glucose, glycated hemoglobin (HbA1c), lipid profile, liver profile and tests 
for viral hepatitis B and C infection. Biochemical measurements were performed using 
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standard laboratory procedures. A subject was considered to have diabetes mellitus if 
there was a self-reported history of diabetes mellitus, if the subject was on anti-diabetic 
medication(s), or if fasting blood sugar (FBS) was ≥ 7.0 mmol/L. A subject was 
considered to have dyslipidemia if there was a self-reported history of dyslipidemia, if 
the subject was on lipid-lowering medication(s), if the serum total cholesterol (TC) was 
≥ 5.2 mmol/L, if the serum triglyceride (TG) was ≥ 1.7 mmol/L, if the serum high-density 
lipoprotein (HDL) was < 1.0 mmol/L for men or < 1.3 mmol/L for women, or if the serum 
low-density lipoprotein (LDL) was ≥ 3.4 mmol/L. The Elecsys HBsAg II assay and the 
Elecsys Anti-HCV II assay (Roche, Mannheim, Germany) were used to test for viral 
hepatitis B and C infection, respectively. 
Liver biopsy and histological assessment  
Ultrasonography-guided percutaneous liver biopsy was performed by either one 
of two experienced operators (WKC, SM) using 18 G Temno ® II semi-automatic biopsy 
needle (Cardinal Health, Dublin, Ohio, USA) (Figure 8.1). Liver biopsy slides were 
stained with hematoxylin and eosin stain and masson trichrome stain. Liver biopsy slides 
were examined by an experienced histopathologist (NRNM) who was blinded to clinical 
data. Histopathological findings were reported according to the Non-Alcoholic 
Steatohepatitis Clinical Research Network Scoring System (Kleiner et al., 2005). The 
NAFLD activity score (NAS) is the sum of scores for hepatic steatosis (0 – 3), lobular 
inflammation (0 – 3) and hepatocyte ballooning (0 – 2). NAS 0 – 2 is not diagnostic of 
NASH, 3 – 4 is borderline NASH and 5 – 8 is definite NASH. Hepatic steatosis were 
graded as follows: S0 = steatosis < 5 %, S1 = steatosis 5 % – 33 %, S2 = steatosis 33 % 
– 66 %, and S3 = steatosis > 66 % (Figure 8.2a – d). Steatosis was considered significant 
at a grade of ≥ S1. Fibrosis was staged 0 – 4 (0 = no fibrosis, 1 = mild fibrosis, 2 = 
moderate fibrosis, 3 = severe fibrosis, 4 = cirrhosis).  
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Figure 8.1 (clockwise from left): Ultrasound-guided percutaneous liver biopsy; 
ultrasound image showing the echogenic liver biopsy needle within the liver 
parenchyma; a liver biopsy specimen placed in a container containing formalin. 
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Figure 8.2a Steatosis grade S0. 
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Figure 8.2b Steatosis grade S1. 
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Figure 8.2c Steatosis grade S2 
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Figure 8.2d Steatosis grade S3 
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Transient elastography 
Transient elastography was performed by either one of two experienced operators 
(WKC, SM) using Fibroscan 502 Touch with M probe (EchoSens, Paris, France) on the 
same day of the liver biopsy procedure (Figure 8.3). Ten measurements were obtained 
for each patient. Adequate pressure of the probe on the skin surface, good layering on TM 
mode and a straight imaginary line on A mode were ensured for each measurement. An 
examination was considered successful when valid measurements were ≥ 80 % and 
IQR/median for liver stiffness estimation was ≤ 30 %. Subjects with unsuccessful 
examination were excluded from analysis. 
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Figure 8.3 Transient elastography using Fibroscan 502 Touch with M probe  
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Statistical analysis 
Data were analyzed using SPSS 15.0. Continuous variables were expressed as 
mean ± standard deviation or median (interquartile range) as appropriate. Categorical 
variables were expressed as percentages. Simple (i.e. univariate) and multiple (i.e. 
multivariate) linear regression analyses were performed to identify factors associated with 
CAP. Boxplots were used to show the distribution of CAP according to grades of 
steatosis, lobular inflammation and ballooning, and stages of fibrosis. CAP values for 
different groups were compared using Mann-Whitney U test and Kruskal-Wallis test. 
Univariate and multivariate logistic regression analyses were performed to identify 
factors associated with significant hepatic steatosis. Significance was assumed when p < 
0.05. 
The performance of CAP for diagnosis of hepatic steatosis was determined using 
areas under receiver operating characteristics curves (AUROC). AUROCs were 
interpreted as follows: 0.90 – 1.00 = excellent, 0.80 – 0.90 = good, 0.70 – 0.80 = fair, < 
0.70 = poor. Optimal cut-off values for CAP for diagnosis of hepatic steatosis were the 
values that provided the greatest sum of sensitivity and specificity. The sensitivity, 
specificity, positive predictive value and negative predictive value using the optimal cut-
off values were determined. For the purposes of analysis, all controls were regarded as 
having steatosis grade S0.  
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8.2.2 Results 
Patient and control characteristics 
A total of 105 NAFLD patients had liver biopsy during the study period. Four 
patients were excluded as transient elastography was unsuccessful. Data for 101 patients 
were analyzed. The mean age was 50.3 ± 11.3 years old and consisted of 51.5 % male. 
Ninety seven (87.1 %) patients were obese. Eight patients had 1 invalid transient 
elastography measurement before 10 valid measurements were successfully obtained i.e. 
success rate 91 %. All other patients had 10 consecutive valid measurements. The 
frequency of various steatosis grades were as follows: S0 = 63 (60 controls and 3 patients 
with liver biopsy), S1 = 33, S2 = 51, S3 = 14. Patient and control characteristics are shown 
in Table 8.1.  
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Table 8.1 Characteristics of non-NAFLD controls and NAFLD patients  
 Non-NAFLD controls 
n = 60 
NAFLD patients 
n = 101 
Age, years 24.1 ± 0.9 50.3 ± 11.3 
Male, % 36.7 51.5 
Body mass index, kg per m2  20.8 ± 3.4 29.4 ± 3.9  
Obesity, % 6.7 87.1 
Waist circumference, cm 71.7 ± 9.2 97.7 ± 9.5 
Central obesity, % 8.3 96.0 
Diabetes mellitus, % 0 52.5 
Hypertension, % 15.0 88.1 
Dyslipidemia, % 31.7 95.0 
Fasting blood glucose, mmol/L 4.6 ± 0.3 6.3 ± 2.3 
HbA1c, % – 6.7 ± 1.6 
Triglyceride, mmol/L 0.83 ± 0.35 1.76 ± 0.76 
Total cholesterol, mmol/L 4.74 ± 0.67 5.00 ± 1.17 
High-density lipoprotein, mmol/L 1.56 ± 0.34 1.12 ± 0.23 
Low-density lipoprotein, mmol/L 2.80 ± 0.64 3.12 ± 1.03 
Alkaline phosphatase, IU/L  62 ± 15 80 ± 23 
Alanine aminotransferase, IU/L 21 (17 – 24) 71 (44 – 115) 
Aspartate aminotransferase, IU/L  18 (15 – 21) 41 (29 – 65) 
Gamma glutamyl transpeptidase, IU/L 19 (16 – 25) 75 (47 – 125) 
Transient elastography 
Success rate, % 
Median E, kPa 
IQR/median for E, % 
Median CAP, dB/m 
IQR/median for CAP, % 
 
98.1 ± 3.7 
4.8 (4.0 – 6.1) 
12.5 (9.0 – 16.0) 
184 (149 – 217) 
20 (15 – 34) 
 
99.2 ± 2.6 
7.8 (5.9 – 11.7) 
1.8 (0.9 – 12.0) 
318 (287 – 345) 
16 (8 – 26) 
Liver biopsy length, mm – 14.7 ± 3.9 
Number of portal tracts – 8.3 ± 2.7 
Steatosis score, % 
S0 
S1 
S2 
S3 
 
– 
– 
– 
– 
 
3.0 
32.7 
50.5 
13.9 
NAFLD activity score, % 
0 – 2 
3 – 4 
5 – 8 
 
– 
– 
– 
 
5.9 
48.5 
45.5 
Fibrosis score, % 
F0 
F1 
F2 
F3 
F4 
 
– 
– 
– 
– 
– 
 
30.7 
44.6 
5.9 
15.8 
3.0 
 
E = estimated liver stiffness, IQR = interquartile range
 
 
119 
 
Factors associated with CAP on univariate and multivariate analyses 
Factors associated with CAP on univariate (i.e. simple) and multivariate (i.e. 
multiple) linear regression analyses are shown in Table 8.2. On univariate analysis, age, 
BMI, WC, ALT, AST, FBS, TG, TC and HDL were associated with CAP but gender and 
LDL were not. Steatosis grade and the NAFLD activity score were associated with CAP. The 
association between NAFLD activity score and CAP was contributed by the steatosis 
component of the score as the NAFLD activity score was no longer associated with CAP 
when the steatosis component was removed from the score. Lobular inflammation and 
ballooning grades, and fibrosis stage were not associated with CAP. Age was not included in 
the multivariate analysis as non-NAFLD controls were significantly younger than NAFLD 
patients due to the selection process of the former. BMI and WC were not analyzed together 
in multivariate analysis as these parameters were closely associated. BMI was entered into 
multivariate analysis instead of WC as the former had a stronger association with CAP on 
univariate analysis. On multivariate analysis, only BMI, TG and steatosis grade remained 
significantly associated with CAP.  
  
 
 
120 
 
Table 8.2 Univariate (i.e. simple) and multivariate (i.e. multiple) linear regression analyses of factors associated with CAP 
 Univariate Multivariate 
OR (95 % CI) p OR (95 % CI) p 
Age 3.31 (2.72 – 3.90) < 0.001 – – 
Gender -18.48 (-42.67 – 5.70) 0.133 – – 
Body mass index 9.94 (8.45 – 11.44) < 0.001 4.34 (2.46 – 6.22) < 0.001 
Waist circumference 3.71 (3.20 – 4.22) < 0.001 – – 
Fasting blood glucose 13.64 (7.96 – 19.32) < 0.001 2.51 (-1.56 – 6.57) 0.225 
Triglyceride 57.59 (44.82 – 70.36) < 0.001 13.59 (0.85 – 26.33) 0.037 
Total cholesterol 18.09 (6.45 – 29.84) 0.003 4.15 (-4.07 – 12.37) 0.320 
High-density lipoprotein cholesterol -116.78 (-146.65 – -86.91) < 0.001  -17.40 (-46.29 – 11.49) 0.236 
Low-density lipoprotein cholesterol 20.58 (7.48 – 33.68) 0.092 – – 
Alkaline phosphatase 1.05 (0.53 – 1.58) < 0.001 0.08 (-0.29 – 0.45) 0.660 
Alanine aminotransferase 0.79 (0.58 – 1.01) < 0.001 -0.17 (-0.47 – 0.13) 0.264 
Aspartate aminotransferase 1.24 (0.87 – 1.61) < 0.001 0.47 (0.00 – 0.95) 0.050 
Gamma glutamyl transpeptidase 0.38 (0.23 – 0.53) < 0.001 -0.07 (-0.19 – 0.05) 0.241 
Steatosis grade 56.36 (48.43 – 64.29) < 0.001 29.16 (17.96 – 40.37) < 0.001 
Lobular inflammation grade 7.96 (-7.00 – 22.92) 0.294 – – 
Ballooning grade 0.54 (-14.10 – 15.17) 0.942 – – 
NAS 8.05 (1.17 – 14.94) 0.022 – – 
NAS without steatosis component 2.65 (-5.72 – 11.00) 0.532 – – 
Fibrosis stage 1.03 (-7.33 – 9.40) 0.807 – – 
 
CAP = controlled attenuation parameter, NAS = non-alcoholic fatty liver disease activity score
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CAP for the detection and quantification of hepatic steatosis 
CAP according to steatosis grade is shown in Figure 8.4a. The median CAP and its 
interquartile range for steatosis grades S0, S1, S2 and S3 was 184 (152 – 218), 305 dB/m 
(276 dB/m – 340 dB/m), 320 dB/m (305 dB/m – 346 dB/m) and 324 dB/m (291 dB/m – 351 
dB/m), respectively. Although there was an overall significant increase in CAP across the 
steatosis grades (p < 0.001), the difference in CAP was only significant between steatosis 
grades S0 and S1 (p < 0.001). The AUROC, optimal cut-off for CAP, sensitivity, specificity, 
positive predictive value and negative predictive value for estimation of steatosis grades ≥ 
S1, S2 and S3 are shown in Table 8.3. The AUROC for estimation of steatosis grades ≥ S1, 
S2 and S3 was similar when only patients with liver biopsy specimen ≥ 15 mm and ≥ 6 portal 
tracts were analyzed (0.98, 0.65 and 0.59, respectively).  
CAP according to steatosis grades in non-obese and obese subjects are illustrated in 
Figure 8.4b and Figure 8.4c, respectively. The diagnostic performance of CAP for 
estimation of steatosis grades in obese and non-obese subjects is shown in Tables 8.4a and 
8.4b, respectively. The diagnostic performance of CAP was poor in obese subjects compared 
to non-obese patients with the exception of detection of significant hepatic steatosis. Among 
non-obese patients, the AUROC for estimation of steatosis grades ≥ S1 and S2 were 0.99 and 
0.99, respectively. Among obese patients, the AUROC for estimation of steatosis grades ≥ 
S1, S2 and S3 were 0.92, 0.64 and 0.58, respectively. There was no significant trend in CAP 
according to grades of lobular inflammation and ballooning, and stages of fibrosis (Figure 
8.5a – 8.5c).  
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Figure 8.4a Boxplot showing CAP according to steatosis grades in the overall study 
population 
Number of subjects for each of the steatosis grades: S0 = 63, S1 = 33, S2 = 51, S3 = 14. 
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Figure 8.4b Boxplot showing CAP according to steatosis grades among non-obese 
subjects 
Number of subjects for each of the steatosis grades: S0 = 58, S1 = 5, S2 = 6. 
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Figure 8.4c Boxplot showing CAP according to steatosis grades among obese subjects 
Number of subjects for each of the steatosis grades: S0 = 5, S1 = 28, S2 = 45, S3 = 14. 
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Table 8.3 The AUROC, the optimal cut-offs for CAP, and the sensitivity, specificity, 
positive predictive value and negative predictive value for estimation of steatosis grades 
1, 2 and 3 
 S1 S2 S2* S3 S3* 
AUROC 0.97 0.86 0.86 0.75 0.75 
Optimal cut-off, dB/m 263 263 281 281 283 
Sensitivity 91.8 96.9 89.2 100.0 92.9 
Specificity 93.7 67.7 74.0 53.1 54.4 
Positive predictive value  95.7 67.0 69.9 16.9 16.2 
Negative predictive value 88.1 97.0 91.0 100.0 98.8 
 
Optimal cut-off is the value for CAP that provided the greatest sum of sensitivity and 
specificity for estimation of steatosis equal to or greater than the respective grades. 
*Alternative optimal cut-off is the next CAP value above the optimal cut-off that 
provided the greatest sum of sensitivity and specificity for estimation of steatosis equal 
to or greater than the respective grades. 
AUROC = area under the receiver operating characteristics curve, CAP = controlled 
attenuation parameter, S = steatosis grade  
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Table 8.4a The AUROC, the optimal cut-offs for CAP, and the sensitivity, specificity, 
positive predictive value and negative predictive value for estimation of hepatic steatosis 
grades 1, 2 and 3 in non-obese subjects (n = 69) 
 S1 S2 S3 
N 11 6 0 
AUROC 0.99 0.99 – 
Optimal cut-off, dB/m 239 313 – 
Sensitivity, % 100 100 – 
Specificity, % 91.4 98.4 – 
Positive predictive value, %  68.8 85.7 – 
Negative predictive value, % 91.4 98.4 – 
 
Optimal cut-off is the value for CAP that provided the greatest sum of sensitivity and 
specificity for estimation of steatosis equal to or greater than the respective grades. 
Estimation of AUROC could not be performed for diagnosis of hepatic steatosis grade 3 
in non-obese subjects as there were no non-obese subjects with hepatic steatosis grade 3. 
AUROC = area under the receiver operating characteristics curve, CAP = controlled 
attenuation parameter, S = steatosis grade, N = number of subjects with corresponding 
steatosis grade and above 
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Table 8.4b The AUROC, the optimal cut-offs for CAP, and the sensitivity, specificity, 
positive predictive value and negative predictive value for estimation of hepatic 
steatosis grades 1, 2 and 3 in obese subjects (n = 92) 
 S1 S2 S3 
N 87 59 14 
AUROC 0.92 0.64 0.58 
Optimal cut-off, dB/m 280 309 278 
Sensitivity, % 83.9 69.5 100.0 
Specificity, % 100.0 63.6 23.1 
Positive predictive value, %  100.0 77.4 18.9 
Negative predictive value, % 26.3 53.8 100.0 
 
Optimal cut-off is the value for CAP that provided the greatest sum of sensitivity and 
specificity for estimation of steatosis equal to or greater than the respective grades. 
AUROC = area under the receiver operating characteristics curve, CAP = controlled 
attenuation parameter, S = steatosis grade, N = number of subjects with corresponding 
steatosis grade and above 
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Figure 8.5a Boxplots showing CAP according to lobular inflammation grades 
Number of subjects for each of the lobular inflammation grades: grade 0 = 4, grade 1 = 52, 
grade 2 = 42, grade 3 = 3. 
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Figure 8.5b Boxplots showing CAP according to ballooning grades 
Number of subjects for each of the ballooning grades: grade 0 = 16, grade 1 = 59, grade 2 = 
26. 
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Figure 8.5c Boxplots showing CAP according to fibrosis stages 
Number of subjects for each of the fibrosis stages: F0 = 31, F1 = 45, F2 = 6, F3 = 16, F4 = 
3. 
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Factors associated with significant hepatic steatosis on univariate and 
multivariate analyses 
 Factors that were associated with significant hepatic steatosis on univariate analysis 
were age, BMI, WC, FBS, TG, HDL, LDL, ALP, ALT, AST, GGT and CAP. However, on 
multivariate analysis, only CAP remained an independent determinant of significant hepatic 
steatosis (Table 8.5).   
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Table 8.5 Univariate and multivariate logistic regression analyses of factors associated with significant hepatic steatosis 
 Univariate analysis Multivariate analysis 
OR (95 % CI) p OR (95 % CI) p 
Age 1.31 (1.19 – 1.44) < 0.001 –  
Male gender 1.89 (0.99 – 3.61) 0.055 –  
Body mass index 1.86 (1.54 – 2.25) < 0.001 1.20 (0.85 – 1.69) 0.293 
Waist circumference 1.30 (1.19 – 1.41) < 0.001 –  
Fasting blood sugar 6.04 (2.87 – 12.71) < 0.001 1.40 (0.54 – 3.64) 0.975 
Triglyceride 88.97 (22.57 – 350.79) < 0.001 46.85 (0.26 –8483) 0.147 
Total cholesterol 1.33 (0.96 – 1.84) 0.092 –  
High-density lipoprotein cholesterol 0.00 (0.00 – 0.027) < 0.001 0.01 (0.00 – 12.02) 0.194 
Low-density lipoprotein cholesterol 1.50 (1.03 – 2.19) 0.034 0.20 (0.03 – 1.31) 0.093 
Alkaline phosphatase 1.05 (1.03 – 1.07) < 0.001 1.04 (0.96 – 1.13) 0.365 
Alanine aminotransferase 1.09 (1.06 – 1.12) < 0.001 1.03 (0.96 – 1.11) 0.408 
Aspartate aminotransferase 1.12 (1.08 – 1.17) < 0.001 0.94 (0.84 – 1.05) 0.942 
Gamma glutamyl transpeptidase 1.08 (1.05 – 1.11) < 0.001 1.03 (1.00 – 1.06) 0.094 
Controlled attenuation parameter 1.05 (1.04 – 1.07) < 0.001 1.05 (1.02 – 1.10) 0.008 
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8.2.3 Discussion 
In this study on NAFLD patients, we found that CAP was excellent for the diagnosis 
of hepatic steatosis ≥ S1 (AUROC of 0.97) but less accurate for the diagnosis of hepatic 
steatosis ≥ S2 and S3 with an AUROC of 0.86 and 0.75, respectively. CAP was reported to 
be excellent for the diagnosis of steatosis in the first published study on this technique by 
Sasso et al. The AUROC for the diagnosis of hepatic steatosis grades ≥ S1, S2 and S3 was 
reported to be 0.91, 0.95 and 0.89, respectively (Sasso et al., 2010). However, such excellent 
results have not been reproduced in most subsequent studies. Overall, the performance of 
CAP was good for the diagnosis of hepatic steatosis grade ≥ S1 with AUROC of 0.79 – 0.89, 
but was only fair for steatosis grade ≥ S2 and S3 with AUROC of 0.72 – 0.79 and 0.70 – 
0.76, respectively (Chon et al., 2013; de Ledinghen et al., 2012; Kumar et al., 2013; Masaki 
et al., 2013; Myers et al., 2012).     
To date, all published studies on CAP included patients with chronic liver disease of 
various etiologies except one which included only patients with chronic hepatitis C (Sasso et 
al., 2012). In patients with chronic hepatitis C, the performance of CAP was good with an 
AUROC of 0.80, 0.86 and 0.88 for estimating hepatic steatosis equal to or greater than S1, 
S2 and S3, respectively (Sasso et al., 2012). In contrast, the performance of CAP was lower 
in our cohort of NAFLD patients due to substantial overlap in CAP among grades S1, S2 and 
S3 of hepatic steatosis. In addition, we found that the performance of CAP appeared to be 
compromised by an increased BMI. We demonstrated that CAP was independently 
associated with BMI and that the ability of CAP to estimate hepatic steatosis dropped 
remarkably in obese subjects when compared to non-obese subjects. We suspect that the 
increased subcutaneous tissue thickness in subjects with greater BMI may have affected CAP 
measurement. Further studies are needed to confirm this observation and to see if adjustments 
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can be made to improve the performance of CAP in NAFLD patients with an increased BMI 
particularly when non-invasive estimation of hepatic steatosis is arguably more important in 
these patients.    
Liver stiffness measurement with Fibroscan has been shown to provide an excellent 
estimate of fibrosis stage in NAFLD patients (Yoneda et al., 2007). The procedure is non-
invasive, operator-independent, and provides immediate result. CAP has been incorporated 
in the newer models of Fibroscan and is derived from the same radio-frequency data that is 
used for liver stiffness measurement so that the result will also be available immediately at 
the end of the examination. However, in clinical practice, there is really little added benefit 
of knowing the CAP when performing liver stiffness measurement for patients already 
diagnosed with NAFLD, particularly when CAP is not reliable in distinguishing the different 
grades of hepatic steatosis. CAP also does not appear useful to follow changes in hepatic 
steatosis over time in NAFLD patients due to the substantial overlap in CAP between the 
different grades of steatosis. However, in cases where hepatic steatosis has reduced to 
become insignificant, the change can be reliably detected by CAP. Otherwise, numerical 
change in CAP is difficult to interpret and may be due to reasons other than a change in 
degree of hepatic steatosis e.g. a different site of measurement, a different operator. A study 
showed that while CAP was operator-independent with an absolute difference of 20 dB which 
was not significant between operators, this difference was sufficient to result in poor 
concordance for the classification of hepatic steatosis (Recio et al., 2013). 
Ultrasound examination of the liver is reasonably good for the detection of moderate 
to severe hepatic steatosis but is operator- and machine-dependent, and less reliable for 
detecting mild steatosis (Saadeh et al., 2002). While CAP is able to detect the presence of 
mild steatosis, it does not provide images with anatomical details. In clinical practice, patients 
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with elevated serum aminotransferase level would have an ultrasound examination which 
will be able to demonstrate fatty liver in most cases of NAFLD and exclude other pathology 
at the same time. However, incorporating a method to measure ultrasound attenuation similar 
to CAP during ultrasound examination will theoretically remove operator- and machine-
dependence in diagnosis of fatty liver and improve detection of mild steatosis. The usefulness 
of CAP as a screening tool to detect significant hepatic steatosis in the population is unclear 
and deserves further study. CAP may also be useful as a non-invasive method to assess for 
the presence of significant hepatic steatosis in potential liver donor.  
To date, this is the largest study on CAP on a homogenous cohort of NAFLD patients. 
The study was carried out prospectively according to a planned protocol so that the data 
collected was robust. Liver biopsy and Fibroscan were performed on the same day to 
minimize differences in findings due to changes over time. The procedures were carried out 
by experienced operators to ensure good quality of specimens and measurements. However, 
as in any study using liver histology as the reference, the study may be limited by sampling 
and observer variability. Nevertheless, we performed further analysis including only patients 
with “better” liver biopsy specimens and found no difference in our study findings. Our 
controls in this study did not have a liver biopsy for ethical reasons, and the cases with grade 
S0 steatosis in this study may have been over-estimated. However, the fact that CAP was 
able to delineate clearly between S0 and S1 in this study implies that the control cases truly 
had no steatosis.     
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8.2.4 Conclusion 
CAP is excellent for the detection of significant hepatic steatosis but is less useful for 
distinguishing the different grades of significant hepatic steatosis in NAFLD patients. CAP 
appears to be affected by an increased BMI and further studies to address this limitation is 
necessary to improve the diagnostic performance of CAP. CAP is non-invasive, operator-
independent and provides immediate results. However, its usefulness in NAFLD patients 
may be limited in clinical practice, unless its diagnostic performance is improved.  
 
 
 
 
 
 
 
 
 
 
 
Note: Findings from this study was presented at the Asian Pacific Association for the Study 
of the Liver 2014 Meeting in Brisbane, Australia, and was listed as a Poster of Distinction. 
The abstract was published in a supplementary issue of Hepatology International (Chan et 
al., 2014). The findings from this study was also presented at the Malaysian Society of 
Gastroenterology and Hepatology Annual Scientific Meeting in 2014. The full article has 
been published in the Journal of Gastroenterology and Hepatology (Chan et al., 2014).         
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8.3 Plasma cytokeratin-18 fragment level for the diagnosis of NASH 
Cytokeratin 18 (CK-18) is the major intermediate filament protein in liver cells and 
it is cleaved by caspases that are activated during apoptosis of liver cells, a process which 
plays an important role in non-alcoholic steatohepatitis (NASH) (Feldstein et al., 2003). CK-
18 fragment, namely CK18Asp396 (M30), has been studied for the diagnosis of NASH with 
varying results (Cusi et al., 2014; Diab et al., 2008; Feldstein et al., 2009; Shen et al., 2012; 
Shen et al., 2012; Tamimi et al., 2011; Wieckowska et al., 2006; Yilmaz et al., 2007). In this 
study, we aim to evaluate plasma M30 as well as regular serum liver enzymes, namely alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyl 
transpeptidase (GGT) for the diagnosis of NASH.           
8.3.1 Methods 
Consecutive adult patients (aged ≥ 18 years) with non-alcoholic fatty liver disease 
(NAFLD) who were scheduled for a liver biopsy were prospectively recruited between 
November 2012 and October 2013 for this study. The diagnosis of NAFLD was based on 
ultrasonography finding of fatty liver and exclusion of significant alcohol intake, use of 
medications that can cause fatty liver, viral hepatitis B and C infection, and other causes of 
chronic liver disease where indicated (Chalasani et al., 2012). This study was approved by 
the University of Malaya Medical Centre’s Ethics Committee and all patients who 
participated provided informed consent. 
Demographic, anthropometric, relevant clinical and laboratory data were obtained 
using a standard protocol on the day of the liver biopsy procedure. Weight and height were 
measured using standard equipment. Body mass index (BMI) was calculated by dividing 
weight in kilogram by the square of height in meters. Waist circumference (WC) was 
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measured at the mid-point between the lowest margin of the least palpable rib and the top of 
the iliac crest in the standing position. Blood pressure was measured in the sitting position 
using standardized equipment.  A patient was considered hypertensive if there was a self-
reported history of hypertension, if the patient was on anti-hypertensive medication(s), if the 
systolic blood pressure was ≥ 130 mmHg, or if the diastolic blood pressure was ≥ 85 mmHg.  
All patients had venous blood drawn after an overnight fast on the day of the liver 
biopsy procedure for complete blood count, blood sugar, glycated hemoglobin (HbA1c), lipid 
profile, liver profile, tests for viral hepatitis B and C infection, and for measurement of 
plasma M30 level. Biochemical measurements were performed using standard laboratory 
procedures. A patient was considered to have diabetes mellitus if there was a self-reported 
history of diabetes mellitus, if the patient was on anti-diabetic medication(s), or if fasting 
blood sugar was ≥ 7.0 mmol/L. A patient was considered to have dyslipidemia if there was a 
self-reported history of dyslipidemia, if the patient was on lipid-lowering medication(s), if 
the serum total cholesterol (TC) was ≥ 5.2 mmol/L, if the serum triglyceride (TG) was ≥ 1.7 
mmol/L, if the serum high-density lipoprotein (HDL) was < 1.0 mmol/L for men or < 1.3 
mmol/L for women, or if the serum low-density lipoprotein (LDL) was ≥ 3.4 mmol/L. Our 
laboratory’s upper limit of normal for liver enzymes were as follow: alkaline phosphatase 
(ALP) 136 IU/L, AST 37 IU/L, ALT 65 IU/L and GGT 55 IU/L. The Elecsys HBsAg II assay 
and the Elecsys Anti-HCV II assay (Roche, Mannheim, Germany) were used to test for viral 
hepatitis B and C infection, respectively. 
Controls were recruited from persons attending the Endoscopy Unit, University of 
Malaya Medical Centre for investigation of dyspepsia or screening colonoscopy. All controls 
had no history of chronic liver disease and had an ultrasound examination to exclude fatty 
liver. The presence of hypertension, diabetes mellitus and dyslipidemia was based on self-
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report. BMI and WC was determined as described above. Venous blood was drawn after an 
overnight fast for liver profile and for measurement of plasma M30 level. Percutaneous liver 
biopsy was not performed for controls due to ethical considerations. 
Measurement of plasma M30 level 
The blood sample for measurement of plasma M30 level was collected in a plain tube 
on the same day of the liver biopsy procedure. The blood sample was processed to plasma 
and stored at – 80 ˚C until further analysis. The plasma was subsequently used for 
quantitative measurement of M30 using the M30-Apoptosense ELISA kit (PEVIVA, 
Bromma, Sweden). The test was performed for all samples in a single session by a single 
investigator (PS).  
Liver biopsy and histological assessment  
Ultrasonography-guided percutaneous liver biopsy was performed by either one of 
two experienced operators (WKC, SM) using 18 G Temno ® II semi-automatic biopsy needle 
(Cardinal Health, Dublin, Ohio, USA). Liver biopsy specimens were processed using 
standard laboratory procedures. Liver biopsy slides were stained with hematoxylin and eosin 
stain and masson trichrome stain. Liver biopsy slides were examined by an experienced 
histopathologist (NRNM) who was blinded to clinical data. Histopathological findings were 
reported according to the Non-Alcoholic Steatohepatitis Clinical Research Network Scoring 
System (Kleiner et al., 2005). The NAFLD activity score (NAS) is the sum of scores for 
hepatic steatosis (0 – 3), lobular inflammation (0 – 3) and hepatocyte ballooning (0 – 2). 
Specifically, lobular inflammation was graded as follows: grade 0 = none, grade 1 = less than 
2 foci, grade 2 = 2 – 4 foci, grade 3 = more than 4 foci (Figure 8.6a – d), while ballooning 
was graded as follows: grade 0 = none, grade 1 = few or mild, grade 2 = many or prominent 
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(Figure 8.7a – c). NAS 0 – 2 is not diagnostic of NASH, 3 – 4 is borderline NASH and 5 – 
8 is definite NASH. Patients with NAS < 5 was considered as non-NASH while patients with 
NAS ≥ 5 were considered to have NASH (Figure 8.8a – b). Fibrosis was staged 0 – 4 (0 = 
no fibrosis, 1 = mild fibrosis, 2 = moderate fibrosis, 3 = severe fibrosis, 4 = cirrhosis).  
Statistical analysis 
Data were analyzed using a standard statistical software program (SPSS 15.0). 
Continuous variables were expressed as mean ± standard deviation or median (interquartile 
range) and analyzed using student’s t-test, Mann-Whitney U test or Kruskal-Wallis test, as 
appropriate. Categorical variables were expressed as percentages and analyzed using chi-
square test. Significance was assumed when p < 0.05. Boxplots were used to compare the 
distribution of plasma M30 and serum ALT, AST and GGT levels between healthy controls 
and NAFLD patients, and between NASH and non-NASH patients. The performance of 
plasma M30 and serum ALT, AST and GGT levels for prediction of NAFLD and NASH was 
determined using area under receiver-operating characteristics curve (AUROC). AUROC 
was interpreted as follows: 0.90 – 1.00 = excellent, 0.80 – 0.90 = good, 0.70 – 0.80 = fair, < 
0.70 = poor. The sensitivity, specificity, positive predictive value and negative predictive 
value using cut-off values for high sensitivity, highest overall accuracy and high specificity 
were determined. Boxplots were also used to compare the distribution of plasma M30 and 
serum ALT, AST and GGT levels across the different grades of steatosis, lobular 
inflammation and ballooning, and across the different stages of fibrosis.  
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Figure 8.6a Lobular inflammation (arrow) 
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Figure 8.6b Lobular inflammation grade 1 
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Figure 8.6c Lobular inflammation grade 2 
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Figure 8.6d Lobular inflammation grade 3 
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Figure 8.7a Hepatocyte ballooning (arrow) 
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Figure 8.7b Hepatocyte ballooning grade 1 
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Figure 8.7c Hepatocyte ballooning grade 2 
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Figure 8.8a Non-NASH 
Patients with NAS < 5 was considered as non-NASH while patients with NAS ≥ 5 were 
considered to have NASH. 
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Figure 8.8b NASH 
Patients with NAS < 5 was considered as non-NASH while patients with NAS ≥ 5 were 
considered to have NASH. 
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8.3.2 Results 
Patient characteristics 
Ninety-three NAFLD subjects and 20 controls were recruited during the period of 
study. The characteristics of subjects are shown in Table 8.6. The controls and NAFLD 
subjects were well-matched in age and gender. NAFLD subjects had greater BMI and WC 
and had higher prevalence of diabetes mellitus, hypertension and dyslipidemia compared to 
controls. There was a lower proportion of males among NASH subjects compared to non-
NASH subjects. NASH and non-NASH subjects were similar in age, BMI, WC and 
prevalence of diabetes mellitus, hypertension and dyslipidemia. The quality of liver biopsy 
specimen as reflected by its length and the number of portal tracts, were also similar between 
NASH and non-NASH subjects. NASH subjects showed greater steatosis, lobular 
inflammation, ballooning and fibrosis. 
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Table 8.6 Characteristics of controls and NAFLD patients 
 Controls 
n = 20 
NAFLD patients 
n = 93 
Non-NASH patients 
n = 54 
NASH patients 
n = 39 
Age, years 50.6 ± 16.8 51.0 ± 11.1 50.2 ± 11.3 52.2 ± 10.8 
†Male, %  30.0 51.6 63.0 35.9 
*BMI, kg per m2  22.5 ± 2.8 29.4 ± 3.8 29.1 ± 3.7 29.8 ± 4.0 
*WC, cm  81.8 ± 7.6 97.7 ± 9.7 96.8 ± 9.7 98.8 ± 9.7 
*Diabetes mellitus, %   0 59.1 51.9 69.2 
*Hypertension, %  20.0 88.2 85.2 92.3 
*Dyslipidemia, %  40.0 96.8 94.4 100 
Liver biopsy length, mm – 15.0 ± 3.9 14.5 ± 4.2 15.7 ± 3.5 
Number of portal tracts – 8 (7 – 10) 8 (6 – 10) 9 (7 – 11) 
†Steatosis 
S0 
S1 
S2 
S3 
 
– 
– 
– 
– 
 
3.2 
34.4 
47.3 
15.1 
 
5.6 
42.6 
48.1 
3.7 
 
0 
23.1 
46.2 
30.8 
‡Lobular inflammation 
0 
1 
2 
3 
 
– 
– 
– 
– 
 
4.3 
53.8 
38.7 
3.2 
 
7.4 
81.5 
11.1 
0 
 
0 
15.4 
76.9 
7.7 
‡Ballooning 
0 
1 
2 
 
– 
– 
– 
 
14.0 
60.2 
25.8 
 
24.1 
70.4 
5.6 
 
0 
46.2 
53.8 
‡Fibrosis 
F0 
F1 
F2 
 
– 
– 
– 
 
30.1 
43.0 
6.5 
 
44.4 
42.6 
1.9 
 
10.3 
43.6 
12.8 
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 Controls 
n = 20 
NAFLD patients 
n = 93 
Non-NASH patients 
n = 54 
NASH patients 
n = 39 
F3 
F4 
– 
– 
18.3 
2.2 
7.4 
3.7 
33.3 
0 
 
*Significant at p < 0.001 between healthy controls and NAFLD patients  
†Significant at p < 0.05 
‡Significant at p < 0.001, between non-NASH and NASH patients 
Patients with NAS < 5 was considered as non-NASH while patients with NAS ≥ 5 were considered to have NASH. 
BMI = body mass index, WC = waist circumference, NAS = non-alcoholic fatty liver disease activity score 
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Plasma M30 and serum ALT, AST and GGT levels in controls and NAFLD 
patients 
Plasma M30 levels were significantly higher in patients with NAFLD (median 349 
U/L, IQR 257 U/L – 612 U/L) than in controls (median 162 U/L, IQR 103 U/L – 215 U/L, p 
< 0.001) (Figure 8.9a). Although plasma M30 levels were higher in patients with NASH 
(median 435 U/L, IQR 279 U/L – 758 U/L) compared to non-NASH patients (median 332 
U/L, IQR 249 U/L – 534 U/L), the difference was not significant statistically (p = 0.145) 
(Figure 8.10a).  
Serum ALT levels were significantly higher in patients with NAFLD (median 70 
IU/L, IQR 44 IU/L – 109 IU/L) than in controls (median 26 IU/L, IQR 22 IU/L – 32 IU/L, p 
< 0.001) (Figure 8.9b). More importantly, serum ALT levels were significantly higher in 
NASH patients (median 86 IU/L, IQR 55 IU/L – 121 IU/L) compared to non-NASH patients 
(median 61 IU/L, IQR 44 IU/L – 93 IU/L, p < 0.05) (Figure 8.10b).  
Serum AST levels were significantly higher in patients with NAFLD (median 41 
IU/L, IQR 28 IU/L – 64 IU/L) than in controls (median 20 IU/L, IQR 18 IU/L – 27 IU/L, p 
< 0.001) (Figure 8.9c). Serum AST levels were also significantly higher in NASH patients 
(median 58 IU/L, IQR 38 IU/L – 78 IU/L) compared to non-NASH patients (median 34 IU/L, 
IQR 25 IU/L – 46 IU/L, p < 0.001) (Figure 8.10c).  
Serum GGT levels were significantly higher in patients with NAFLD (median 75 
IU/L, IQR 47 IU/L – 125 IU/L) than in controls (median 33 IU/L, IQR 22 IU/L – 45 IU/L, p 
< 0.001) (Figure 8.9d). Serum GGT levels were also significantly higher in NASH patients 
(median 97 IU/L, IQR 53 IU/L – 151 IU/L)  compared to non-NASH patients (median 56 
IU/L, IQR 40 IU/L – 101 IU/L, p < 0.05) (Figure 8.10d).  
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Figure 8.9 Plasma M30 and serum ALT, AST and GGT levels in healthy controls and NAFLD patients 
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Figure 8.10 Plasma M30 and serum ALT, AST and GGT levels in non-NASH and NASH patients  
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Prediction of NAFLD and NASH 
The receiver operating characteristic curves of plasma M30 and serum ALT, AST 
and GGT for prediction of NAFLD and NASH are shown in Figures 8.11a and 8.11b, 
respectively. Plasma M30 and serum ALT levels were excellent for prediction of NAFLD 
with AUROC of 0.91 and 0.95, respectively. Serum AST and GGT levels were good for 
prediction of NAFLD with AUROC of 0.87 and 0.85, respectively. Serum AST level was 
fair for prediction of NASH among NAFLD patients with AUROC of 0.75. Plasma M30 and 
serum ALT and GGT levels were poor for prediction of NASH among NAFLD patients with 
AUROC of 0.59, 0.64 and 0.68, respectively. The sensitivity, specificity, positive predictive 
value and negative predictive value when using the different cut-offs of plasma M30 and 
serum ALT, AST and GGT levels for prediction of NAFLD and NASH are shown in Tables 
8.7 and 8.8, respectively. 
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Figure 8.11 The receiver operating characteristic curves of plasma M30 and serum ALT, AST and GGT for prediction of (a) NAFLD, and 
(b) NASH 
AUROC: 0.90 – 1.00 = excellent, 0.80 – 0.90 = good, 0.70 – 0.80 = fair, < 0.70 = poor   
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Table 8.7 The sensitivity, specificity, positive predictive value and negative predictive value when using the different cut-offs of plasma M30 
and serum ALT, AST and GGT for prediction of NAFLD 
 *Cut-off, U/L or IU/L Sensitivity, % Specificity, % PPV, % NPV, % 
Plasma M30 162 95.7 45.0 89.0 69.2 
 263 74.2 95.0 98.6 44.2 
 278 67.7 100 100 40.0 
Serum ALT 27 95.7 55.0 90.8 73.3 
 35 90.3 95.0 98.8 67.9 
 47 73.1 100 100 44.4 
Serum AST 21 92.5 55.0 90.5 61.1 
 33† 65.6 100 100 38.5 
Serum GGT 32 90.3 50.0 89.4 52.6 
 46 78.5 80.0 94.8 44.4 
 55 62.4 95.0 98.3 35.2 
 
*Cut-off with high sensitivity, highest overall accuracy and high specificity were presented 
†Cut-off for highest overall accuracy and high specificity were the same 
ALT = alanine aminotransferase, AST aspartate aminotransferase, GGT = gamma glutamyl transpeptidase, PPV = positive predictive value, 
NPV = negative predictive value 
 
  
 
 
159 
 
Table 8.8 The sensitivity, specificity, positive predictive value and negative predictive value when using the different cut-offs of plasma M30 
and serum ALT, AST and GGT for prediction of NASH 
 *Cut-off, U/L or IU/L Sensitivity, % Specificity, % PPV, % NPV, % 
Plasma M30 293 71.8 40.7 46.7 66.7 
 432 56.4 63.0 52.4 66.7 
 474 43.6 64.8 47.2 61.4 
Serum ALT 53 79.5 40.7 49.2 73.3 
 67 71.8 59.3 56.0 74.4 
 100 41.0 79.6 59.3 65.2 
Serum AST 30 84.6 40.7 50.8 78.6 
 48 69.2 77.8 69.2 77.8 
 65 43.6 90.7 77.3 69.0 
Serum GGT 49 84.6 42.6 51.6 79.3 
 84 64.1 70.4 61.0 73.1 
 109 46.2 77.8 60.0 66.7 
 
*Cut-off with high sensitivity, highest overall accuracy and high specificity were presented 
ALT = alanine aminotransferase, AST aspartate aminotransferase, GGT = gamma glutamyl transpeptidase, PPV = positive predictive value, 
NPV = negative predictive value 
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Plasma M30 and serum ALT, AST and GGT according to steatosis, 
ballooning, lobular inflammation and fibrosis 
Plasma M30 and serum ALT and AST levels did not show any significant trend when 
analyzed according to steatosis grades. Although serum GGT level showed a significant trend 
when analyzed according to steatosis grades, the difference in serum GGT level was only 
significant between patients with grade 2 and 3 steatosis (Figure 8.12). 
Serum ALT and AST levels showed significant increasing trend with increasing 
grades of lobular inflammation. However, this was not seen with plasma M30 and serum 
GGT levels. Serum ALT and AST levels were significantly higher in patients with grade 2 
compared to grade 1 lobular inflammation. However, serum ALT and AST levels were not 
significantly different between patients with grade 2 and grade 3 lobular inflammation, and 
between patients with grade 1 and patients without lobular inflammation (Figure 8.13).  
Serum ALT and AST levels showed significant increasing trend with increasing 
grades of ballooning. However, this was not seen with plasma M30 and serum GGT levels. 
Serum ALT levels were significantly higher in patients with grade 1 compared to patients 
without ballooning. However, serum ALT levels were not significantly different between 
patients with grade 1 and grade 2 ballooning. Serum AST levels were significantly higher in 
patients with grade 2 compared to grade 1 ballooning and in patients with grade 1 compared 
to patients without ballooning (Figure 8.14).  
Plasma M30 level did not show any significant trend when analyzed according to 
fibrosis stages. There was significant difference in serum ALT, AST and GGT levels across 
fibrosis stages. However, only the difference in serum ALT and AST for stage 1 and stage 2 
fibrosis was significant (Figure 8.15).   
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Figure 8.12 Plasma M30 and serum ALT, AST and GGT levels according to steatosis grades 
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Figure 8.13 Plasma M30 and serum ALT, AST and GGT levels according to lobular inflammation grades 
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Figure 8.14 Plasma M30 and serum ALT, AST and GGT levels according to ballooning grades 
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Figure 8.15 Plasma M30 and serum ALT, AST and GGT levels according to fibrosis stages 
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Prediction of ballooning and lobular inflammation 
 In view of the above findings, analysis was carried out to determine the accuracy of 
plasma M30 and serum ALT, AST and GGT levels for prediction of presence of ballooning 
and presence of more severe lobular inflammation. Lobular inflammation grade 0 and grade 
1 were considered less severe while grade 2 and grade 3 were considered more severe. The 
receiver operating characteristic curves of plasma M30 and serum ALT, AST and GGT for 
prediction of more severe lobular inflammation and presence of ballooning are shown in 
Figures 8.16a and 8.16b, respectively. Serum ALT and AST levels were fair for prediction 
of presence of ballooning with AUROC of 0.72 and 0.77, respectively. Serum AST level was 
fair for prediction of presence of more severe lobular inflammation with AUROC of 0.78. 
Plasma M30 and serum GGT levels were poor for prediction of presence of ballooning and 
presence of more severe lobular inflammation. The sensitivity, specificity, positive predictive 
value and negative predictive value when using the different cut-offs of plasma M30 and 
serum ALT, AST and GGT levels for prediction of more severe lobular inflammation and 
presence of ballooning are shown in Tables 8.9 and 8.10, respectively. 
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Figure 8.16 The receiver operating characteristic curves of plasma M30 and serum ALT, AST and GGT for prediction of (a) more severe 
lobular inflammation*, and (b) ballooning 
*Lobular inflammation grade 0 and 1 were considered less severe while grade 2 and 3 were considered more severe 
AUROC: 0.90 – 1.00 = excellent, 0.80 – 0.90 = good, 0.70 – 0.80 = fair, < 0.70 = poor   
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Table 8.9 The sensitivity, specificity, positive predictive value and negative predictive value when using the different cut-offs of plasma M30 
and serum ALT, AST and GGT for prediction of presence of ballooning 
 *Cut-off, U/L or IU/L Sensitivity, % Specificity, % PPV, % NPV, % 
Plasma M30 268 76.3 46.2 89.7 24.0 
 317 63.8 61.5 91.1 21.6 
 474 40.0 69.2 88.9 15.8 
Serum ALT 45 77.5 46.2 89.9 25.0 
 57 68.8 76.9 94.8 28.6 
 89 40.0 84.6 94.1 18.6 
Serum AST 25 90.0 46.2 91.1 42.9 
 29 80.0 69.2 94.1 36.0 
 51 40.0 84.6 94.1 18.6 
Serum GGT 37 91.2 53.8 92.4 50.0 
 42 87.5 61.5 93.3 44.4 
 95 38.8 76.9 91.2 16.9 
 
*Cut-off with high sensitivity, highest overall accuracy and high specificity were presented 
ALT = alanine aminotransferase, AST aspartate aminotransferase, GGT = gamma glutamyl transpeptidase, PPV = positive predictive value, 
NPV = negative predictive value 
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Table 8.10 The sensitivity, specificity, positive predictive value and negative predictive value when using the different cut-offs of plasma 
M30 and serum ALT, AST and GGT for prediction of presence of more severe lobular inflammation* 
 Cut-off, U/L or IU/L † Sensitivity, % Specificity, % PPV, % NPV, % 
Plasma M30 277 79.5 40.7 49.2 73.3 
 432 59.0 64.8 54.8 68.6 
 560 38.5 79.6 57.7 64.2 
Serum ALT 53 79.5 40.7 49.2 73.3 
 66 74.4 59.3 56.9 76.2 
 109 38.5 85.2 65.2 65.7 
Serum AST 30 84.6 40.7 50.8 78.6 
 42 76.9 70.4 65.2 80.9 
 69 38.5 94.4 83.3 68.0 
Serum GGT 53 69.2 40.7 45.8 64.7 
 84 56.4 64.8 53.7 67.3 
 111 38.5 74.1 51.7 62.5 
 
*Lobular inflammation grade 0 and 1 were considered less severe while grade 2 and 3 were considered more severe 
†Cut-off with high sensitivity, highest overall accuracy and high specificity were presented 
ALT = alanine aminotransferase, AST aspartate aminotransferase, GGT = gamma glutamyl transpeptidase, PPV = positive predictive value, 
NPV = negative predictive value 
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8.3.3 Discussion  
The potential use of plasma M30 level as a non-invasive test to determine histological 
disease severity in NAFLD patients was first reported by Wieckowska et al. In their study of 
44 consecutive patients with suspected NAFLD at the time of liver biopsy, plasma CK-18 
levels were markedly increased in patients with NASH compared to patients with simple 
steatosis or normal liver biopsies. Plasma M30 level was excellent to distinguish patients 
with NASH from patients with simple steatosis or normal liver biopsies with an AUROC of 
0.93. Two patients with borderline NASH were not included in the analysis (Wieckowska et 
al., 2006). In a subsequent multi-centre validation study consisting of 139 patients, Feldstein 
et al reported that plasma M30 level was good to distinguish NAFLD patients with NASH 
from those without NASH or with borderline NASH with an AUROC of 0.83. However, it 
is important to note that this population consisted of a relatively small percentage of patients 
with borderline NASH (19 %) (Feldstein et al., 2009). Subsequently, Shen et al reported an 
AUROC of 0.66 for plasma M30 level to distinguish NAFLD patients with NASH from 
patients without NASH. Interestingly, the study population consisted of a larger percentage 
of patients with borderline NASH (49.7 %) (Shen et al., 2012). In our study population which 
consisted of a similar percentage of patients with borderline NASH (52.7 %), we too found 
that plasma M30 was less useful for distinguishing NAFLD patients with NASH from those 
without NASH with an AUROC of 0.59. In a recently published study consisting of 318 
patients, Cusi et al similarly reported that plasma M30 level was less useful for NASH 
diagnosis with an AUROC of 0.65(Cusi et al., 2014). 
 We found that serum AST level was fair in distinguishing NAFLD patients with 
NASH from those without NASH or with borderline NASH with an AUROC of 0.75. Serum 
AST level was fair in predicting the presence of ballooning and the presence of more severe 
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lobular inflammation with an AUROC of 0.77 and 0.78, respectively. Serum ALT and GGT 
levels were less useful. Other tests for diagnosis of NASH such as measurement of total cell 
death markers M65 and M65ED, adipocyte fatty acid binding protein (AFABP) and 
fibroblast growth factors 21 (FGF21) have been studied but were not better with AUROC of 
0.71, 0.70, 0.59 and 0.62, respectively. It appears that an accurate non-invasive test for NASH 
remains elusive. However, we should not forget that NASH is a continuous spectrum and 
markers may be variably expressed in each individual so that finding a test that confirms the 
presence or absence of NASH using a pre-determined cut-off may be difficult if not 
impossible. It may be more realistic to aim for a test that would reflect changes in severity of 
NASH when followed over time. For example, Suzuki et al reported that the combination of 
baseline and rate of change of serum ALT and AST levels had an AUROC of 0.72 and 0.73, 
respectively, in predicting improvement, and an AUROC of 0.75 and 0.77, respectively, in 
predicting worsening of histological inflammation in NASH patients. The AUROC improved 
to 0.88 and 0.89, respectively, when baseline histology was taken into consideration (Suzuki 
et al., 2006). In a separate study of 36 patients without NASH at baseline among which 10 
patients developed NASH at 36 months, Shen and colleagues showed that changes in M30 
was good in predicting development of NASH with an AUROC of 0.82. Using 35 U/L as the 
cut-off for increment in M30, development of NASH could be predicted with sensitivity and 
specificity of 80.0 % and 81.5 %, respectively (Shen et al., 2012). The use of changes in 
plasma M30 and serum ALT and AST levels to predict changes in histology, particularly 
inflammation and ballooning, should be compared and deserves further studies in larger 
group of patients.   
Our study was carried out prospectively according to a planned protocol so that the 
data collected was robust. Collection of blood sample was done on the same day as the liver 
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biopsy procedure to minimize difference in findings due to changes over time. Despite our 
best effort, the study had several limitations. Firstly, as in any study using histopathological 
examination of liver biopsy specimen as reference, our study may be limited by sampling 
variability and observer variability. Secondly, we were not able to perform liver biopsy in 
controls due to ethical reason and the absence of NAFLD was based on ultrasonography 
which may lack sensitivity in detection of mild hepatic steatosis. Nevertheless, this would 
only reduce the difference seen between controls and NAFLD patients, which remained 
highly significant. 
8.3.4 Conclusion 
Neither plasma M30 nor serum ALT, AST or GGT levels were good enough for 
diagnosis of NASH among NAFLD patients. While other more accurate yet simple and non-
invasive tests are needed for diagnosis of NASH, the use of changes in plasma M30 and 
serum ALT and AST levels to predict changes in histology, particularly inflammation and 
ballooning, should be compared and deserves further studies in larger group of patients.     
 
 
 
Note: A poster on the findings from this study was presented at the Asia-Pacific Digestive 
Week 2014 in Bali, Indonesia, and the abstract was published in a supplementary issue of the 
Journal of Gastroenterology and Hepatology (Chan et al., 2014). The findings from this study 
was also presented at the Malaysian Society of Gastroenterology and Hepatology Annual 
Scientific Meeting in 2014. The full article has been published in PLoS One (Chan et al., 
2014).               
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8.4  NAFLD fibrosis score and liver stiffness measurement for the 
estimation of hepatic fibrosis  
Liver fibrosis and cirrhosis is the common end result of chronic liver disease. The 
degree of liver fibrosis gives an idea about the severity of the chronic liver disease. This 
provides information on prognosis and helps identify patients for intervention. 
Histopathological examination of a liver biopsy specimen is the best standard for assessment 
of liver fibrosis. However, liver biopsy is invasive and associated with a small risk of 
complications. Technical expertise is also required, from obtaining a good specimen to 
processing and accurately interpreting the result. It is not practical to subject all non-alcoholic 
fatty liver disease (NAFLD) patients to a liver biopsy to assess liver fibrosis, particularly 
when the disease is so common. It is also not practical to subject NAFLD patients to repeated 
liver biopsies to monitor disease status in clinical practice.  
Several non-invasive tests are available for assessment of liver fibrosis in NAFLD 
patients. The NAFLD fibrosis score is calculated from readily available parameters and can 
be used to predict the absence or presence of advanced fibrosis in NAFLD patients (Angulo 
et al., 2007). In a meta-analysis of 13 studies consisting of 3064 patients, the NAFLD fibrosis 
score had an area under the receiver operating characteristic curve (AUROC) of 0.85 for 
predicting advanced fibrosis. However, using the NAFLD fibrosis score alone, 20 % – 58 % 
of patients will fall in the indeterminate group (Musso et al., 2011). These patients will 
require further evaluation, for example by histopathological examination of a liver biopsy 
specimen.  
Transient elastography has also been used to measure liver stiffness, which has been 
shown to correlate well with hepatic fibrosis. In a meta-analysis of 5 studies, transient 
elastography had an AUROC of 0.94 for predicting advanced fibrosis (Musso et al., 2011). 
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Combining the NAFLD fibrosis score and liver stiffness measurement for the prediction of 
advanced fibrosis in NAFLD patients seemed feasible and various algorithms have been 
proposed recently based on previously reported performance of the individual tests (Machado 
et al., 2013; Musso et al., 2011). We aimed to prospectively evaluate the combination of 
NAFLD fibrosis score and liver stiffness measurement in predicting advanced fibrosis in 
NAFLD patients. 
8.4.1 Methods 
Consecutive adult patients (aged ≥ 18 years) with NAFLD who were scheduled for a 
liver biopsy were prospectively recruited between November 2012 and October 2013 for the 
training cohort and between November 2013 and April 2014 for the validation cohort of this 
study. The diagnosis of NAFLD was based on ultrasonography finding of fatty liver and 
exclusion of significant alcohol intake, use of medications that can cause fatty liver, viral 
hepatitis B and C infection, and other causes of chronic liver disease where indicated. This 
study was approved by the University of Malaya Medical Centre’s Ethics Committee and all 
patients who participated provided informed consent. 
Demographic, anthropometric, relevant clinical and laboratory data were obtained 
using a standard protocol on the day of the liver biopsy procedure. Weight and height were 
measured using standard equipment. Body mass index (BMI) was calculated by dividing 
weight in kilogram by the square of height in meters. Patients with BMI ≥ 25.0 kg per m2 
were considered obese (Anuurad et al., 2003). Waist circumference (WC) was measured at 
the mid-point between the lowest margin of the least palpable rib and the top of the iliac crest 
in the standing position. Central obesity was defined as WC > 90 cm for men and > 80 cm 
for women (Alberti et al., 2005). Blood pressure was measured in the sitting position using 
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standardized equipment.  A patient was considered hypertensive if there was a self-reported 
history of hypertension, if the patient was on anti-hypertensive medication(s), if the systolic 
blood pressure was ≥ 130 mmHg, or if the diastolic blood pressure was ≥ 85 mmHg.  
All patients had venous blood drawn after an overnight fast for complete blood count, 
blood sugar, glycated hemoglobin (HbA1c), lipid profile, liver profile and tests for viral 
hepatitis B and C infection. Biochemical measurements were performed using standard 
laboratory procedures. A patient was considered to have diabetes mellitus if there was a self-
reported history of diabetes mellitus, if the patient was on anti-diabetic medication(s), or if 
fasting blood sugar was ≥ 7.0 mmol/L. A patient was considered to have dyslipidemia if there 
was a self-reported history of dyslipidemia, if the patient was on lipid-lowering 
medication(s), if the serum total cholesterol (TC) was ≥ 5.2 mmol/L, if the serum triglyceride 
(TG) was ≥ 1.7 mmol/L, if the serum high-density lipoprotein (HDL) was < 1.0 mmol/L for 
men or < 1.3 mmol/L for women, or if the serum low-density lipoprotein (LDL) was ≥ 3.4 
mmol/L. Our laboratory’s upper limit of normal for liver enzymes were as follow: alkaline 
phosphatase (ALP) 136 IU/L, aspartate aminotransferase (AST) 37 IU/L, alanine 
aminotransferase (ALT) 65 IU/L and gamma-glutamyl transpeptidase (GGT) 55 IU/L.  
Serum ALP, AST, ALT and GGT above these levels were considered as elevated. The 
Elecsys HBsAg II assay and the Elecsys Anti-HCV II assay (Roche, Mannheim, Germany) 
were used to test for viral hepatitis B and C infection, respectively. 
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Liver biopsy and histological assessment  
Ultrasonography-guided percutaneous liver biopsy was performed by either one of 
two experienced operators (WKC, SM) using an 18 G Terumo ® II semi-automatic biopsy 
needle (Cardinal Health, Dublin, Ohio, USA). Liver biopsy specimens were processed using 
standard laboratory procedures. Liver biopsy slides were stained with hematoxylin and eosin 
stain and masson trichrome stain. Liver biopsy slides were examined by an experienced 
histopathologist (NRNM) who was blinded to clinical data. Histopathological findings were 
reported according to the Non-Alcoholic Steatohepatitis Clinical Research Network Scoring 
System (Kleiner et al., 2005). The NAFLD activity score (NAS) is the sum of scores for 
hepatic steatosis (0 – 3), lobular inflammation (0 – 3) and hepatocyte ballooning (0 – 2). NAS 
0 – 2 is not diagnostic of NASH, 3 – 4 is probable NASH and 5 – 8 is definite NASH. Fibrosis 
was staged 0 – 4 (0 = no fibrosis, 1 = mild fibrosis, 2 = moderate fibrosis, 3 = severe fibrosis, 
4 = cirrhosis) (Figure 8.17a – d). Advanced fibrosis was defined as fibrosis stage ≥ F3. 
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Figure 8.17a Fibrosis stage F1 
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Figure 8.17b Fibrosis stage F2 
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Figure 8.17c Fibrosis stage F3 
  
 
 
179 
 
 
Figure 8.17d Fibrosis stage F4  
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NAFLD fibrosis score 
The NAFLD fibrosis score was calculated using the formula: – 1.675 + 0.037 x age 
(years) + 0.094 x BMI (kg/m2) + 1.13 x impaired fasting glucose/diabetes (yes = 1, no = 0) 
+ 0.99 x AST/ALT ratio – 0.013 x platelet (109/L) – 0.66 x albumin (g/dL). A score of < – 
1.455 was considered as predictive of absence of advanced fibrosis (F0 – F2) while a score 
of > 0.675 was considered predictive of presence of advanced fibrosis (F3 – F4). A score 
between – 1.455 and 0.675 was considered indeterminate (Angulo et al., 2007). The use of 
NAFLD fibrosis score for prediction of advanced fibrosis was evaluated. 
Transient elastography 
Transient elastography was performed by either one of two experienced operators 
(WKC, SM) using Fibroscan 502 Touch with M probe (EchoSens, Paris, France) on the same 
day of the liver biopsy procedure. Ten measurements were obtained for each patient. 
Adequate pressure of the probe on the skin surface, good layering on TM mode and a straight 
imaginary line on A mode were ensured for each measurement. An examination was 
considered successful when valid measurements were ≥ 80 % and IQR/median for liver 
stiffness measurement was ≤ 30 %. Patients with unsuccessful examination were excluded 
from analysis. Previously reported optimal cut-offs for estimation of the different stages of 
liver fibrosis were used (Yoneda et al., 2007). The use of liver stiffness measurement for 
prediction of different stages of fibrosis was evaluated. The optimal cut-off for advanced 
fibrosis was 8 kPa. A higher cut-off to predict the presence of advanced fibrosis was 
determined using data from the training cohort and tested in the validation cohort. This model 
reduced the false positive rate of liver stiffness measurement for predicting the presence of 
advanced fibrosis but resulted in a grey zone.   
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Combining NAFLD fibrosis score and liver stiffness measurement for 
prediction of advanced fibrosis  
The combination of NAFLD fibrosis score and liver stiffness measurement for 
prediction on advanced fibrosis was evaluated. An algorithm combining the NAFLD fibrosis 
score and liver stiffness measurement was developed based on findings from the training 
cohort and subsequently tested in the validation cohort. The percentages of misclassifications 
and number of patients requiring liver biopsy were evaluated when using the NAFLD fibrosis 
score alone, liver stiffness measurement alone, both tests for all patients and the algorithm.  
Statistical analysis 
Data were analyzed using SPSS 15.0. Continuous variables were expressed as mean 
± standard deviation or median (interquartile range), and analyzed using student’s t-test or 
Mann-Whitney test, as appropriate. Categorical variables were expressed as percentages, and 
analyzed using chi-square test or Fisher’s exact test, as appropriate. Boxplots were used to 
show the distribution of liver stiffness measurements for each fibrosis stage. Liver stiffness 
measurements between and across fibrosis stages were compared using Mann-Whitney U 
test and Kruskal-Wallis test, respectively. Significance was assumed when p < 0.05. The 
sensitivity, specificity, positive predictive value and negative predictive value of the NAFLD 
fibrosis score, liver stiffness measurement and the 2 combination models for predicting liver 
fibrosis were determined.  
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8.4.2 Results 
Patient characteristics 
A total of 105 NAFLD patients had liver biopsy during the study period for the 
training cohort. Four patients were excluded as transient elastography was unsuccessful. Data 
for 101 patients were analyzed. A total of 48 NAFLD patients underwent a liver biopsy 
during the study period for the validation cohort. Two patients were excluded as transient 
elastography was unsuccessful. Data for 46 patients were analyzed. Patient characteristics 
are shown in Table 8.11. Demographic, anthropometric, clinical and laboratory data were 
comparable between the two groups.
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Table 8.11 Patient characteristics 
 Overall 
n = 147 
Training cohort 
n = 101 
Validation cohort 
n = 46 
p 
Age, years 50.5 ± 11.7 50.3 ± 11.3 50.9 ± 12.5 0.775 
Male, % 54.4 51.5 60.9 0.289 
Body mass index, kg per m2  29.3 ± 4.5 29.6 ± 3.9  28.8 ± 5.7 0.313 
Obesity, % 83.7 87.1 76.1 0.093 
Waist circumference, cm 98.2 ± 10.1 97.7 ± 9.5 99.3 ± 11.2 0.370 
Central obesity, % 95.2 96.0 93.5 0.678 
Diabetes mellitus, % 52.4 52.5 52.2 0.973 
Hypertension, % 89.1 89.9 91.3 1.000 
Dyslipidemia, % 94.6 95.0 93.5 0.706 
Fasting blood glucose, mmol/L 6.3 ± 2.2 6.3 ± 2.3 6.5 ± 1.9 0.557 
HbA1c, % 6.5 ± 1.5  6.7 ± 1.6 6.3 ± 1.3 0.169 
Triglyceride, mmol/L 1.73 ± 0.74 1.76 ± 0.76 1.66 ± 0.68 0.432 
Total cholesterol, mmol/L 4.98 ± 1.15 5.00 ± 1.17 4.92 ± 1.12 0.663 
High-density lipoprotein, mmol/L 1.15 ± 0.26 1.12 ± 0.23 1.21 ± 0.30 0.066 
Low-density lipoprotein, mmol/L 3.07 ± 1.03  3.12 ± 1.03 2.96 ± 1.03 0.363 
Alkaline phosphatase, IU/L  84 ± 27 80 ± 23 91 ± 33 0.026 
Alanine aminotransferase, IU/L 71 (48 – 111) 71 (44 – 115) 68 (49 – 107) 0.874 
Aspartate aminotransferase, IU/L  41 (29 – 66) 42 (29 – 66) 40 (29 – 70) 0.820 
Gamma glutamyl transpeptidase, IU/L 82 (47 – 128) 75 (47 – 125) 94 (56 – 135)  0.152 
Liver biopsy length, mm 14.9 ± 3.7 14.7 ± 3.9 15.3 ± 3.2 0.369 
Number of portal tracts 8.4 ± 2.9 8.3 ± 2.7 8.4 ± 3.2 0.857 
Steatosis score, % 
S0, less than 5 % 
S1, 5 – 33 % 
S2, 34 – 66 % 
S3, more than 66 % 
 
2.0 
31.3 
46.9 
19.7 
 
3.0 
32.7 
50.5 
13.9 
 
0 
28.3 
39.1 
32.6 
 
0.045 
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 Overall 
n = 147 
Training cohort 
n = 101 
Validation cohort 
n = 46 
p 
NAFLD activity score, % 
0 – 2, not diagnostic of NASH 
3 – 4, probable NASH 
5 – 8, definite NASH 
 
35.4 
33.3 
31.3 
 
6.0 
48.5 
45.5 
 
10.9 
36.9 
52.2 
 
0.362 
Fibrosis score, % 
0, no fibrosis 
1, mild fibrosis 
2, moderate fibrosis 
3, severe fibrosis 
4, cirrhosis 
 
29.3 
41.5 
8.2 
19.0 
2.0 
 
30.7 
44.6 
5.9 
15.8 
3.0 
 
26.1 
34.8 
13.0 
26.1 
0 
 
0.198 
Transient elastography 
Success rate, % 
Median E, kPa 
IQR/median for E, % 
Median CAP, dB/m 
IQR/median for CAP, % 
 
98.3 ± 7.1 
7.8 (5.9 – 11.8) 
13 (9 – 17) 
321 (294 – 346) 
7 (5 – 10) 
 
99.2 ± 2.6 
7.8 (5.9 – 11.4) 
12 (8 – 16) 
315 (285 – 343) 
7 (5 – 11) 
 
96.3 ± 11.9 
8.0 (5.9 – 11.9) 
15 (10 – 20) 
332 (309 – 352) 
7 (6 – 10) 
 
0.020 
0.545 
0.015 
0.046 
0.634 
*p value comparing the training and validation cohort 
S = steatosis grade, NAFLD = non-alcoholic fatty liver disease, NASH = non-alcoholic steatohepatitis, E = estimated liver stiffness, IQR = 
interquartile range, CAP = controlled attenuation parameter
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NAFLD fibrosis score for prediction of advanced fibrosis 
In the training cohort, the NAFLD fibrosis score predicted absence of advanced 
fibrosis in 66 patients and presence of advanced fibrosis in 4 patients. The NAFLD fibrosis 
score was indeterminate for 31 patients. Of the 66 patients predicted as not having advanced 
fibrosis, 63 patients were correctly identified while 3 patients were not. Of the 4 patients 
predicted to have advanced fibrosis, 2 patients were correctly identified while 2 patients were 
not. The sensitivity, specificity, positive predictive value and negative predictive value for 
advanced fibrosis was 40.0 %, 96.9 %, 50.0 % and 95.5 %, respectively.  
In the validation cohort, the NAFLD fibrosis score predicted absence of advanced 
fibrosis in 32 patients and presence of advanced fibrosis in 1 patient. The NAFLD fibrosis 
score was indeterminate for 13 patients. Of the 32 patients predicted as not having advanced 
fibrosis, 28 patients were correctly identified while 4 patients were not. The patient predicted 
to have advanced fibrosis did have advanced fibrosis. The sensitivity, specificity, positive 
predictive value and negative predictive value for advanced fibrosis was 20.0 %, 100.0 %, 
100.0 % and 87.5 %, respectively.  
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Liver stiffness measurement for estimation of fibrosis stage 
Liver stiffness measurements according to histological fibrosis stage are shown in 
Figure 8.18. The median liver stiffness measurements (with 95 % confidence intervals) for 
F0, F1, F2, F3 and F4 were 5.40 kPa (4.40 kPa – 7.20 kPa), 6.95 kPa (5.90 kPa – 9.58 kPa), 
9.90 kPa (8.63 kPa – 12.35 kPa), 13.90 kPa (10.70 kPa – 17.70 kPa) and 26.30 kPa (20.20 
kPa – 35.30 kPa), respectively. There were significant increases in liver stiffness 
measurements with increasing histological fibrosis stage (p < 0.001). The sensitivity, 
specificity, positive predictive value and negative predictive value of liver stiffness 
measurement for estimating the various fibrosis stages in the training cohort is as shown in 
Table 8.12.        
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Figure 8.18 Liver stiffness measurements according to histological fibrosis stage 
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Table 8.12 The sensitivity, specificity, positive predictive value and negative predictive 
value of liver stiffness measurement for estimation of fibrosis stage equal to or greater than 
F1, F2, F3 and F4 in the training cohort using the cut-offs reported by Yoneda et al (Yoneda 
et al., 2007) 
 F1 F2 F3 F4 
Optimal cut-off, kPa  5.60 6.65 8.00 17.0 
Sensitivity, % 89.4 100.0 95.0 100.0 
Specificity, % 81.4 70.0 80.2 96.2 
Positive predictive value, % 81.9 44.1 45.2 37.5 
Negative predictive value, % 89.1 100.0 98.9 100.0 
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Liver stiffness measurement for prediction of advanced fibrosis 
In the training cohort, 55 patients were predicted not to have advanced fibrosis while 
46 patients were predicted to have advanced fibrosis. Of the 55 patients predicted not to have 
advanced fibrosis, 54 patients were correctly identified whilst 1 patient was not. Of the 46 
patients predicted to have advanced fibrosis, 18 patients were correctly identified whilst 28 
patients were not. A higher cut-off with greater specificity for prediction of advanced fibrosis 
was determined using the training cohort. The cut-off determined was 17 kPa. Using this 
higher cut-off, 9 patients were predicted to have advanced fibrosis while 37 patients were in 
the grey zone of 8 – 17 kPa. Of the 9 patients predicted to have advanced fibrosis using this 
higher cut-off, 8 patients were correctly identified while 1 patient was not. Using liver 
stiffness measurement < 8 kPa to predict absence of advanced fibrosis and ≥ 17 kPa to predict 
presence of advanced fibrosis, the sensitivity, specificity, positive predictive value and 
negative predictive value was 88.9 %, 98.2 %, 88.9 % and 98.2 %, respectively.  
In the validation cohort, 23 patients were predicted not to have advanced fibrosis 
whilst 23 patients were predicted to have advance fibrosis. Of the 23 patients predicted not 
to have advanced fibrosis, 22 patients were correctly identified and 1 patient was not. Of the 
23 patients predicted to have advanced fibrosis, 11 patients were correctly identified whilst 
12 patients were not. Using the 17 kPa cut-off, 4 patients were predicted to have advanced 
fibrosis and 19 patients were in the grey zone of 8 – 17 kPa. All 4 patients who were predicted 
to have advanced fibrosis had advanced fibrosis on histology. Using liver stiffness 
measurement < 8 kPa to predict absence of advanced fibrosis and ≥ 17 kPa to predict presence 
of advanced fibrosis, the sensitivity, specificity, positive predictive value and negative 
predictive value was 80.0 %, 100 %, 100 % and 98.2 %, respectively.  
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Combining the NAFLD fibrosis score and liver stiffness measurement for 
prediction of advanced fibrosis  
 In the training cohort, liver stiffness measurement was unhelpful in patients already 
predicted not to have advanced fibrosis using the NAFLD fibrosis score (Figure 8.19). If 
NAFLD fibrosis score alone was used, only 3 of the 66 patients (4.5 %) identified not to have 
advanced fibrosis would be misclassified. Although the combination of NAFLD fibrosis 
score and liver stiffness measurement could accurately identify patients without advanced 
fibrosis when they agree with each other, there was disagreement in 22 of the 66 patients 
(33.3 %). In other words, a substantial proportion of patients would need to undergo a liver 
biopsy to confirm their fibrosis stage when liver stiffness measurement was used in addition 
to the NAFLD fibrosis score to identify the small percentage of patients that would otherwise 
be misclassified as not having advanced fibrosis based on the NAFLD fibrosis score alone.  
There were only 4 patients predicted to have advanced fibrosis using the NAFLD 
fibrosis score, making it difficult to draw any conclusions regarding the role of liver stiffness 
measurement in this group of patients. While further studies with larger number of such 
patients are needed, it seemed reasonable that patients in whom the methods agree would not 
require a liver biopsy to confirm the presence of advanced fibrosis while patients in whom 
the methods disagree should have a liver biopsy to confirm the presence or absence of 
advanced fibrosis.  
As for patients in the indeterminate group based on the NAFLD fibrosis score, using 
the 8 and 17 kPa cut-offs for liver stiffness measurement increased the accuracy to predict 
the absence and presence of advanced fibrosis. All 7 patients predicted to have advanced 
fibrosis using this higher cut-off had advanced fibrosis. On the other hand, only 1 of the 8 
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patients identified as not having advanced fibrosis, actually had advanced fibrosis. The 16 
patients in the grey zone of 8 – 17 kPa should be considered for a liver biopsy.  
Based on these findings, we developed a 2-step algorithm for non-invasive prediction 
of advanced fibrosis in NAFLD patients (Figure 8.20). The sensitivity, specificity, positive 
predictive value and negative predictive value using this strategy to predict advanced fibrosis 
in the training cohort was 69.2 %, 98.6 %, 90.0 % and 94.6 %, respectively. Seventeen 
patients (16.8 %) would be considered for a liver biopsy. This strategy halved the number of 
patients requiring a liver biopsy compared to using the NAFLD fibrosis score alone while 
maintaining the accuracy for prediction of advanced fibrosis.  
The distribution of patients according to their NAFLD fibrosis score and liver 
stiffness measurement, and the status of advanced fibrosis in the validation cohort is as shown 
in Figure 8.21. In the validation cohort, the sensitivity, specificity, positive predictive value 
and negative predictive value was 42.9%, 100 %, 100 % and 88.6 %, respectively. Eight 
patients (17.4 %) would be considered for a liver biopsy.  
The percentages of misclassifications and patients requiring a liver biopsy using the 
NAFLD fibrosis score alone, liver stiffness measurement alone, both tests for all patients and 
the 2-step algorithm in the training and validation cohorts are shown in Tables 8.13 and 8.14, 
respectively. In the training cohort, the combination of NAFLD fibrosis score and liver 
stiffness measurement for all patients provided no advantage over using either of the tests 
alone. This was confirmed in the validation cohort.     
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Figure 8.19 Distribution of patients according to their NAFLD fibrosis score and liver stiffness measurement, and the status of advanced 
fibrosis in the training cohort 
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Figure 8.20 Proposed algorithm for the prediction of advanced fibrosis using a combination of NAFLD fibrosis score and liver stiffness 
measurement  
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Figure 8.21 Distribution of patients according to their NAFLD fibrosis score and liver stiffness measurement, and the status of advanced 
fibrosis in the validation cohort 
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Table 8.13 The percentages of misclassifications and patients requiring a liver biopsy using the NAFLD fibrosis score alone, transient 
elastography alone, and the 2 models combining the NAFLD fibrosis score and liver stiffness measurement in the training cohort 
 Misclassifications, % Patients requiring a liver biopsy, % 
NAFLD fibrosis score alone 7.1 30.7 
Liver stiffness measurement alone 30.7 0 
Liver stiffness measurement alone (with grey zone)  2.0 36.6 
Both tests for all patients 2.0 36.6 
2-step approach 6.0 16.8 
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Table 8.14 The percentages of misclassifications and patients requiring a liver biopsy using the NAFLD fibrosis score alone, transient 
elastography alone, and the 2 models combining the NAFLD fibrosis score and liver stiffness measurement in the validation cohort 
 Misclassifications, % Patients requiring a liver biopsy, % 
NAFLD fibrosis score alone 8.7 28.3 
Liver stiffness measurement alone 28.3 0 
Liver stiffness measurement alone (with grey zone)  2.2 41.3 
Both tests for all patients 2.2 43.5 
2-step approach 8.7 17.4 
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8.4.3 Discussion 
 While the survival of patients with simple steatosis approach that of the general 
population, patients with NASH have a higher mortality which is mainly attributed to 
progression of the liver disease. In a meta-analysis, patients with NASH had a liver-related 
mortality of 11 % – 17.5 % compared to 1.7 % – 2.7 % in patients with simple steatosis. 
Furthermore, NASH patients with advanced fibrosis had an even higher liver-related 
mortality compared to those without advanced fibrosis (Musso et al., 2011). Hence, assessing 
the severity of liver fibrosis in NAFLD patients is important to guide prognosis and to plan 
management. Due to the limitations of liver biopsy, non-invasive tests for estimation of liver 
fibrosis are gaining popularity. Evidence to support the use of non-invasive tests to predict 
patient outcomes are also beginning to emerge. In a retrospective study of 320 patients of 
which nearly 50 % had NASH with advanced fibrosis, Angulo and colleagues showed that 
the NAFLD fibrosis score predicted adverse liver-related outcomes with an AUROC of 0.86 
(Angulo et al., 2013). 
The strength of the NAFLD fibrosis score lies in its convenience of use and accuracy. 
Besides using readily available parameters, a freely-available and user-friendly on-line 
calculator makes it even more appealing (Mofrad et al., 2003). However, using the NAFLD 
fibrosis score alone, a substantial proportion of patients will fall in the indeterminate group. 
In the training cohort of our study population, the NAFLD fibrosis score resulted in 
misclassifications in only 7.1 % of patients but 30.7 % of patients were in the indeterminate 
group and would have required further evaluation with a liver biopsy. On the other hand, 
liver stiffness measurement was associated with a high false positive rate for advanced 
fibrosis resulting in misclassifications in 30.7 % of patients. A higher cut-off for predicting 
the presence of advanced fibrosis was determined and tested in our study to overcome the 
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high false positive rate. While misclassifications declined to 2.0 %, 38.6 % of patients were 
in the grey zone and would have required further evaluation with a liver biopsy.    
Our study clearly demonstrated that using both the NAFLD fibrosis score and liver 
stiffness measurement for all patients provided no advantage over using either of the tests 
alone. However, a 2-step algorithm using the NAFLD fibrosis score followed by liver 
stiffness measurement for patients with indeterminate and high NAFLD fibrosis score could 
reduce the number of patients requiring a liver biopsy whilst maintaining the accuracy of 
predicting advanced fibrosis. Combinations of non-invasive tests to predict fibrosis have 
been studied for other chronic liver diseases, such as the combination of liver stiffness 
measurement with Fibrometer for chronic hepatitis C (Boursier et al., 2011), and with 
Enhanced Liver Fibrosis for chronic hepatitis B (Wong et al., 2014). To the best of our 
knowledge, this is the first study to prospectively evaluate the combination of liver stiffness 
measurement and NAFLD fibrosis score for predicting advanced fibrosis in NAFLD patients.   
The study was carried out prospectively according to a planned protocol so that the 
data collected was robust. Liver biopsy and transient elastography were performed on the 
same day to minimize differences in findings due to changes over time. The procedures were 
carried out by experienced operators to ensure a good quality of specimens and 
measurements. However, as in any study using liver histology as the gold standard reference, 
the study may be limited by sampling and observer variability. Further studies should be 
carried out to determine the feasibility and cost-effectiveness of using this 2-step approach 
to identify NAFLD patients with advanced fibrosis to guide management and whether it 
could be used to predict patient outcomes.   
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8.4.4 Conclusion 
The use of liver stiffness measurement for patients with indeterminate and high 
NAFLD fibrosis scores allows accurate prediction of advanced fibrosis and reduced the 
number of patients requiring a liver biopsy. The combination of NAFLD fibrosis score and 
liver stiffness measurement for all patients provided no advantage over using either of the 
tests alone.   
 
 
 
 
 
 
 
 
 
 
 
 
Note: A poster on the findings from this study was presented at the Asia-Pacific Digestive 
Week 2014 in Bali, Indonesia, and the abstract was published in a supplementary issue of 
the Journal of Gastroenterology and Hepatology (Chan et al., 2014). The findings from this 
study was also presented at the Malaysian Society of Gastroenterology and Hepatology 
Annual Scientific Meeting in 2014. The full article has been accepted for publication in 
Hepatology International (Chan et al., 2014).  
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Chapter 9 
NAFLD in young adults 
9.1 Introduction 
As elucidated in Chapter 3 and reiterated in other earlier chapters of this thesis, non-
alcoholic fatty liver disease (NAFLD) has been rapidly increasing in the Asian-Pacific and 
has been estimated to affect up to 30 % of the general population (Chan et al., 2013). In 
Malaysia, the prevalence of NAFLD in the general population has been estimated to be 22.7 
% based on a study on individuals attending a health-check in a suburban medical facility 
(Goh et al., 2012). The prevalence of NAFLD among diabetics has been estimated to be 49.6 
% based on a separate study on a hospital clinic population (Chan et al., 2013) (see Chapter 
4). Both studies found an inordinately high prevalence of NAFLD among the Malays and 
Indians compared to the Chinese. There has been no published study on the prevalence of 
NAFLD among young adults in Malaysia. Whether the prevalence of NAFLD is different 
among young adults of different ethnic origin is unknown. Moreover, published studies that 
looked specifically at the prevalence of NAFLD and associated factors among young adults 
were limited in the existing literature. Hence, we embarked on this study to determine the 
prevalence of NAFLD among young adults and to identify associated factors. We also aimed 
to see if the prevalence of NAFLD were different among young adults of different ethnic 
origin.     
9.2 Patients and Methods 
This was a cross-sectional study on students pursuing their tertiary education at the 
Faculty of Medicine, University of Malaya who responded to an advertisement put up to 
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invite students to participate in the study. The study was approved by the University of 
Malaya Medical Centre’s Medical Ethics Committee and informed consent was obtained 
from all included subjects.  
Demographic and anthropometric data and relevant clinical and laboratory data were 
obtained using a standard protocol. Alcohol intake was estimated using the quantity-
frequency method (Goddard, 2007). Alcohol intake was estimated based on subject’s self-
reported frequency and quantity of intake of each of the 3 main types of alcoholic beverages 
i.e. beer, wine and spirit. Frequency of intake was divided into 7 categories i.e. almost every 
day, 5 or 6 days a week, 3 or 4 days a week, once or twice a week, once or twice a month, 
once every couple of months and once or twice a year. Each of these categories provided a 
multiplying factor for calculation of alcohol intake per week. Information on average intake 
during each drinking session was captured using common serving measurements and this 
was translated into units of alcohol based on the volume consumed and the alcohol by volume 
for each of the types of alcoholic beverages. Units of alcohol consumed in a week in the form 
of beer, wine and spirit was calculated separately and summed up to give an estimate of 
alcohol intake per week for each patient. Significant alcohol intake was defined as more than 
21 units per week for men and more than 14 units per week for women (Chalasani et al., 
2012).    
Frequency and duration of physical activities of moderate and vigorous intensity were 
determined for each student. According to recommendations by the American College of 
Sports Medicine and the American Heart Association, the following are the minimal amount 
of physical activity required to achieve substantial health benefits over and above the routine 
light-intensity physical activities of daily living: (1) 30 minutes of moderate-intensity 
physical activity 5 days per week, (2) 20 minutes of vigorous-intensity physical activity 3 
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days per week, or (3) a combination of moderate- and vigorous-intensity physical activity of 
more than 450 MET-minutes per week (Haskell et al., 2007). The term “physically active” 
was used to refer to students who reported any of these levels of physical activity in the study.      
Weight and height were measured using standardized equipment. BMI was calculated 
by dividing weight in kilogram by the square of height in meters. Subjects were categorized 
as underweight (BMI < 18.5 kg per m2), normal (18.5 kg per m2 ≤ BMI < 23.0 kg per m2), 
overweight (23.0 kg per m2 ≤ BMI < 25.0 kg per m2) or obese (BMI ≥ 25.0 kg per m2) 
(Anuurad et al., 2003). Waist circumference (WC) was measured at the mid-point between 
the lowest margin of the least palpable rib and the top of the iliac crest in the standing 
position. Central obesity was defined as WC > 90 cm for men and > 80 cm for women 
(Alberti et al., 2005). Blood pressure was measured in the sitting position using standardized 
equipment.    
All subjects had venous blood drawn after an overnight fast for blood glucose, 
glycated hemoglobin (HbA1c), lipid profile, liver profile, and viral hepatitis B and C 
serology. Biochemical measurements were performed using standard laboratory procedures. 
Impaired fasting glucose (IFG) was defined as fasting blood glucose (FBS) ≥ 5.5 mmol/L. A 
patient was considered to have dyslipidemia if the serum total cholesterol (TC) was ≥ 5.2 
mmol/L, if the serum triglyceride (TG) was ≥ 1.7 mmol/L, if the serum high-density 
lipoprotein (HDL) was < 1.0 mmol/L for men or < 1.3 mmol/L for women, or if the serum 
low-density lipoprotein (LDL) was ≥ 3.4 mmol/L. A patient was considered to have 
metabolic syndrome if three or more of the following were present: (1) central obesity, (2) 
systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg, (3) IFG, 
(4) hypertriglyceridemia, or (5) low serum HDL (according to the aforementioned cut-offs) 
(Alberti et al., 2009). Our laboratory’s upper limit of normal for liver enzymes were as 
 
 
203 
 
follow: alkaline phosphatase (ALP) 136 IU/L, aspartate aminotransferase (AST) 37 IU/L, 
alanine aminotransferase (ALT) 65 IU/L and gamma-glutamyl transpeptidase (GGT) 55 
IU/L.  Serum ALP, AST, ALT and GGT above these levels were considered as elevated. In 
addition, a more stringent cut-off of 30 IU/L for men and 19 IU/L for women was used for 
serum ALT level during data analysis. The Elecsys HBsAg II assay and the Elecsys Anti-
HCV II assay (Roche, Mannheim, Germany) were used to test for viral hepatitis B and C 
infection, respectively. 
Diagnosis of NAFLD was by trans-abdominal ultrasonography and following 
exclusion of significant alcohol intake, use of medications known to cause fatty liver and 
other causes of chronic liver disease. The following criteria were used for ultrasonographic 
diagnosis of fatty liver: increased echogenicity, posterior attenuation and loss of intra-hepatic 
architectural details (Joy et al., 2003). Investigators involved in other parts of the study were 
blinded to the ultrasonography findings, vice versa.     
Statistical analysis 
 With an estimated prevalence of 12.5 % based on a previous study that included 
adolescents (Alavian et al., 2009), a sample size of 169 patients was needed to estimate the 
prevalence with 95 % confidence and 5 % precision. Data were analyzed using SPSS 15.0. 
Continuous variables were expressed as mean ± standard deviation or median (inter-quartile 
range), and analyzed using student’s t-test or Mann-Whitney U test where appropriate. 
Categorical variables were expressed as percentage and analyzed using chi-square test or 
Fisher’s exact test where appropriate. Independent factors associated with NAFLD were 
identified using multiple logistic regression analysis. Significance was assumed at p < 0.05. 
9.3 Results   
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Subject characteristics 
Four hundred and seventy two subjects were included in the analysis (Figure 9.1). 
Mean age of the study population was 23.2 ± 2.4 years old comprising of 40.5 % men. The 
racial distribution was as follow: Chinese 53.6 %, Malay 30.3%, Indian 15.5 % and others 
0.6 %. Central obesity was seen in 18.2 % of the study population. Thirteen subjects (2.8 %) 
had the metabolic syndrome. 
Prevalence of NAFLD and associated factors 
The prevalence of NAFLD was 8.1 % (38/472). Characteristics of subjects with and 
without NAFLD are shown in Table 9.1. Subjects with NAFLD were older, had greater BMI 
and WC, and recorded higher SBP and DBP. They had higher FBS, serum TG and LDL 
levels and lower serum HDL level. Serum ALP, ALT, AST and GGT levels were higher in 
subjects with NAFLD. All subjects who had NAFLD had insulin resistance. Family history 
of diabetes mellitus, dyslipidemia or hypertension was not found to be associated with 
NAFLD. Prevalence of NAFLD was not significantly different between subjects who were 
“physically active” and those who were not. 
The prevalence of NAFLD was significantly higher among males compared to 
females (17.9 % vs. 3.3 %, p < 0.001). The prevalence of NAFLD was highest among the 
Indians followed by the Malays and the Chinese. This paralleled the prevalence of obesity 
among the different ethnic groups (Table 9.2).  Highest prevalence of NAFLD was seen 
among Indian and Malay males at 33.3 % and 25.5 %, respectively. The prevalence of 
NAFLD among Chinese males was 6.8 %.  
Univariate and multivariate analyses of factors associated with NAFLD 
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Univariate and multivariate analyses of factors associated with NAFLD are shown in 
Table 9.3. Obesity (instead of central obesity) and elevated serum ALT level using the 
standard laboratory cut-off (instead of the more stringent cut-off) were entered into the 
multivariate analysis as these had stronger association with NAFLD. Independent factors 
associated with NAFLD were: age, male gender, obesity and elevated serum ALT level.  
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Figure 9.1 Flow chart illustrating the details of subjects included/excluded in the analysis 
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Table 9.1 Characteristics of subjects with and without NAFLD 
 NAFLD P 
Yes No 
Age, years 25.2 ± 4.5 23.0 ± 2.1  < 0.001 
Male 76.3 % 37.3 % < 0.001 
Race 
Malay 
Chinese 
Indian 
Others 
 
44.7 % 
23.7 % 
28.9 % 
2.6 % 
 
29.0 % 
56.2 % 
14.3 % 
0.5 % 
 
0.001 
Family history of diabetes mellitus 57.9 % 69.5 % 0.139 
Family history of hypertension 52.6 % 56.8 % 0.618 
Family history of ischemic heart disease 15.8 % 8.3 % 0.122 
“Physically active”  34.2 % 41.7 % 0.368 
Smoking 5.3 % 1.4 % 0.076 
Body mass index, kg per m2 28.7 ± 4.5 20.9 ± 3.2 < 0.001 
Obese 81.6 % 8.8 % < 0.001 
Waist circumference, cm 96.4 ± 10.1 74.4 ± 9.5 < 0.001 
Centrally obese 81.6 % 12.7 % < 0.001 
Metabolic syndrome 18.9 % 1.2 % < 0.001 
Systolic blood pressure (SBP), mmHg 124 ± 12 115 ± 11 < 0.001 
SBP ≥ 130 mmHg 37.8 % 11.6% < 0.001 
Diastolic blood pressure (DBP), mmHg 79 ± 9 75 ± 9 0.003 
DBP ≥ 85 mmHg 21.6 % 12.3 % 0.105 
Fasting blood sugar, mmol/L 4.9 ± 0.4 4.6 ± 0.4 < 0.001 
Impaired fasting glucose 5.4 % 1.4 % 0.126 
HOMA IR* 3.6 (2.2 – 4.9) 1.5 (1.0 – 2.1) < 0.001 
Insulin resistant 100.0 % 57.5 % < 0.001 
Total cholesterol (TC), mmol/L 4.7 (4.2 – 5.3) 4.6 (4.1 – 5.1) 0.322 
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 NAFLD P 
Yes No 
TC  ≥ 5.2 mmol/L 29.7 % 22.1 % 0.291 
High-density lipoprotein (HDL), mmol/L 1.2 (1.1 – 1.4) 1.5 (1.3 – 1.7) < 0.001 
HDL < 1.0 mmol/L for men and < 1.3 mmol/L for women  24.3 % 9.0 % 0.003 
Low-density lipoprotein (LDL), mmol/L 2.9 (2.6 – 3.4) 2.7 (2.3 – 3.2) 0.018 
LDL  ≥ 3.4 mmol/L 21.6 % 16.8 % 0.495 
Triglyceride (TG), mmol/L 1.0 (0.7 – 1.6) 0.7 (0.5 – 0.9) < 0.001 
TG  ≥ 1.7 mmol/L  21.6 % 2.6 % < 0.001 
Alkaline phosphatase (ALP), IU/L 82 (65 – 95) 69 (58 – 81) 0.001 
ALP ≥ 136 IU/L 2.7 % 0.7 % 0.281 
Alanine aminotransferase (ALT), IU/L 49 (40 – 72) 27 (21 – 33) < 0.001 
ALT  ≥ 65 IU/L 29.7 % 2.1 % < 0.001 
ALT  ≥ 30 IU/L for men and ≥ 19 IU/L for women  97.3 % 66.7 % < 0.001 
Aspartate aminotransferase (AST), IU/L 24 (21 – 32) 17 (14 – 21) < 0.001 
AST  ≥ 37 IU/L  8.1 % 3.2 % 0.143 
Gamma glutamyl transpeptidase (GGT), IU/L 35 (25 – 42)  21 (17 – 26)   < 0.001 
GGT  ≥ 55 IU/L  5.4 % 1.6 % 0.154 
*n = 228 for HOMA IR and insulin resistance  
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Table 9.2 Prevalence of NAFLD and obesity according to race and gender 
 NAFLD Central obesity 
Malay 
Overall 
Male 
Female 
 
11.9 % (17/143) 
25.5 % (12/47) 
5.2 % (5/96) 
 
22.4 % (32/143) 
42.6 % (20/47) 
12.5 % (12/96) 
Chinese 
Overall 
Male 
Female 
 
3.6 % (9/253) 
6.8 % (8/118) 
0.7 % (1/135) 
 
8.3 % (21/253) 
11.0 % (13/118) 
5.9 % (8/135) 
Indian 
Overall 
Male 
Female 
 
15.1 % (11/73) 
33.3 % (8/24) 
6.1 % (3/49) 
 
20.5 % (15/73) 
33.3 % (8/24) 
14.3 % (7/49) 
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Table 9.3 Univariate and multivariate analyses of factors associated with NAFLD  
 Univariate analysis Multivariate analysis 
 OR 95 % CI p OR 95 % CI p 
Age 1.30 1.16 – 1.46 < 0.001 1.18 1.00 – 1.38 0.046 
Male 5.41 2.50 – 11.72 < 0.001 4.92 1.44 – 16.79 0.011 
Race 
Malay 
Chinese 
Indian 
 
3.66 
1 
4.81 
 
1.59 – 8.44 
– 
1.91 – 12.12 
 
0.002 
– 
0.001 
 
2.82 
1 
4.14 
 
0.85 – 9.41 
– 
0.98 – 17.45 
 
0.091 
– 
0.053 
Obese 29.38 12.31 – 70.12 < 0.001 19.24 6.94 – 53.32 < 0.001 
SBP ≥ 130 mmHg 5.01 2.45 – 10.23 < 0.001 1.15 0.35 – 3.81 0.816 
TG ≥ 1.7 mmol/L 11.85 4.55 – 30.88 < 0.001 5.11 0.94 – 27.73 0.058 
HDL < 1.0 mmol/L for men and < 1.3 
mmol/L for women 
3.14 1.39 – 7.12 0.006 2.00 0.49 – 8.14 0.332 
ALT ≥ 65 mmol/L 19.19 7.33 – 50.28 < 0.001 9.96 2.42 – 40.95 0.001 
 
SBP = systolic blood pressure, TG = triglyceride, HDL = high-density lipoprotein, ALT = alanine aminotransferase
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9.4 Discussion 
 As discussed in Chapter 3, the prevalence of NAFLD among young children has been 
reported to be between 2.1 % and 4.5 % in studies from the Asian-Pacific region. In studies 
that included adolescents, the prevalence was higher and ranged between 7.1 % and 16.9 %. 
Hence, the estimated prevalence of 8.1 % for young Malaysian adults is still consistent with 
the fact that prevalence of NAFLD increases with increasing age. While the overall 
prevalence is relatively low, it is alarming to note the very high prevalence of NAFLD among 
young Indian and Malay males, which were estimated to be 33.3 % and 25.5 %, respectively. 
The inordinately higher prevalence of NAFLD among the Indians and Malays has been 
observed in two separate studies on multi-racial Malaysian populations (Goh et al., 2012; 
Chan et al., 2013). The current study confirms that differences in prevalence of NAFLD 
among the different ethnic groups in Malaysia can be observed as early as young adulthood. 
This supports that genetic differences probably have a role in the difference in prevalence of 
NAFLD among the different ethnic groups. As presented in Chapter 4, dietary differences 
among the different ethnic groups may also play an important role (Chan et al., 2013).  
This study also clearly showed that the prevalence of NAFLD was significantly 
higher in males compared to females across the different ethnic groups. In younger 
populations, NAFLD has been consistently shown to be more prevalent among men than 
women, but such trend was no longer observed in older populations suggesting the potential 
influence of sex hormones in the development of the disease. This study also clearly showed 
that NAFLD is associated with traditional risk factors for cardiovascular diseases. The 
difference in prevalence of NAFLD in the different ethnic groups and the clustering of 
cardiovascular risk factors in patients with NAFLD would explain the higher prevalence of 
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ischemic heart disease in Indians and Malays compared to Chinese that has been reported in 
previous studies (Danaraj et al., 1959; J. Lee et al., 2001). Although none of the subjects with 
NAFLD had diabetes mellitus based on fasting glucose, the diagnosis of diabetes mellitus in 
subjects with NAFLD can only be reliably excluded with an oral glucose tolerance test. A 
study from Hong Kong demonstrated that nearly half of NAFLD patients with diabetes 
mellitus or impaired glucose tolerance had normal fasting glucose (Wong et al., 2006). 
All young adults with NAFLD in our study had insulin resistance. Insulin resistance 
is important in the pathogenesis of NAFLD (Dowman et al., 2010). Over half of subjects 
without NAFLD also had insulin resistance. These subjects may be at increased risk of 
developing NAFLD. Although serum ALT level was significantly higher in subjects with 
NAFLD and elevated serum ALT level remained an independent factor associated with 
NAFLD on multivariate analysis, it is not accurate enough for diagnosis of NALFD. When 
our laboratory cut-off was used, the sensitivity and specificity for diagnosis of NALFD was 
29.7 % and 97.9 %, respectively. When the more stringent cut-off was used, sensitivity 
increased to 97.3 % but at the expense of specificity which dropped to 33.3 %.    
There are limited published studies that looked specifically at the prevalence of 
NAFLD and associated factors among young adults. Moreover, our study compared young 
adults of different ethnic origins. However, as our study population consisted of subjects who 
were pursuing their tertiary education and who volunteered, the study population may be 
arguably more health conscious. Hence, the true prevalence of NAFLD may have been 
underestimated. Nevertheless, this study provided useful insights into the epidemiology of 
NAFLD in a young adult population and the differences among the different ethnic groups. 
The diagnosis of NAFLD was by ultrasonography and following careful exclusion of other 
causes of chronic liver disease. Ultrasonography is by far the most common method to 
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diagnose fatty liver in clinical practice and in epidemiological studies with good sensitivity 
and specificity. Ultrasonography is better than serum aminotransferase level alone in 
diagnosis of NALFD but is not as accurate as histopathological examination of liver biopsy 
specimen. However, a liver biopsy is invasive and is not feasible in a study of this nature.   
9.5  Conclusion 
The overall prevalence of NAFLD among young Malaysian adults was found to be 
relatively low. However, an inordinately high prevalence of NALFD was observed among 
Indian and Malay males consistent with the higher prevalence of obesity in these groups. 
This study confirms that differences in prevalence of NAFLD among the different ethnic 
groups in Malaysia can be observed as early as young adulthood.  Independent factors 
associated with NAFLD were: age, male gender, obesity and elevated serum ALT level.  
 
 
 
 
 
Note: The findings from this study was presented at the Malaysian Society of 
Gastroenterology and Hepatology Annual Scientific Meeting in 2013. A poster on the 
findings from this study was also presented at the World Congress of Gastroenterology 2013 
in Shanghai, China, and the abstract was published in a supplementary issue of the Journal 
of Gastroenterology and Hepatology (Chan et al., 2013). The full article has been published 
in Hepatology International (Chan et al., 2013).   
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Chapter 10 
Summary and conclusions 
This thesis describes the findings from epidemiological and clinical studies on non-
alcoholic fatty liver disease (NAFLD) that I had the opportunity to carry out over the few 
years that I was working in the Gastroenterology and Hepatology Unit of the University of 
Malaya and the University of Malaya Medical Centre. 
In Chapter 2, a short review on the historical aspects and the current concepts of 
NAFLD, including the definition, pathogenesis, association with the metabolic syndrome 
and diagnosis were presented. This was followed by an extensive review of the 
epidemiology of the disease in the Asian-Pacific in Chapter 3. The prevalence of NAFLD 
has increased rapidly over the years and is now comparable to that in Western countries. 
The prevalence of NAFLD among patients with diabetes mellitus was studied and 
the findings were presented in Chapter 4. Half of the patients attending the diabetic clinic 
had NAFLD and it was independently associated with central obesity and elevated serum 
alanine aminotransferase (ALT) level. The prevalence of NAFLD was found to be higher 
among the Malays and Indians compared to the Chinese consistent with the higher 
prevalence of central obesity and the higher percentage of calorie intake from fat in the 
former groups of patients.  
In Chapter 5, findings from further analysis on dietary intake and physical activity 
of diabetic patients with and without NAFLD were presented. Low level of physical 
activity and high percentage calorie intake from fat, high cholesterol food and high 
saturated fatty acid food was associated with NAFLD in centrally obese but not in lean 
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diabetic patients suggesting that low level of physical activity and poor dietary habits have 
different impact on NAFLD in diabetic patients with and without central obesity.   
In Chapter 6, ultrasonography-diagnosed NAFLD was found not to be associated 
with ischemic heart disease (IHD) among diabetic patients. Possible explanations for this 
finding were discussed. Independent factors associated with IHD identified were older age, 
lower levels of physical activity, greater WC and higher HbA1c levels. 
The progressive nature of non-alcoholic steatohepatitis (NASH), the more severe 
form of NAFLD, was clearly demonstrated in the cohort study presented in Chapter 7. 
Based on the findings from this study, NAFLD patients with persistently elevated serum 
liver enzymes should be suspected of having worsened NAFLD activity score and all 
patients diagnosed with NASH should be considered for specific interventions to prevent 
disease progression.  
In Chapter 8, we evaluated the use of non-invasive methods for assessment of 
severity of liver disease in NAFLD. Controlled attenuation parameter is excellent for the 
detection of significant hepatic steatosis but is less useful for distinguishing the different 
grades of significant hepatic steatosis in NAFLD patients. Neither plasma M30 nor serum 
ALT, aspartate aminotransferase (AST) or gamma glutamyl transpeptidase (GGT) levels 
were good enough for diagnosis of NASH among NAFLD patients. A more accurate yet 
simple and non-invasive test for diagnosis and follow-up of NASH is needed. The NAFLD 
fibrosis score, combined with liver stiffness measurement when necessary, allows accurate 
prediction of advanced fibrosis and reduces the need for liver biopsy in NAFLD patients. 
In Chapter 9, findings from the study on the prevalence of NAFLD among young 
adults were presented. The prevalence of NAFLD among young adults was relatively low 
but an inordinately high prevalence of NALFD was observed among Indian and Malay 
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males consistent with the higher prevalence of obesity in these groups. The study also 
confirmed that differences in prevalence of NAFLD among the different ethnic groups in 
Malaysia can be observed as early as young adulthood.   
The studies that have been performed for the writing of this thesis have yielded 
useful information on NAFLD and represent the majority of studies of their kind performed 
in Malaysia to date. However, there is no doubt that further studies are necessary to solve 
many of the unanswered questions, particularly in the treatment of this increasingly 
common and potentially serious condition that will continue to inflict and affect many 
Malaysians in time to come. 
 
 
       
 
 
217 
 
References 
Adams, L. A., Lymp, J. F., St Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & 
Angulo, P. (2005). The natural history of nonalcoholic fatty liver disease: a population-
based cohort study. Gastroenterology, 129(1), 113-121.  
Adibi, A., Kelishadi, R., Beihaghi, A., Salehi, H., & Talaei, M. (2009). Sonographic fatty 
liver in overweight and obese children, a cross sectional study in Isfahan. Endokrynol Pol, 
60(1), 14-19.  
Agarwal, A. K., Jain, V., Singla, S., Baruah, B. P., Arya, V., Yadav, R., & Singh, V. P. 
(2011). Prevalence of non-alcoholic fatty liver disease and its correlation with coronary risk 
factors in patients with type 2 diabetes. J Assoc Physicians India, 59, 351-354.  
Ahmed, A. M., Hassan, M. S., Abd-Elsayed, A., Hassan, H., Hasanain, A. F., & Helmy, A. 
(2011). Insulin resistance, steatosis, and fibrosis in Egyptian patients with chronic Hepatitis 
C virus infection. Saudi J Gastroenterol, 17(4), 245-251.  
Akahoshi, M., Amasaki, Y., Soda, M., Tominaga, T., Ichimaru, S., Nakashima, E., . . . 
Yano, K. (2001). Correlation between fatty liver and coronary risk factors: a population 
study of elderly men and women in Nagasaki, Japan. Hypertens Res, 24(4), 337-343.  
Alavian, S. M., Mohammad-Alizadeh, A. H., Esna-Ashari, F., Ardalan, G., & Hajarizadeh, 
B. (2009). Non-alcoholic fatty liver disease prevalence among school-aged children and 
adolescents in Iran and its association with biochemical and anthropometric measures. 
Liver Int, 29(2), 159-163.  
Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., . . 
. International Association for the Study of, Obesity. (2009). Harmonizing the metabolic 
syndrome: a joint interim statement of the International Diabetes Federation Task Force on 
Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart 
Association; World Heart Federation; International Atherosclerosis Society; and 
International Association for the Study of Obesity. Circulation, 120(16), 1640-1645.  
Alberti, K. G., Zimmet, P., Shaw, J., & Group, I. D. F. Epidemiology Task Force 
Consensus. (2005). The metabolic syndrome--a new worldwide definition. Lancet, 
366(9491), 1059-1062.  
Amarapurkar, D., Kamani, P., Patel, N., Gupte, P., Kumar, P., Agal, S., . . . Deshpande, A. 
(2007). Prevalence of non-alcoholic fatty liver disease: population based study. Ann 
Hepatol, 6(3), 161-163.  
 
 
218 
 
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., . . . Day, C. 
P. (2007). The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in 
patients with NAFLD. Hepatology, 45(4), 846-854.  
Anuurad, E., Shiwaku, K., Nogi, A., Kitajima, K., Enkhmaa, B., Shimono, K., & Yamane, 
Y. (2003). The new BMI criteria for asians by the regional office for the western pacific 
region of WHO are suitable for screening of overweight to prevent metabolic syndrome in 
elder Japanese workers. J Occup Health, 45(6), 335-343.  
Argo, C. K., Northup, P. G., Al-Osaimi, A. M., & Caldwell, S. H. (2009). Systematic 
review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol, 
51(2), 371-379. 
Assy, N., Djibre, A., Farah, R., Grosovski, M., & Marmor, A. (2010). Presence of coronary 
plaques in patients with nonalcoholic fatty liver disease. Radiology, 254(2), 393-400.  
Aygun, C., Kocaman, O., Sahin, T., Uraz, S., Eminler, A. T., Celebi, A., . . . Hulagu, S. 
(2008). Evaluation of metabolic syndrome frequency and carotid artery intima-media 
thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. 
Dig Dis Sci, 53(5), 1352-1357.  
Ayonrinde, O. T., Olynyk, J. K., Beilin, L. J., Mori, T. A., Pennell, C. E., de Klerk, N., . . . 
Adams, L. A. (2011). Gender-specific differences in adipose distribution and 
adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology, 53(3), 
800-809.  
Bae, J. C., Cho, Y. K., Lee, W. Y., Seo, H. I., Rhee, E. J., Park, S. E., . . . Kim, B. I. (2010). 
Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels 
in nondiabetic subjects. Am J Gastroenterol, 105(11), 2389-2395.  
Bedogni, G., Miglioli, L., Masutti, F., Tiribelli, C., Marchesini, G., & Bellentani, S. (2005). 
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition 
and liver study. Hepatology, 42(1), 44-52.  
Bhatia, L. S., Curzen, N. P., Calder, P. C., & Byrne, C. D. (2012). Non-alcoholic fatty liver 
disease: a new and important cardiovascular risk factor? Eur Heart J, 33(10), 1190-1200.  
Boursier, J., de Ledinghen, V., Zarski, J. P., Rousselet, M. C., Sturm, N., Foucher, J., . . . 
Cales, P. (2011). A new combination of blood test and fibroscan for accurate non-invasive 
diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol, 106(7), 1255-
1263.  
 
 
219 
 
Brzozowska, M. M., Ostapowicz, G., & Weltman, M. D. (2009). An association between 
non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol, 
24(2), 243-247.  
Caballeria, L., Pera, G., Auladell, M. A., Toran, P., Munoz, L., Miranda, D., . . . Aizpurua, 
M. M. (2010). Prevalence and factors associated with the presence of nonalcoholic fatty 
liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol, 22(1), 24-32.  
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., . . . 
American College of, Gastroenterologyh. (2012). The diagnosis and management of non-
alcoholic fatty liver disease: practice guideline by the American Gastroenterological 
Association, American Association for the Study of Liver Diseases, and American College 
of Gastroenterology. Gastroenterology, 142(7), 1592-1609.  
Chan, W. K., Cheah, P. L., Ida Normiha Hilmi, & Goh, K. L. (2012). Clinical and 
histological follow-up of a cohort of patients with NAFLD. J Gastroenterol Hepatol, 
27(Suppl. 5), 242.  
Chan, W. K., Hilmi, I. N., Cheah, P. L., & Goh, K. L. (2014). Progression of non-alcoholic 
fatty liver disease – a prospective clinicopathological follow-up study. J Dig Dis, 15(10), 
545-552. 
Chan, W. K., & Goh, K. L. (2013). Epidemiology of a fast-emerging disease in the Asia-
Pacific region: non-alcoholic fatty liver disease. Hepatol Int, 7(1), 65-71.  
Chan, W.K., Norhaniza Bahar, Hamizah Razlan, Vijayananthan, A., Sithaneshwar, P., & 
Goh, K.L. (2013). Non-alcoholic fatty liver disease in a young multiracial Asian population 
– a worrying ethnic predilection in Malay and Indian males. Hepatol Int, 8(1), 121-127.  
Chan, W. K., Norhaniza Bahar, Hamizah Razlan, Vijayananthan, A., Sthaneshwar, P., & 
Goh, K. L. (2013). Prevalence of NAFLD and associated factors in a young multi-racial 
Malaysian population. J Gastroenterol Hepatol, 28(Suppl. 3), 407.  
Chan, W. K., Nik Mustapha, N. R., & Mahadeva, S. (2014). Controlled attenuation 
parameter for the detection and quantification of hepatic steatosis in non-alcoholic fatty 
liver disease. J Gastroenterol Hepatol, 29(7), 1470-1476. 
Chan, W. K., Nik Mustapha, N. R., & Mahadeva, S. (2014). Controlled attenuation 
parameter for the detection and quantification of hepatic steatosis in non-alcoholic fatty 
liver disease. Hepatol Int, 8(Suppl. 1), 353-354. 
 
 
220 
 
Chan, W. K., Nik Mustapha, N. R., & Mahadeva, S. (2014). A novel 2-step approach 
combining the NAFLD fibrosis score and liver stiffness measurement for predicting 
advanced fibrosis. Hepatol Int, in press.  
Chan, W. K., Nik Mustapha, N. R., & Mahadeva, S. (2014). Combination of NAFLD 
fibrosis score and liver stiffness measurement for predicting advanced fibrosis in non-
alcoholic fatty liver disease. J Gastroenterol Hepatol, 29(Suppl. 3), 183-184. 
Chan, W. K., Sthaneshwar, P., Nik Mustapha, N. R., & Mahadeva, S. (2014). Limited 
utility of plasma M30 in detecting non-alcoholic steatohepatitis – a comparison with 
routine biochemical markers. PLoS One, 9(9), e105903. 
Chan, W. K., Sthaneshwar, P., Nik Mustapha, N. R., & Mahadeva, S. (2014). Limited 
utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis – a 
comparison with routine biochemical markers. J Gastroenterol Hepatol, 29(Suppl. 3), 182-
183.   
Chan, W. K., Tan, A. T., Vethakkan S. R., Tah, P. C., Vijayananthan, A., & Goh, K. L. 
(2012). Prevalence of NAFLD among diabetic patients in the outpatient clinic of a 
Malaysian hospital and associated factors. J Gastroenterol Hepatol, 27(Suppl. 5), 241-242.  
Chan, W. K., Tan, A. T., Vethakkan S. R., Tah, P. C., Vijayananthan, A., & Goh, K. L. 
(2013). Non-alcoholic fatty liver disease (NAFLD) in diabetics – prevalence and predictive 
factors in a multi-racial hospital clinic population in Malaysia. J Gastroenterol Hepatol, 
28(8), 1375-83.  
Chan, W. K., Tan, A. T., Vethakkan S. R., Tah, P. C., Vijayananthan, A., & Goh, K. L. 
(2013). US-diagnosed NAFLD is not associated with IHD among long-standing poorly-
controlled diabetics. J Gastroenterol Hepatol, 28(Suppl. 3), 407.  
Chan, W. K., Tan, A. T., Vethakkan, S. R., Tah, P. C., Vijayananthan, A., & Goh, K. L. 
(2014). Ultrasonography-diagnosed non-alcoholic fatty liver disease is not associated with 
prevalent ischemic heart disease among diabetics in a multiracial Asian hospital clinic 
population. Clin Res Hepatol Gastroenterol, 38(3), 284-291. 
Chan, W. K., Tan, A. T., Vethakkan S. R., Tah, P. C., Vijayananthan, A., & Goh, K. L. 
(2014). Low physical activity and energy dense Malaysian foods are associated with non-
alcoholic fatty liver disease in centrally obese but not in non-centrally obese patients with 
diabetes mellitus. Asia Pac J Clin Nutr, in press. 
 
 
221 
 
Chen, C. H., Huang, M. H., Yang, J. C., Nien, C. K., Etheredge, G. D., Yang, C. C., . . . 
Yueh, S. K. (2006). Prevalence and risk factors of gallstone disease in an adult population 
of Taiwan: an epidemiological survey. J Gastroenterol Hepatol, 21(11), 1737-1743.  
Chen, C. H., Huang, M. H., Yang, J. C., Nien, C. K., Yang, C. C., Yeh, Y. H., & Yueh, S. 
K. (2006). Prevalence and risk factors of nonalcoholic fatty liver disease in an adult 
population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese 
adults. J Clin Gastroenterol, 40(8), 745-752.  
Chen, C. H., Huang, M. H., Yang, J. C., Nien, C. K., Yang, C. C., Yeh, Y. H., & Yueh, S. 
K. (2007). Prevalence and etiology of elevated serum alanine aminotransferase level in an 
adult population in Taiwan. J Gastroenterol Hepatol, 22(9), 1482-1489.  
Chen, Z. W., Chen, L. Y., Dai, H. L., Chen, J. H., & Fang, L. Z. (2008). Relationship 
between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver 
disease. J Zhejiang Univ Sci B, 9(8), 616-622.  
Chon, Y. E., Jung, K. S., Kim, S. U., Park, J. Y., Park, Y. N., Kim, D. Y., . . . Han, K. H. 
(2013). Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients 
with chronic liver diseases: a prospective study of a native Korean population. Liver Int. 
doi: 10.1111/liv.12282 
Cortez-Pinto, H., Jesus, L., Barros, H., Lopes, C., Moura, M. C., & Camilo, M. E. (2006). 
How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr, 
25(5), 816-823.  
Cusi, K., Chang, Z., Harrison, S., Lomonaco, R., Bril, F., Orsak, B., . . . Tio, F. (2014). 
Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients 
with non-alcoholic fatty liver disease. J Hepatol, 60(1), 167-174.  
Dai, H., Chu, L., Song, S., Li, W., Zhang, L., Wu, Z., . . . Duan, Q. (2009). Prevalence of 
and risk factors for fatty liver disease in a professional population of Wuhan, China. Public 
Health, 123(8), 545-548.  
Danaraj, T. J., Acker, M. S., Danaraj, W., Wong, H. O., & Tan, B. Y. (1959). Ethnic group 
differences in coronary heart disease in Singapore: an analysis of necropsy records. Am 
Heart J, 58, 516-526.  
Das, K., Mukherjee, P. S., Ghosh, A., Ghosh, S., Mridha, A. R., Dhibar, T., . . . 
Chowdhury, A. (2010). Nonobese population in a developing country has a high prevalence 
of nonalcoholic fatty liver and significant liver disease. Hepatology, 51(5), 1593-1602.  
 
 
222 
 
Dassanayake, A. S., Kasturiratne, A., Rajindrajith, S., Kalubowila, U., Chakrawarthi, S., De 
Silva, A. P., . . . de Silva, H. J. (2009). Prevalence and risk factors for non-alcoholic fatty 
liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol, 
24(7), 1284-1288.  
de Ledinghen, V., Vergniol, J., Foucher, J., Merrouche, W., & le Bail, B. (2012). Non-
invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and 
transient elastography. Liver Int, 32(6), 911-918.  
Diab, D. L., Yerian, L., Schauer, P., Kashyap, S. R., Lopez, R., Hazen, S. L., & Feldstein, 
A. E. (2008). Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic 
steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol, 6(11), 1249-1254.  
Kim D., Kim W.R., Kim H.J., Therneau T.M. (2013). Association between noninvasive  
fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the 
United States. Hepatology, 57(4), 1357-1365.  
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. 
J. (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with 
nonalcoholic fatty liver disease. J Clin Invest, 115(5), 1343-1351. doi: 10.1172/JCI23621 
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010). Pathogenesis of non-
alcoholic fatty liver disease. QJM, 103(2), 71-83.  
Ekstedt, M., Franzen, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., 
& Kechagias, S. (2006). Long-term follow-up of patients with NAFLD and elevated liver 
enzymes. Hepatology, 44(4), 865-873.  
Fan, J. G., Li, F., Cai, X. B., Peng, Y. D., Ao, Q. H., & Gao, Y. (2007). The importance of 
metabolic factors for the increasing prevalence of fatty liver in Shanghai factory workers. J 
Gastroenterol Hepatol, 22(5), 663-668.  
Fan, J. G., Zhu, J., Li, X. J., Chen, L., Lu, Y. S., Li, L., . . . Chen, S. Y. (2005). Fatty liver 
and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol, 20(12), 
1825-1832.  
Fang, J. G., Zhu, J., Li, X. J., Li, R., Dai, F., Song, X. M., . . . Chen, S. Y. (2005). 
[Epidemiological survey of prevalence of fatty liver and its risk factors in a general adult 
population of Shanghai]. Zhonghua Gan Zang Bing Za Zhi, 13(2), 83-88.  
 
 
223 
 
Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D., & Gores, 
G. J. (2003). Hepatocyte apoptosis and fas expression are prominent features of human 
nonalcoholic steatohepatitis. Gastroenterology, 125(2), 437-443.  
Feldstein, A. E., Wieckowska, A., Lopez, A. R., Liu, Y. C., Zein, N. N., & McCullough, A. 
J. (2009). Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic 
steatohepatitis: a multicenter validation study. Hepatology, 50(4), 1072-1078.  
Finelli, C., & Tarantino, G. (2012). Is there any consensus as to what diet or lifestyle 
approach is the right one for NAFLD patients? J Gastrointestin Liver Dis, 21(3), 293-302.  
Fotbolcu, H., Yakar, T., Duman, D., Karaahmet, T., Tigen, K., Cevik, C., . . . Dindar, I. 
(2010). Impairment of the left ventricular systolic and diastolic function in patients with 
non-alcoholic fatty liver disease. Cardiol J, 17(5), 457-463.  
Fu, J. F., Liang, L., Wang, C. L., Hong, F., Dong, G. P., & Li, Y. (2006). [Nonalcoholic 
steatohepatitis in obese children: the prevalence and possible mechanism]. Zhejiang Da Xue 
Xue Bao Yi Xue Ban, 35(1), 64-68.  
Gao, A. B., Xiao, Q., Li, L. Y., Gao, Y., Zhang, H. N., & Miao, J. (2008). [Epidemiological 
survey of the association between non alcoholic fatty liver disease and metabolic syndrome 
in civil servants of Chongqing city]. Zhonghua Yu Fang Yi Xue Za Zhi, 42(2), 107-110.  
Gentile, C. L., Frye, M. A., & Pagliassotti, M. J. (2011). Fatty acids and the endoplasmic 
reticulum in nonalcoholic fatty liver disease. Biofactors, 37(1), 8-16.  
Goddard, E. (2007). Estimating alcohol consumption from survey data: updated method of 
converting volumes to units. In National Statistics Methodological Series No. 37. Newport: 
National Statistics. 
Goh, S.C., Ho E.L.M., Goh K.L. (2013). Prevalence and risk factors of non-alcoholic fatty 
liver disease in a multiracial suburban Asian population in Malaysia. Hepatol Int, 7(2), 548-
554.  
Hamaguchi, M., Kojima, T., Itoh, Y., Harano, Y., Fujii, K., Nakajima, T., . . . Okanoue, T. 
(2007). The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects 
the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol, 102(12), 2708-
2715.  
 
 
224 
 
Hamaguchi, M., Kojima, T., Takeda, N., Nagata, C., Takeda, J., Sarui, H., . . . Yoshikawa, 
T. (2007). Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. 
World J Gastroenterol, 13(10), 1579-1584.  
Haskell, W. L., Lee, I. M., Pate, R. R., Powell, K. E., Blair, S. N., Franklin, B. A., . . . 
American Heart, Association. (2007). Physical activity and public health: updated 
recommendation for adults from the American College of Sports Medicine and the 
American Heart Association. Circulation, 116(9), 1081-1093.  
Hou, X. H., Zhu, Y. X., Lu, H. J., Chen, H. F., Li, Q., Jiang, S., . . . Jia, W. P. (2011). Non-
alcoholic fatty liver disease's prevalence and impact on alanine aminotransferase associated 
with metabolic syndrome in the Chinese. J Gastroenterol Hepatol, 26(4), 722-730.  
Hsiao, P. J., Kuo, K. K., Shin, S. J., Yang, Y. H., Lin, W. Y., Yang, J. F., . . . Yu, M. L. 
(2007). Significant correlations between severe fatty liver and risk factors for metabolic 
syndrome. J Gastroenterol Hepatol, 22(12), 2118-2123.  
Hudgins, L. C., Hellerstein, M. K., Seidman, C. E., Neese, R. A., Tremaroli, J. D., & 
Hirsch, J. (2000). Relationship between carbohydrate-induced hypertriglyceridemia and 
fatty acid synthesis in lean and obese subjects. J Lipid Res, 41(4), 595-604.  
Hui, A. Y., Wong, V. W., Chan, H. L., Liew, C. T., Chan, J. L., Chan, F. K., & Sung, J. J. 
(2005). Histological progression of non-alcoholic fatty liver disease in Chinese patients. 
Aliment Pharmacol Ther, 21(4), 407-413.  
Hwang, S. J., Luo, J. C., Chu, C. W., Lai, C. R., Lu, C. L., Tsay, S. H., . . . Lee, S. D. 
(2001). Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical 
correlation. J Gastroenterol Hepatol, 16(2), 190-195.  
Hwang, S. T., Cho, Y. K., Park, J. H., Kim, H. J., Park, D. I., Sohn, C. I., . . . Jin, W. 
(2010). Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. 
J Gastroenterol Hepatol, 25(3), 562-567.  
Jamali, R., Khonsari, M., Merat, S., Khoshnia, M., Jafari, E., Bahram Kalhori, A., . . . 
Pourshams, A. (2008). Persistent alanine aminotransferase elevation among the general 
Iranian population: prevalence and causes. World J Gastroenterol, 14(18), 2867-2871.  
Jimba, S., Nakagami, T., Takahashi, M., Wakamatsu, T., Hirota, Y., Iwamoto, Y., & 
Wasada, T. (2005). Prevalence of non-alcoholic fatty liver disease and its association with 
impaired glucose metabolism in Japanese adults. Diabet Med, 22(9), 1141-1145.  
 
 
225 
 
Joy, D., Thava, V. R., & Scott, B. B. (2003). Diagnosis of fatty liver disease: is biopsy 
necessary? Eur J Gastroenterol Hepatol, 15(5), 539-543.  
Kang, W. M., Zhang, J. S., Wang, M. S., Gu, Y. C., & Yu, J. C. (2009). Prevalence of 
metabolic syndrome and its associations with other metabolic disorders and cardiovascular 
changes in health examination population in Beijing. Chin Med Sci J, 24(4), 227-230.  
Kim, C. H., & Younossi, Z. M. (2008). Nonalcoholic fatty liver disease: a manifestation of 
the metabolic syndrome. Cleve Clin J Med, 75(10), 721-728.  
Kim, H. J., Lee, K. E., Kim, D. J., Kim, S. K., Ahn, C. W., Lim, S. K., . . . Cha, B. S. 
(2004). Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic 
adults. Arch Intern Med, 164(19), 2169-2175.  
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., 
. . . Nonalcoholic Steatohepatitis Clinical Research, Network. (2005). Design and validation 
of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41(6), 
1313-1321.  
Kojima, S., Watanabe, N., Numata, M., Ogawa, T., & Matsuzaki, S. (2003). Increase in the 
prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J 
Gastroenterol, 38(10), 954-961.  
Kumar, M., Rastogi, A., Singh, T., Behari, C., Gupta, E., Garg, H., . . . Sarin, S. K. (2013). 
Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does 
etiology affect performance? J Gastroenterol Hepatol, 28(7), 1194-1201.  
Kuo, C. F., Yu, K. H., Luo, S. F., Chiu, C. T., Ko, Y. S., Hwang, J. S., . . . See, L. C. 
(2010). Gout and risk of non-alcoholic fatty liver disease. Scand J Rheumatol, 39(6), 466-
471.  
L. Gerber, M. Otgonsuren, A. Mishra, C. Escheik, A. Birerdinc, M. Stepanova, Z. M. 
Younossi. (2012). Non-alcoholic fatty liver disease (NAFLD) is associated with low level 
of physical activity: a population-based study. Aliment Pharmacol Ther, 36(8), 772-81.  
Lai, S. W., Tan, C. K., & Ng, K. C. (2002). Epidemiology of fatty liver in a hospital-based 
study in Taiwan. South Med J, 95(11), 1288-1292.  
Lee, D. H., Silventoinen, K., Hu, G., Jacobs, D. R., Jr., Jousilahti, P., Sundvall, J., & 
Tuomilehto, J. (2006). Serum gamma-glutamyltransferase predicts non-fatal myocardial 
 
 
226 
 
infarction and fatal coronary heart disease among 28,838 middle-aged men and women. 
Eur Heart J, 27(18), 2170-2176.  
Lee, J., Heng, D., Chia, K. S., Chew, S. K., Tan, B. Y., & Hughes, K. (2001). Risk factors 
and incident coronary heart disease in Chinese, Malay and Asian Indian males: the 
Singapore Cardiovascular Cohort Study. Int J Epidemiol, 30(5), 983-988.  
Leite, N. C., Salles, G. F., Araujo, A. L., Villela-Nogueira, C. A., & Cardoso, C. R. (2009). 
Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 
diabetes mellitus. Liver Int, 29(1), 113-119.  
Li, H., Wang, Y. J., Tan, K., Zeng, L., Liu, L., Liu, F. J., . . . Tang, H. (2009). Prevalence 
and risk factors of fatty liver disease in Chengdu, Southwest China. Hepatobiliary Pancreat 
Dis Int, 8(4), 377-382.  
Li, Y., Xu, C., Yu, C., Xu, L., & Miao, M. (2009). Association of serum uric acid level 
with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol, 50(5), 1029-1034.  
 
Lin, Y. C., Lo, H. M., & Chen, J. D. (2005). Sonographic fatty liver, overweight and 
ischemic heart disease. World J Gastroenterol, 11(31), 4838-4842.  
Liu, C. J., Jeng, Y. M., Chen, P. J., Lai, M. Y., Yang, H. C., Huang, W. L., . . . Chen, D. S. 
(2005). Influence of metabolic syndrome, viral genotype and antiviral therapy on 
superimposed fatty liver disease in chronic hepatitis C. Antivir Ther, 10(3), 405-415.  
Lu, S. N., Wang, L. Y., Chang, W. Y., Chen, C. J., Su, W. P., Chen, S. C., . . . Hsieh, M. Y. 
(1990). Abdominal sonographic screening in a single community. Gaoxiong Yi Xue Ke Xue 
Za Zhi, 6(12), 643-646.  
Ludwig, J., Viggiano, T. R., McGill, D. B., & Oh, B. J. (1980). Nonalcoholic 
steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc, 
55(7), 434-438.  
Machado, M., Marques-Vidal, P., & Cortez-Pinto, H. (2006). Hepatic histology in obese 
patients undergoing bariatric surgery. J Hepatol, 45(4), 600-606.  
Machado, M. V., & Cortez-Pinto, H. (2013). Non-invasive diagnosis of non-alcoholic fatty 
liver disease. A critical appraisal. J Hepatol, 58(5), 1007-1019.  
 
 
227 
 
Maheshwari, A., & Thuluvath, P. J. (2006). Cryptogenic cirrhosis and NAFLD: are they 
related? Am J Gastroenterol, 101(3), 664-668.  
Malik, A., Cheah, P. L., Hilmi, I. N., Chan, S. P., & Goh, K. L. (2007). Non-alcoholic fatty 
liver disease in Malaysia: a demographic, anthropometric, metabolic and histological study. 
J Dig Dis, 8(1), 58-64.  
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., . . . Rizzetto, 
M. (2003). Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. 
Hepatology, 37(4), 917-923.  
Masaki, K., Takaki, S., Hyogo, H., Kobayashi, T., Fukuhara, T., Naeshiro, N., . . . 
Chayama, K. (2013). Utility of controlled attenuation parameter measurement for assessing 
liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res, 43(11), 1182-
1189.  
Mayer-Davis, E. J., D'Agostino, R., Jr., Karter, A. J., Haffner, S. M., Rewers, M. J., Saad, 
M., & Bergman, R. N. (1998). Intensity and amount of physical activity in relation to 
insulin sensitivity: the Insulin Resistance Atherosclerosis Study. JAMA, 279(9), 669-674.  
Merat, S, Yarahmadi, S, Tahaghoghi, S, Alizadeh, Z, Sedighi, N, Mansournia, N, . . . 
Malekzadeh, R. (2009). Prevalence of fatty liver disease among type 2 diabetes mellitus 
patients and its relation to insulin resistance. Middle East Journal of Digestive Diseases, 
1(2), 74-79.  
Minakari, M., Sameni, F. K., Shalmani, H. M., Molaee, M., & Zali, M. R. (2008). Hepatic 
steatosis in Iranian patients with chronic hepatitis C. Med Princ Pract, 17(2), 126-130.  
Mofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., . . . 
Sanyal, A. J. (2003). Clinical and histologic spectrum of nonalcoholic fatty liver disease 
associated with normal ALT values. Hepatology, 37(6), 1286-1292.  
Mohan, V., Farooq, S., Deepa, M., Ravikumar, R., & Pitchumoni, C. S. (2009). Prevalence 
of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of 
glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract, 84(1), 84-91.  
Mohd Razif Shahril, Suhaina Sulaiman, Soraya Hanie Shaharudin, Nurismah Isa, Sharifah 
Noor Akmal Syed Hussain. (2008). Semi-quantitative food frequency questionnaire for 
assessment of energy, total fat, fatty acids, and vitamin A, C and E intake among Malaysian 
women: comparison with three days 24-hour diet recalls. Jurnal Sains Kesihatan Malaysia, 
6(2), 75-91.  
 
 
228 
 
Molleston, J. P., White, F., Teckman, J., & Fitzgerald, J. F. (2002). Obese children with 
steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol, 97(9), 2460-2462.  
Moscatiello, S., Manini, R., & Marchesini, G. (2007). Diabetes and liver disease: an 
ominous association. Nutr Metab Cardiovasc Dis, 17(1), 63-70.  
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2011). Meta-analysis: natural 
history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-
invasive tests for liver disease severity. Ann Med, 43(8), 617-649.  
Myers, R. P., Pollett, A., Kirsch, R., Pomier-Layrargues, G., Beaton, M., Levstik, M., . . . 
Elkashab, M. (2012). Controlled Attenuation Parameter (CAP): a noninvasive method for 
the detection of hepatic steatosis based on transient elastography. Liver Int, 32(6), 902-910.  
World Health Organization. (2005). Global Physical Activity Questionnaire (GPAQ) 
Analysis Guide. Retrieved from 
http//.www.who.int/chp/steps/resources/GPAQ_Analysis_Guide.pdf 
Ouyang, X., Cirillo, P., Sautin, Y., McCall, S., Bruchette, J. L., Diehl, A. M., . . . 
Abdelmalek, M. F. (2008). Fructose consumption as a risk factor for non-alcoholic fatty 
liver disease. J Hepatol, 48(6), 993-999.  
Oya, J., Nakagami, T., Sasaki, S., Jimba, S., Murakami, K., Kasahara, T., . . . Iwamoto, Y. 
(2010). Intake of n-3 polyunsaturated fatty acids and non-alcoholic fatty liver disease: a 
cross-sectional study in Japanese men and women. Eur J Clin Nutr, 64(10), 1179-1185.  
Angulo, P., Bugianesi, E., Bjornsson, E.S., Charatcharoenwitthaya, P., Millis, P.R., 
Barrera, F., … George, J. (2013). Simple noninvasive systems predict long-term outcomes 
of patients with nonalcoholic fatty liver disease. Gastroenterology, 145(4) 782-789.  
Page, J. M., & Harrison, S. A. (2009). NASH and HCC. Clin Liver Dis, 13(4), 631-647.  
Park, S. H., Jeon, W. K., Kim, S. H., Kim, H. J., Park, D. I., Cho, Y. K., . . . Kim, B. I. 
(2006). Prevalence and risk factors of non-alcoholic fatty liver disease among Korean 
adults. J Gastroenterol Hepatol, 21(1 Pt 1), 138-143.  
Parks, E. J. (2002). Dietary carbohydrate's effects on lipogenesis and the relationship of 
lipogenesis to blood insulin and glucose concentrations. Br J Nutr, 87 Suppl 2, S247-253.  
 
 
229 
 
Qua, C. S., & Goh, K. L. (2011). Liver cirrhosis in Malaysia: peculiar epidemiology in a 
multiracial Asian country. J Gastroenterol Hepatol, 26(8), 1333-1337.  
Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., & Marchesini, G. (2010). A position 
statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol, 
53(2), 372-384.  
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., . . . Group, Lido 
Study. (2005). Sampling variability of liver biopsy in nonalcoholic fatty liver disease. 
Gastroenterology, 128(7), 1898-1906.  
Recio, E., Cifuentes, C., Macias, J., Mira, J. A., Parra-Sanchez, M., Rivero-Juarez, A., . . . 
Neukam, K. (2013). Interobserver concordance in controlled attenuation parameter 
measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient 
elastography. Eur J Gastroenterol Hepatol, 25(8), 905-911.  
Roberts, S. B., & Leibel, R. L. (1998). Excess energy intake and low energy expenditure as 
predictors of obesity. Int J Obes Relat Metab Disord, 22(5), 385-386.  
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., . . . Hobbs, 
H.H. (2008). Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver 
disease. Nat Genet, 40(12), 1461-1465.   
Rungsinaporn, K., & Phaisakamas, T. (2008). Frequency of abnormalities detected by 
upper abdominal ultrasound. J Med Assoc Thai, 91(7), 1072-1075.  
Ruttmann, E., Brant, L. J., Concin, H., Diem, G., Rapp, K., & Ulmer, H. (2005). Gamma-
glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological 
investigation in a cohort of 163,944 Austrian adults. Circulation, 112(14), 2130-2137.  
Saadeh, S., Younossi, Z. M., Remer, E. M., Gramlich, T., Ong, J. P., Hurley, M., . . . 
Sheridan, M. J. (2002). The utility of radiological imaging in nonalcoholic fatty liver 
disease. Gastroenterology, 123(3), 745-750.  
Sagi, R., Reif, S., Neuman, G., Webb, M., Phillip, M., & Shalitin, S. (2007). Nonalcoholic 
fatty liver disease in overweight children and adolescents. Acta Paediatr, 96(8), 1209-1213.  
Saito, Y., Yagyu, K., Hattori, Y., Ohno, K., Okamoto, N., Takahashi, A., . . . et al. (1989). 
[A study on fatty liver in health examination participants]. Nihon Eiseigaku Zasshi, 44(5), 
953-961.  
 
 
230 
 
Sanyal, A. J., Banas, C., Sargeant, C., Luketic, V. A., Sterling, R. K., Stravitz, R. T., . . . 
Mills, A. S. (2006). Similarities and differences in outcomes of cirrhosis due to 
nonalcoholic steatohepatitis and hepatitis C. Hepatology, 43(4), 682-689.  
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., . 
. . Nash, C. R. N. (2010). Pioglitazone, vitamin E, or placebo for nonalcoholic 
steatohepatitis. N Engl J Med, 362(18), 1675-1685.  
Sasso, M., Beaugrand, M., de Ledinghen, V., Douvin, C., Marcellin, P., Poupon, R., . . . 
Miette, V. (2010). Controlled attenuation parameter (CAP): a novel VCTE guided 
ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary 
study and validation in a cohort of patients with chronic liver disease from various causes. 
Ultrasound Med Biol, 36(11), 1825-1835.  
Sasso, M., Tengher-Barna, I., Ziol, M., Miette, V., Fournier, C., Sandrin, L., . . . 
Beaugrand, M. (2012). Novel controlled attenuation parameter for noninvasive assessment 
of steatosis using Fibroscan((R)): validation in chronic hepatitis C. J Viral Hepat, 19(4), 
244-253.  
Sathiaraj, E., Chutke, M., Reddy, M. Y., Pratap, N., Rao, P. N., Reddy, D. N., & 
Raghunath, M. (2011). A case-control study on nutritional risk factors in non-alcoholic 
fatty liver disease in Indian population. Eur J Clin Nutr, 65(4), 533-537.  
Schindhelm, R. K., Dekker, J. M., Nijpels, G., Bouter, L. M., Stehouwer, C. D., Heine, R. 
J., & Diamant, M. (2007). Alanine aminotransferase predicts coronary heart disease events: 
a 10-year follow-up of the Hoorn Study. Atherosclerosis, 191(2), 391-396.  
Shen, J., Chan, H. L., Wong, G. L., Chan, A. W., Choi, P. C., Chan, H. Y., . . . Wong, V. 
W. (2012). Assessment of non-alcoholic fatty liver disease using serum total cell death and 
apoptosis markers. Aliment Pharmacol Ther, 36(11-12), 1057-1066.  
Shen, J., Chan, H. L., Wong, G. L., Choi, P. C., Chan, A. W., Chan, H. Y., . . . Wong, V. 
W. (2012). Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum 
biomarkers. J Hepatol, 56(6), 1363-1370.  
Shi, H. B., Fu, J. F., Liang, L., Wang, C. L., Zhu, J. F., Zhou, F., & Zhao, Z. Y. (2009). 
[Prevalence of nonalcoholic fatty liver disease and metabolic syndrome in obese children]. 
Zhonghua Er Ke Za Zhi, 47(2), 114-118.  
 
 
231 
 
Shi, J. P., Fan, J. G., Wu, R., Gao, X. Q., Zhang, L., Wang, H., & Farrell, G. C. (2008). 
Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese 
patients with chronic hepatitis B infection. J Gastroenterol Hepatol, 23(9), 1419-1425.  
Shibata, M., Kihara, Y., Taguchi, M., Tashiro, M., & Otsuki, M. (2007). Nonalcoholic fatty 
liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes 
Care, 30(11), 2940-2944.  
Singh, S. P., Nayak, S., Swain, M., Rout, N., Mallik, R. N., Agrawal, O., . . . Rao, M. 
(2004). Prevalence of nonalcoholic fatty liver disease in coastal eastern India: a preliminary 
ultrasonographic survey. Trop Gastroenterol, 25(2), 76-79.  
Soderberg, C., Stal, P., Askling, J., Glaumann, H., Lindberg, G., Marmur, J., & Hultcrantz, 
R. (2010). Decreased survival of subjects with elevated liver function tests during a 28-year 
follow-up. Hepatology, 51(2), 595-602.  
Solga, S., Alkhuraishe, A. R., Clark, J. M., Torbenson, M., Greenwald, A., Diehl, A. M., & 
Magnuson, T. (2004). Dietary composition and nonalcoholic fatty liver disease. Dig Dis 
Sci, 49(10), 1578-1583.  
Subramanian, S., Goodspeed, L., Wang, S., Kim, J., Zeng, L., Ioannou, G. N., . . . Chait, A. 
(2011). Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL 
receptor-deficient mice. J Lipid Res, 52(9), 1626-1635.  
Suzuki, A., Lymp, J., Sauver, J. S., Angulo, P., & Lindor, K. (2006). Values and limitations 
of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int, 
26(10), 1209-1216.  
Tamimi, T. I., Elgouhari, H. M., Alkhouri, N., Yerian, L. M., Berk, M. P., Lopez, R., . . . 
Feldstein, A. E. (2011). An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J 
Hepatol, 54(6), 1224-1229.  
Targher, G., Bertolini, L., Padovani, R., Poli, F., Scala, L., Tessari, R., . . . Falezza, G. 
(2006). Increased prevalence of cardiovascular disease in Type 2 diabetic patients with 
non-alcoholic fatty liver disease. Diabet Med, 23(4), 403-409.  
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., . . . Arcaro, G. 
(2007). Prevalence of nonalcoholic fatty liver disease and its association with 
cardiovascular disease among type 2 diabetic patients. Diabetes Care, 30(5), 1212-1218.  
 
 
232 
 
Targher, G., Pichiri, I., Zoppini, G., Trombetta, M., & Bonora, E. (2012). Increased 
prevalence of cardiovascular disease in Type 1 diabetic patients with non-alcoholic fatty 
liver disease. J Endocrinol Invest, 35(5), 535-540.  
Tee, E.S., Mohd Ismail Noor, Mohd Nasir Azudin, & Khatijah Idris. (1997). Nutrient 
Composition of Malaysian Foods 4th Edition. Kuala Lumpur: Institute for Medical 
Research. 
Institute for Public Health. (2008). The Third National Health and Morbidity Survey 
(NHMS III). Malaysia: Ministry of Health. 
Thoma, C., Day, C. P., & Trenell, M. I. (2012). Lifestyle interventions for the treatment of 
non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol, 56(1), 255-266.  
Tilg, H., & Moschen, A. R. (2010). Evolution of inflammation in nonalcoholic fatty liver 
disease: the multiple parallel hits hypothesis. Hepatology, 52(5), 1836-1846.  
Tominaga, K., Kurata, J. H., Chen, Y. K., Fujimoto, E., Miyagawa, S., Abe, I., & Kusano, 
Y. (1995). Prevalence of fatty liver in Japanese children and relationship to obesity. An 
epidemiological ultrasonographic survey. Dig Dis Sci, 40(9), 2002-2009.  
Toshimitsu, K., Matsuura, B., Ohkubo, I., Niiya, T., Furukawa, S., Hiasa, Y., . . . Onji, M. 
(2007). Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition, 23(1), 
46-52.  
Tsai, C. H., Li, T. C., & Lin, C. C. (2008). Metabolic syndrome as a risk factor for 
nonalcoholic fatty liver disease. South Med J, 101(9), 900-905.  
Tsuruta, G., Tanaka, N., Hongo, M., Komatsu, M., Horiuchi, A., Hamamoto, K., . . . 
Tanaka, E. (2010). Nonalcoholic fatty liver disease in Japanese junior high school students: 
its prevalence and relationship to lifestyle habits. J Gastroenterol, 45(6), 666-672.  
Wan, Y. P., Xu, R. Y., Fang, H., Lu, L. P., Zhang, X. M., & Cai, W. (2007). [The 
prevalence of non-alcoholic fatty liver disease and its related risk factors in 1180 school 
children in Shanghai]. Zhonghua Gan Zang Bing Za Zhi, 15(9), 644-648.  
Wang, Z., Xia, B., Ma, C., Hu, Z., Chen, X., & Cao, P. (2007). Prevalence and risk factors 
of fatty liver disease in the Shuiguohu district of Wuhan city, central China. Postgrad Med 
J, 83(977), 192-195.  
 
 
233 
 
Wannamethee, G., Ebrahim, S., & Shaper, A. G. (1995). Gamma-glutamyltransferase: 
determinants and association with mortality from ischemic heart disease and all causes. Am 
J Epidemiol, 142(7), 699-708.  
Westerbacka, J., Lammi, K., Hakkinen, A. M., Rissanen, A., Salminen, I., Aro, A., & Yki-
Jarvinen, H. (2005). Dietary fat content modifies liver fat in overweight nondiabetic 
subjects. J Clin Endocrinol Metab, 90(5), 2804-2809.  
Wieckowska, A., Zein, N. N., Yerian, L. M., Lopez, A. R., McCullough, A. J., & Feldstein, 
A. E. (2006). In vivo assessment of liver cell apoptosis as a novel biomarker of disease 
severity in nonalcoholic fatty liver disease. Hepatology, 44(1), 27-33.  
Wong, G. L., Chan, H. L., Choi, P. C., Chan, A. W., Yu, Z., Lai, J. W., . . . Wong, V. W. 
(2014). Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement 
with transient elastography for advanced liver fibrosis in chronic hepatitis B. Aliment 
Pharmacol Ther, 39(2), 197-208.  
Wong, V. W., Hui, A. Y., Tsang, S. W., Chan, J. L., Wong, G. L., Chan, A. W., . . . Chan, 
H. L. (2006). Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in 
Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther, 24(8), 
1215-1222.  
Wong, V. W., Vergniol, J., Wong, G. L., Foucher, J., Chan, H. L., Le Bail, B., . . . de 
Ledinghen, V. (2010). Diagnosis of fibrosis and cirrhosis using liver stiffness measurement 
in nonalcoholic fatty liver disease. Hepatology, 51(2), 454-462.  
Wong, V. W., Wong, G. L., Choi, P. C., Chan, A. W., Li, M. K., Chan, H. Y., . . . Chan, H. 
L. (2010). Disease progression of non-alcoholic fatty liver disease: a prospective study with 
paired liver biopsies at 3 years. Gut, 59(7), 969-974.  
Wong, V. W., Wong, G. L., Yip, G. W., Lo, A. O., Limquiaco, J., Chu, W. C., . . . Chan, H. 
L. (2011). Coronary artery disease and cardiovascular outcomes in patients with non-
alcoholic fatty liver disease. Gut, 60(12), 1721-1727.  
Wree, A., Broderick, L., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2013). From 
NAFLD to NASH to cirrhosis – new insights into disease mechanisms. Nat Rev 
Gastroenterol Hepatol, 10(11), 627-636.  
Yasui, K., Sumida, Y., Mori, Y., Mitsuyoshi, H., Minami, M., Itoh, Y., . . . Yoshikawa, T. 
(2011). Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. 
Metabolism, 60(5), 735-739.  
 
 
234 
 
Yilmaz, Y. (2012). Review article: fructose in non-alcoholic fatty liver disease. Aliment 
Pharmacol Ther, 35(10), 1135-1144.  
Yilmaz, Y., Dolar, E., Ulukaya, E., Akgoz, S., Keskin, M., Kiyici, M., . . . Nak, S. G. 
(2007). Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis 
from nonalcoholic steatohepatitis. World J Gastroenterol, 13(6), 837-844.  
Yoneda, M., Yoneda, M., Fujita, K., Inamori, M., Tamano, M., Hiriishi, H., & Nakajima, 
A. (2007). Transient elastography in patients with non-alcoholic fatty liver disease 
(NAFLD). Gut, 56(9), 1330-1331.  
Younossi, Z. M., Gramlich, T., Liu, Y. C., Matteoni, C., Petrelli, M., Goldblum, J., . . . 
McCullough, A. J. (1998). Nonalcoholic fatty liver disease: assessment of variability in 
pathologic interpretations. Mod Pathol, 11(6), 560-565.  
Younossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., & Srishord, 
M. (2011). Changes in the prevalence of the most common causes of chronic liver diseases 
in the United States from 1988 to 2008. Clin Gastroenterol Hepatol, 9(6), 524-530. 
Yun, J. W., Cho, Y. K., Park, J. H., Kim, H. J., Park, D. I., Sohn, C. I., . . . Shin, J. H. 
(2009). Hepatic steatosis and fibrosis in young men with treatment-naive chronic hepatitis 
B. Liver Int, 29(6), 878-883.  
Yun, K. E., Shin, C. Y., Yoon, Y. S., & Park, H. S. (2009). Elevated alanine 
aminotransferase levels predict mortality from cardiovascular disease and diabetes in 
Koreans. Atherosclerosis, 205(2), 533-537.  
Zain, S.M., Mohamed, R, Mahadeva, S., Cheah, P.L., Rampal, S., Basu, R.C., & Mohamed, 
Z. A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity 
in non-alcoholic fatty liver disease. (2012). Hum Genet, 131(7), 1145-1152. 
Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Blendis, L., Halpern, Z., & 
Oren, R. (2007). Long term nutritional intake and the risk for non-alcoholic fatty liver 
disease (NAFLD): a population based study. J Hepatol, 47(5), 711-717.  
Zelber-Sagi, S., Nitzan-Kaluski, D., Halpern, Z., & Oren, R. (2006). Prevalence of primary 
non-alcoholic fatty liver disease in a population-based study and its association with 
biochemical and anthropometric measures. Liver Int, 26(7), 856-863.  
 
 
235 
 
Zhou, J., Jia, W. P., Bao, Y. Q., Ma, X. J., Lu, W., Yu, M., . . . Xiang, K. S. (2007). [Study 
on prevalence and risk factors of fatty liver of patients with type 2 diabetes]. Zhonghua Yi 
Xue Za Zhi, 87(32), 2249-2252.  
Zhou, Y. J., Li, Y. Y., Nie, Y. Q., Ma, J. X., Lu, L. G., Shi, S. L., . . . Hu, P. J. (2007). 
Prevalence of fatty liver disease and its risk factors in the population of South China. World 
J Gastroenterol, 13(47), 6419-6424.  
 
  
 
 
236 
 
List of Publications 
Chan, W. K., & Goh, K. L. (2013). Epidemiology of a fast-emerging disease in the Asia-
Pacific region: non-alcoholic fatty liver disease. Hepatol Int, 7(1), 65-71. 
Chan, W. K., Tan, A. T., Vethakkan S. R., Tah, P. C., Vijayananthan, A., & Goh, K. L. 
(2013). Non-alcoholic fatty liver disease (NAFLD) in diabetics – prevalence and predictive 
factors in a multi-racial hospital clinic population in Malaysia. J Gastroenterol Hepatol, 
28(8), 1375-1383.  
Chan, W.K., Norhaniza Bahar, Hamizah Razlan, Vijayananthan, A., Sithaneshwar, P., & 
Goh, K.L. (2013). Non-alcoholic fatty liver disease in a young multiracial Asian population 
– a worrying ethnic predilection in Malay and Indian males. Hepatol Int, 8(1), 121-127.  
Chan, W. K., Nik Mustapha, N. R., & Mahadeva, S. (2014). Controlled attenuation 
parameter for the detection and quantification of hepatic steatosis in non-alcoholic fatty 
liver disease. J Gastroenterol Hepatol, 29(7), 1470-1476. 
Chan, W. K., Tan, A. T., Vethakkan, S. R., Tah, P. C., Vijayananthan, A., & Goh, K. L. 
(2014). Ultrasonography-diagnosed non-alcoholic fatty liver disease is not associated with 
prevalent ischemic heart disease among diabetics in a multiracial Asian hospital clinic 
population. Clin Res Hepatol Gastroenterol, 38(3), 284-291. 
Chan, W. K., Hilmi, I. N., Cheah, P. L., & Goh, K. L. (2014). Progression of non-alcoholic 
fatty liver disease – a prospective clinicopathological follow-up study. J Dig Dis, 15(10), 
545-552. 
Chan, W. K., Sthaneshwar, P., Nik Mustapha, N. R., & Mahadeva, S. (2014). Limited 
utility of plasma M30 in detecting non-alcoholic steatohepatitis – a comparison with 
routine biochemical markers. PLoS One, 9(9), e105903. 
Chan, W. K., Nik Mustapha, N. R., & Mahadeva, S. (2014). A novel 2-step approach 
combining the NAFLD fibrosis score and liver stiffness measurement for predicting 
advanced fibrosis. Hepatol Int, in press. 
Chan, W. K., Tan, A. T., Vethakkan S. R., Tah, P. C., Vijayananthan, A., & Goh, K. L. 
(2014). Low physical activity and energy dense Malaysian foods are associated with non-
alcoholic fatty liver disease in centrally obese but not in non-centrally obese patients with 
diabetes mellitus. Asia Pac J Clin Nutr, in press.  
 
 
237 
 
Appendix 
Appendix 1 The Global Physical Activity Questionnaire (GPAQ) 
Appendix 2 The semi-quantitative food frequency questionnaire (FFQ)  
Appendix 3 Publications 
 
 1 
 1 3 
SOAL SELIDIK KEKERAPAN PENGAMBILAN MAKANAN 
 
 
Sekarang saya akan bertanya mengenai pengambilan makanan anda dalam tempoh satu tahun lepas. Cuba ingat kembali keadaan dan suasana pada 
ketika itu yang mungkin mempengaruhi tabiat makan puan (contohnya tempat tinggal, pekerjaan, waktu makan dan tempat makan yang biasa).  
 
Perlu diingatkan, kami berminat untuk mengetahui pengambilan makanan BIASA puan, yang bererti makanan dan minuman yang puan ambil lima (5) kali 
atau lebih dalam jangka masa satu tahun. Tandakan () bagi makanan tersebut dan biarkan kosong jika tidak berkaitan. 
 
Saya juga ingin mengetahui kekerapan pengambilan makanan tersebut dan saiz hidangan yang selalu puan amalkan. 
 
Bagi kekerapan pengambilan makanan, sila nyatakannya dengan mengisikan bilangan kekerapan (berapa kali ambil) dan bulatkan kod kekerapan yang 
sesuai SAMA ADA IA DIAMBIL SETIAP  
 
H (HARI) jika puan mengambil makanan tersebut setiap hari secara puratanya 
atau 
M (MINGGU) jika puan tidak mengambil makanan tersebut setiap hari tetapi mengambil makanan tersebut setiap minggu 
atau 
B (BULAN) jika puan tidak mengambil makanan tersebut setiap minggu tetapi mengambil makanan tersebut setiap bulan 
atau 
T (TAHUN) jika puan tidak mengambil makanan tersebut setiap bulan tetapi mengambil makanan tersebut setiap tahun 
 
CONTOH 
   
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
MINUMAN BERIKUT UNTUK SARAPAN PAGI 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
1 Susu segar 
 
. 
KALI    PER           H          M         B          T 
 
1 gelas 
 
 
Contoh ini menunjukkan bahawa susu segar BIASA diambil dan ia diambil 3 kali dalam satu minggu. Sebanyak 1 gelas diambil pada setiap pengambilan 
tersebut. 
 
NOTA: Saya mahu mengetahui apa yang puan biasa makan dalam masa satu minggu. Puan mungkin, sebagai contohnya mengambil sama ada ayam 
goreng berlada atau kari ayam pada hari Rabu. Tolong jangan rekodkan kedua-dua jenis makanan tersebut dalam satu minggu. Adalah digalakkan puan 
melaporkan sesetengah jenis makanan dengan kod kekerapan bulan dari kod kekerapan minggu.  
 2 
 
 
Sekarang kita mulakan dengan pengambilan minuman dan makanan semasa sarapan pagi. Sila baca arahan yang diberikan pada setiap awalan sebelum 
soalan. Terima kasih atas kerjasama yang diberikan. 
 
 
SARAPAN PAGI 
 
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
MINUMAN BERIKUT UNTUK SARAPAN PAGI 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
1  Susu segar 
 
. 
KALI    PER           H          M         B          T 
 
1 gelas 
 
2  Susu berperisa (contoh: Coklat, Starwbery) 
 
. 
KALI    PER           H          M         B          T 
 
1 gelas 
 
3  Susu rendah lemak 
 
. 
KALI    PER           H          M         B          T 
 
1 gelas 
 
4  Susu soya 
 
. 
KALI    PER           H          M         B          T 
 
1 gelas 
 
5  Susu tepung penuh krim 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
6  Susu tepung skim 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
7  Susu pekat manis 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
8  Serbuk teh 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu teh 
 
9  Serbuk kopi (contoh: Nescafe) 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu teh 
 
10  Serbuk coklat (contoh: Milo) 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
11  Gula 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
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BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
MAKANAN BERIKUT UNTUK SARAPAN PAGI 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
12  Roti putih 
 
. 
KALI    PER           H          M         B          T 
 
1 keping 
 
13  Roti mil penuh 
 
. 
KALI    PER           H          M         B          T 
 
1 keping 
 
14  Sapuan roti 
Mentega 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu teh 
 
Margerin 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu teh 
 
Keju kepingan 
 
. 
KALI    PER           H          M         B          T 
 
1 keping 
 
Mentega kacang 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
Kaya 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
Jem buah-buahan 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
15  Roti canai 
 
. 
KALI    PER           H          M         B          T 
 
1 keping 
 
16  Roti canai telur 
 
. 
KALI    PER           H          M         B          T 
 
1 keping 
 
17  Kuah roti canai 
Kuah dhal 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
Kuah kari 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
Kuah sambal 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
18  Nasi lemak (biasa) 
 
. 
KALI    PER           H          M         B          T 
 
1 pinggan 
 
19  Nasi goreng (biasa) 
 
. 
KALI    PER           H          M         B          T 
 
1 pinggan 
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20  Mee/ Bihun/ Kuih-teow goreng (biasa) 
 
. 
KALI    PER           H          M         B          T 
 
1 pinggan 
 
21  Soto ayam 
 
. 
KALI    PER           H          M         B          T 
 
1 mangkuk 
 
22  Lontong dengan masak lodeh 
 
. 
KALI    PER           H          M         B          T 
 
1 mangkuk 
 
23  Emping jagung (bijirin sahaja) (contoh: Corn Flakes) 
 
. 
KALI    PER           H          M         B          T 
 
½ cawan 
 
24  Bijirin coklat (bijirin sahaja) (contoh: Coco Crunch) 
 
. 
KALI    PER           H          M         B          T 
 
½ cawan 
 
25  Bijirin oats (bijirin sahaja) (contoh: Quacker Oats) 
 
. 
KALI    PER           H          M         B          T 
 
½ cawan 
 
26  Bijirin segera (bijirin sahaja) (contoh: Nestum) 
 
. 
KALI    PER           H          M         B          T 
 
½ cawan 
 
27  Cappati 
 
. 
KALI    PER           H          M         B          T 
 
1 keping 
 
28  Dosai 
 
. 
KALI    PER           H          M         B          T 
 
1 keping 
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MAKAN TENGAH HARI / MALAM 
 
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL JENIS 
NASI BERIKUT UNTUK MAKAN TENGAHARI/ MALAM (TANPA LAUK KECUALI 
DINYATAKAN – LAUK DIMASUKKAN PADA BAHAGIAN SOALAN SETERUSNYA) 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
29  Nasi putih 
 
. 
KALI    PER           H          M         B          T 
 
2 senduk 
 
30  Nasi dagang 
 
. 
KALI    PER           H          M         B          T 
 
1 pinggan 
 
31  Nasi tomato 
 
. 
KALI    PER           H          M         B          T 
 
1 pinggan 
 
32  Nasi minyak 
 
. 
KALI    PER           H          M         B          T 
 
1 pinggan 
 
33  Nasi briyani 
 
. 
KALI    PER           H          M         B          T 
 
1 pinggan 
 
34  Nasi kerabu 
 
. 
KALI    PER           H          M         B          T 
 
1 pinggan 
 
35  Nasi ayam (dengan ayam, sup, timun, salad, sos dan kicap) 
 
. 
KALI    PER           H          M         B          T 
 
1 pinggan 
 
BIL TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL MAKANAN ASAS BERIKUT  
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
36  Ayam 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
37  Ikan 
 
. 
KALI    PER           H          M         B          T 
 
1 ekor sederhana 
 
38  Daging lembu/ kambing 
 
. 
KALI    PER           H          M         B          T 
 
1 kotak mancis 
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39  Organ dalaman  
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
40  Makanan laut 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
41  Sayur-sayuran 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
42  Buah-buahan 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
BIL 
SEKARANG, FIKIRKAN MENGENAI AYAM YANG DIMASAK, CARA MEMASAK 
DAN KUAHNYA. TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
AYAM DAN CARA MASAK BERIKUT.  
(LAUK YANG DITAMBAH PADA JENIS MASAKAN LAIN JUGA PERLU 
DISERTAKAN) 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
43  Ayam goreng 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
44  Ayam goreng berlada 
 
Ayam 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
Kuah sambal 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
45  
Kari ayam 
*(pilih satu jenis cara masak 
kuah kari) 
 
Ayam 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
*Kuah kari (bersantan) 
 
. 
. 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
*Kuah kari (bersusu) 
 
*Kuah kari (tanpa santan/susu) 
 
46  Ayam masak lemak 
 
Ayam 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
Kuah masak lemak 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
47  Ayam masak kurma 
 
Ayam 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
Kuah kurma 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
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48  Ayam masak kicap 
 
Ayam 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
Kuah masak kicap 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
49  Rendang ayam 
 
Ayam 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
Kuah rendang 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
50  Sup ayam 
 
Ayam 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
Kuah sup 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
51  Ayam bakar 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
52  Ayam kukus 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
53  Satay ayam 
 
. 
KALI    PER           H          M         B          T 
 
5 cucuk 
 
BIL 
SEKARANG, FIKIRKAN MENGENAI IKAN YANG DIMASAK, CARA MEMASAK 
DAN KUAHNYA. TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
IKAN DAN CARA MASAK BERIKUT.  
(LAUK YANG DITAMBAH PADA JENIS MASAKAN LAIN JUGA PERLU 
DISERTAKAN) 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
54  Ikan goreng 
 
. 
KALI    PER           H          M         B          T 
 
1 ekor sederhana 
 
55  Ikan goreng berlada 
 
Ikan 
 
. 
KALI    PER           H          M         B          T 
 
1 ekor sederhana 
 
Kuah sambal 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
56  
Kari ikan 
*(pilih satu jenis cara masak 
kuah kari) 
 
Ikan 
 
. 
KALI    PER           H          M         B          T 
 
1 ekor sederhana 
 
*Kuah kari (bersantan) 
 
. 
. 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
*Kuah kari (bersusu) 
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*Kuah kari (tanpa santan/susu) 
 
57  Ikan masak lemak 
 
Ikan 
 
. 
KALI    PER           H          M         B          T 
 
1 ekor sederhana 
 
Kuah masak lemak 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
58  Ikan masak kicap 
 
Ikan 
 
. 
KALI    PER           H          M         B          T 
 
1 ekor sederhana 
 
Kuah masak kicap 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
59  Ikan masak masam manis 
 
Ikan 
 
. 
KALI    PER           H          M         B          T 
 
1 ekor sederhana 
 
Kuah masam manis 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
60  Ikan masak asam/ sup/ cuka 
 
Ikan 
 
. 
KALI    PER           H          M         B          T 
 
1 ekor sederhana 
 
Kuah masak asam/ sup/ cuka 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
61  Ikan bakar 
 
. 
KALI    PER           H          M         B          T 
 
1 ekor sederhana 
 
62  Ikan kukus 
 
. 
KALI    PER           H          M         B          T 
 
1 ekor sederhana 
 
BIL 
SEKARANG, FIKIRKAN MENGENAI DAGING LEMBU YANG DIMASAK, CARA 
MEMASAK DAN KUAHNYA. TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
DAGING DAN CARA MASAK BERIKUT.  
(LAUK YANG DITAMBAH PADA JENIS MASAKAN LAIN JUGA PERLU 
DISERTAKAN) 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
63  Daging goreng 
 
. 
KALI    PER           H          M         B          T 
 
1 kotak mancis 
 
64  Daging goreng berlada 
 
Daging 
 
. 
KALI    PER           H          M         B          T 
 
1 kotak mancis 
 
Kuah sambal 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
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65  
Kari daging 
*(pilih satu jenis cara masak 
kuah kari) 
 
Daging 
 
. 
KALI    PER           H          M         B          T 
 
1 kotak mancis 
 
*Kuah kari (bersantan) 
 
. 
. 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
*Kuah kari (bersusu) 
 
*Kuah kari (tanpa santan/susu) 
 
66  Daging masak lemak 
 
Ayam 
 
. 
KALI    PER           H          M         B          T 
 
1 kotak mancis 
 
Kuah masak lemak 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
67  Daging masak kicap 
 
Daging 
 
. 
KALI    PER           H          M         B          T 
 
1 kotak mancis 
 
Kuah masak kicap 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
68  Lain-lain masakan daging 
 
. 
KALI    PER           H          M         B          T 
 
1 kotak mancis 
 
69  Satay daging 
 
. 
KALI    PER           H          M         B          T 
 
5 cucuk 
 
BIL 
SEKARANG, FIKIRKAN MENGENAI DAGING KAMBING YANG DIMASAK, CARA 
MEMASAK DAN KUAHNYA. TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
DAGING KAMBING DAN CARA MASAK BERIKUT.  
(LAUK YANG DITAMBAH PADA JENIS MASAKAN LAIN JUGA PERLU 
DISERTAKAN) 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
70  
Kari daging kambing 
*(pilih satu jenis cara masak 
kuah kari) 
 
Daging kambing 
 
. 
KALI    PER           H          M         B          T 
 
1 kotak mancis 
 
*Kuah kari (bersantan) 
 
. 
. 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
*Kuah kari (bersusu) 
 
*Kuah kari (tanpa santan/susu) 
 
71  Lain-lain masakan daging kambing 
 
. 
KALI    PER           H          M         B          T 
 
1 kotak mancis 
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BIL 
SEKARANG, FIKIRKAN MENGENAI ORGAN DALAMAN YANG DIMASAK, CARA 
MEMASAK DAN KUAHNYA. TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
AYAM DAN CARA MASAK BERIKUT.  
(LAUK YANG DITAMBAH PADA JENIS MASAKAN LAIN JUGA PERLU 
DISERTAKAN) 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
72  Paru lembu goreng 
 
. 
KALI    PER           H          M         B          T 
 1 keping (saiz 
kotak mancis) 
 
73  Paru lembu goreng berlada 
 
Paru lembu 
 
. 
KALI    PER           H          M         B          T 
 1 keping (saiz 
kotak mancis) 
 
Kuah sambal 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
74  Hati ayam goreng 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
75  Lain-lain organ yang dimasak 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL MAKANAN LAUT DAN CARA 
MASAK BERIKUT. (LAUK YANG DITAMBAH PADA JENIS MASAKAN LAIN JUGA 
PERLU DISERTAKAN) 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
76  Ikan bilis goreng 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
77  Ikan bilis sambal (selain  bersama nasi lemak dan kuah roti canai) 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
78  
Sardin dalam tin masak 
sambal 
 
Sardin 
 
. 
KALI    PER           H          M         B          T 
 
1 potong 
 
Kuah sambal 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
79  Sotong sambal 
 
Sotong 
 
. 
KALI    PER           H          M         B          T 
 
1 ekor sederhana 
 
Kuah sambal 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
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80  Sotong masak lain-lain 
 
. 
KALI    PER           H          M         B          T 
 
1 ekor sederhana 
 
81  Udang sambal 
 
Udang 
 
. 
KALI    PER           H          M         B          T 
 1 ekor sederhana 
/5 ekor kecil 
 
Kuah sambal 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
82  Udang masak lain-lain 
 
. 
KALI    PER           H          M         B          T 
 1 ekor sederhana 
/5 ekor kecil 
 
83  Kerang sambal 
 
Kerang 
 
. 
KALI    PER           H          M         B          T 
 
10 ekor 
 
Kuah sambal 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
84  Kerang masak lain-lain 
 
. 
KALI    PER           H          M         B          T 
 
10 ekor 
 
85  
Kari ketam 
*(pilih satu jenis cara masak 
kuah kari) 
 
Ketam 
 
. 
KALI    PER           H          M         B          T 
 
1 ekor 
 
*Kuah kari (bersantan) 
 
. 
. 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
*Kuah kari (bersusu) 
 
*Kuah kari (tanpa santan/susu) 
 
86  Ketam masak lain-lain 
 
. 
KALI    PER           H          M         B          T 
 
1 ekor 
 
BIL 
TANDAKAN (  ) JIKA ANDA BIASA TELUR DAN CARA MASAK BERIKUT. (LAUK 
YANG DITAMBAH PADA JENIS MASAKAN LAIN JUGA PERLU DISERTAKAN) 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
87  Telur ayam goreng (termasuk dadar) 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
88  Telur ayam rebus (selain  bersama nasi lemak) 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
89  Telur asin 
 
. 
KALI    PER           H          M         B          T 
 
½ biji 
 
 12 
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
SAYURAN BERDAUN HIJAU DAN BERWARNA BERIKUT 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
90  Sayur sawi 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
91  Sayur bayam 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
92  Sayur bayam merah 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
93  Sayur kangkung 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
94  Sayur kailan 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
95  Pucuk paku 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
96  Pucuk ubi kayu 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
97  Cekur manis 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
98  Cendawan 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
99  Taugeh 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
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BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
SAYURAN KRUSIFERUS BERIKUT 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
100  Kobis 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
101  Bunga kobis  
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
102  Brokoli 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
103  Petola 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
104  Peria 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
105  Lobak merah 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
106  Tomato 
 
. 
KALI    PER           H          M         B          T 
 
½ biji sederhana 
 
107  Terung 
 
. 
KALI    PER           H          M         B          T 
 
1 potong 
 
108  Kucai 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
109  Labu merah 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
110  Kapsicum (Paprika) 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
111  Sengkuang 
 
. 
KALI    PER           H          M         B          T 
 
1 keping 
 
112  Kentang 
 
. 
KALI    PER           H          M         B          T 
 
½ biji sederhana 
 
113  Kacang panjang 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
114  Kacang buncis 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
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115  Kacang botor 
 
. 
KALI    PER           H          M         B          T 
 
1 batang 
 
116  Kacang pea (pis) 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
ULAM BERIKUT 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
117  Ulam raja 
 
. 
KALI    PER           H          M         B          T 
 
1 tangkai 
 
118  Petai 
 
. 
KALI    PER           H          M         B          T 
 
10 biji 
 
119  Timun 
 
. 
KALI    PER           H          M         B          T 
 
3 potong/ hiris 
 
BIL 
SEKARANG, FIKIRKAN MENGENAI SEMUA SAYUR YANG DIMASAK, CARA 
MEMASAK DAN KUAHNYA. 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
SAYUR DAN CARA MASAK BERIKUT 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
120  Sayur goreng/ tumis air (stir-fry) 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
121  Sup/ Tom yam sayur 
 
Sayur dalam sup 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
Kuah sup/ tom yam 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
122  Sayur masak lemak 
 
Sayur dalam masak lemak 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
Kuah masak lemak 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
 
123  Sayur celur/ rebus 
 
. 
KALI    PER           H          M         B          T 
 
1 sudu makan 
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BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
BUAH-BUAHAN BERIKUT  
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
124  Belimbing 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
125  Betik 
 
. 
KALI    PER           H          M         B          T 
 
1 potong 
 
126  Kiwi 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
127  Lai/ pear 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
128  Pic 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
129  Epal (hijau dan merah) 
 
. 
KALI    PER           H          M         B          T 
 
1 biji  
130  Jambu batu 
 
. 
KALI    PER           H          M         B          T 
 
½ biji  
131  Oren 
 
. 
KALI    PER           H          M         B          T 
 
1 biji  
132  Limau manis/ mandrin 
 
. 
KALI    PER           H          M         B          T 
 
1 biji  
133  Mangga 
 
. 
KALI    PER           H          M         B          T 
 
1 biji  
134  Tembikai 
 
. 
KALI    PER           H          M         B          T 
 
1 potong  
135  Anggur 
 
. 
KALI    PER           H          M         B          T 
 
10 biji  
136  Laici 
 
. 
KALI    PER           H          M         B          T 
 
3 biji  
137  Nenas 
 
. 
KALI    PER           H          M         B          T 
 
1 potong  
138  Pisang 
 
. 
KALI    PER           H          M         B          T 
 
1 biji  
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139  Rambutan 
 
. 
KALI    PER           H          M         B          T 
 
5 biji  
140  Langsat 
 
. 
KALI    PER           H          M         B          T 
 
10 biji  
141  Mata kucing 
 
. 
KALI    PER           H          M         B          T 
 
10 biji  
142  Nangka 
 
. 
KALI    PER           H          M         B          T 
 
3 ulas  
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
BUAH-BUAHAN KERING BERIKUT  
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
143  Kismis (raisin/ sultana) 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
144  Tamar (buah kurma/ dates) 
 
. 
KALI    PER           H          M         B          T 
 
1 potong 
 
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
KEKACANG BERIKUT SETELAH DIMASAK 
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
145  Kacang dhal 
 
. 
KALI    PER           H          M         B          T 
 
¼ cawan 
 
146  Kacang hijau 
 
. 
KALI    PER           H          M         B          T 
 
¼ cawan 
 
147  Kacang kuda 
 
. 
KALI    PER           H          M         B          T 
 
¼ cawan 
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BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
KACANG BERIKUT  
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
148  Badam 
 
. 
KALI    PER           H          M         B          T 
 
¼ cawan 
 
149  Kacang gajus  
 
. 
KALI    PER           H          M         B          T 
 
¼ cawan 
 
150  Kacang tanah 
 
. 
KALI    PER           H          M         B          T 
 
¼ cawan 
 
151  Kacang pistacio 
 
. 
KALI    PER           H          M         B          T 
 
¼ cawan 
 
152  Walnut 
 
. 
KALI    PER           H          M         B          T 
 
¼ cawan 
 
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
PRODUK SOYA BERIKUT  
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
153  Tauhu 
 
. 
KALI    PER           H          M         B          T 
 
1 keping 
 
154  Tempe 
 
. 
KALI    PER           H          M         B          T 
 
½ cawan (kiub) 
 
155  Tau foo fah 
 
. 
KALI    PER           H          M         B          T 
 
1 mangkuk 
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BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
MAKANAN SIAP BERIKUT  
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
156  Mee/ Bihun/ Kuih-teow sup 
 
. 
KALI    PER           H          M         B          T 
 
1 mangkuk 
 
157  Mee/ Bihun bandung 
 
. 
KALI    PER           H          M         B          T 
 
1 mangkuk 
 
158  Mee kari 
 
. 
KALI    PER           H          M         B          T 
 
1 mangkuk 
 
159  Mee hailam 
 
. 
KALI    PER           H          M         B          T 
 
1 mangkuk 
 
160  Mee wantan 
 
. 
KALI    PER           H          M         B          T 
 
1 mangkuk 
 
161  Laksa 
 
. 
KALI    PER           H          M         B          T 
 
1 mangkuk 
 
162  Mee segera (contoh : Maggi Mee) 
 
. 
KALI    PER           H          M         B          T 
 
1 mangkuk 
 
163  Yong tau fu 
 
. 
KALI    PER           H          M         B          T 
 
1 mangkuk 
 
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
PRODUK TERPROSES/ MAKANAN SEGERA BERIKUT  
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
164  Burger ayam 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
165  Burger daging 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
166  Sosej/ frankfurter 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
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167  Nuggets 
 
. 
KALI    PER           H          M         B          T 
 
1 ketul 
 
168  French fries 
 
. 
KALI    PER           H          M         B          T 
 
1 cawan 
 
169  Mc Donald (burger sahaja) 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
170  Kentucky Fried Chicken (ayam sahaja) 
 
. 
KALI    PER           H          M         B          T 
 
2 ketul 
 
 
 
 
MINUMAN 
 
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
MINUMAN BERIKUT  
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
171  Sirap 
 
. 
KALI    PER           H          M         B          T 
 
1 gelas 
 
172  Sirap bandung 
 
. 
KALI    PER           H          M         B          T 
 
1 gelas 
 
173  Limau ais 
 
. 
KALI    PER           H          M         B          T 
 
1 gelas 
 
174  Teh O limau ais 
 
. 
KALI    PER           H          M         B          T 
 
1 gelas 
 
175  Minuman berkarbonat (contoh : Coke, Pepsi) 
 
. 
KALI    PER           H          M         B          T 
 
1 tin 
 
176  Yogurt penuh krim (biasa) 
 
. 
KALI    PER           H          M         B          T 
 
1 cawan 
 
177  Yogurt rendah lemak 
 
. 
KALI    PER           H          M         B          T 
 
1 cawan 
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MINUM PAGI / PETANG 
 
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
KUIH BERGORENG BERIKUT UNTUK MINUM PAGI/ PETANG  
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
178  Cekodok pisang 
 
. 
KALI    PER           H          M         B          T 
 
5 biji kecil 
 
179  Pisang goreng 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
180  Cucur udang/ tepung 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
181  Karipap 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
182  Popia goreng 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
183  Kuih kacang hijau 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
184  Donat 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
185  Vadai kacang dhal 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
KUIH MANIS BERIKUT UNTUK MINUM PAGI/ PETANG  
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
186  Kuih apam  
 
. 
KALI    PER           H          M         B          T 
 
1 biji besar 
 
187  Kuih seri muka 
 
. 
KALI    PER           H          M         B          T 
 
1 potong 
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188  Kuih apam balik 
 
. 
KALI    PER           H          M         B          T 
 
1 potong tebal 
 
189  Lain-lain kuih manis 
 
. 
KALI    PER           H          M         B          T 
 
1 biji/potong 
 
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
KEK BERIKUT UNTUK MINUM PAGI/ PETANG  
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
190  Kek biasa (Butter cake) 
 
. 
KALI    PER           H          M         B          T 
 
1 potong 
 
191  Kek coklat 
 
. 
KALI    PER           H          M         B          T 
 
1 potong 
 
192  Lain-lain jenis kek 
 
. 
KALI    PER           H          M         B          T 
 
1 potong 
 
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
PRODUK PASTRY/ BAKERI BERIKUT UNTUK MINUM PAGI/ PETANG  
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
193  Muffin 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
194  Croissant 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
195  Bun 
Cheese 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
Coklat 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
 
Kacang merah 
 
. 
KALI    PER           H          M         B          T 
 
1 biji 
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MAKANAN RINGAN / SNEK 
 
BIL 
TANDAKAN (  ) JIKA ANDA BIASA MENGAMBIL 
MAKANAN RINGAN/ SNEK BERIKUT  
 
NYATAKAN KEKERAPAN PENGAMBILAN DENGAN 
MENGISIKAN BILANGAN KEKERAPAN PADA KOTAK 
DAN BULATKAN KOD KEKERAPAN  
(H = HARI ; M = MINGGU ; B = BULAN ; T = TAHUN)  
YANG SESUAI 
 
 
BERAPAKAH 
JUMLAH SAIZ 
HIDANGAN 
YANG SELALU 
ANDA MAKAN 
(ISIKAN 
BILANGAN) 
 
SAIZ HIDANGAN 
PIAWAI 
KOSONGKAN 
(UNTUK 
KEGUNAAN 
PENYELIDIK) 
196  Coklat bersusu/ berkismis/ berkacang 
 
. 
KALI    PER           H          M         B          T 
 
1 bar kecil 
 
197  Ais krim pelbagai perisa 
 
. 
KALI    PER           H          M         B          T 
 
1 scoop 
 
198  Biskut cream crackers/ wholemeal 
 
. 
KALI    PER           H          M         B          T 
 
1 keping 
 
199  Biskut coklat/ berkrim manis 
 
. 
KALI    PER           H          M         B          T 
 
1 keping 
 
200  Pelbagai jenis gula-gula 
 
. 
KALI    PER           H          M         B          T 
 
5 biji 
 
 
 
 
 
SEKIAN, TERIMA KASIH DI ATAS KERJASAMA ANDA 
GPAQ Analysis Guide 4
2 The questionnaire 
 
Physical Activity 
Next I am going to ask you about the time you spend doing different types of physical activity in a typical week. Please answer these questions 
even if you do not consider yourself to be a physically active person.  
Think first about the time you spend doing work.  Think of work as the things that you have to do such as paid or unpaid work, study/training, 
household chores, harvesting food/crops, fishing or hunting for food, seeking employment. [Insert other examples if needed].  In answering the 
following questions 'vigorous-intensity activities' are activities that require hard physical effort and cause large increases in breathing or heart 
rate, 'moderate-intensity activities' are activities that require moderate physical effort and cause small increases in breathing or heart rate. 
Question Response Code 
Work 
Does your work involve vigorous-intensity activity that causes 
large increases in breathing or heart rate like [carrying or lifting 
heavy loads, digging or construction work]  for at least 10 
minutes continuously?  
[INSERT EXAMPLES]  (USE SHOWCARD) 
Yes 1 
P1 
No 2     If No, go to P 4 
In a typical week, on how many days do you do vigorous-
intensity activities as part of your work? Number of days └─┘ 
P2 
How much time do you spend doing vigorous-intensity activities 
at work on a typical day? Hours : minutes └─┴─┘: └─┴─┘ 
    hrs                mins 
P3 
(a-b) 
Does your work involve moderate-intensity activity, that causes 
small increases in breathing or heart rate such as brisk walking 
[or carrying light loads]  for at least 10 minutes continuously?   
 [INSERT EXAMPLES]   (USE SHOWCARD) 
Yes 1 
P4 
No 2      If No, go to P 7 
In a typical week, on how many days do you do moderate-
intensity activities as part of your work?  
Number of days 
└─┘ 
P5 
How much time do you spend doing moderate-intensity activities 
at work on a typical day? Hours : minutes 
└─┴─┘: └─┴─┘ 
    hrs                mins 
P6 
(a-b) 
Travel to and from places 
The next questions exclude the physical activities at work that you have already mentioned. 
Now I would like to ask you about the usual way you travel to and from places.  For example to work, for shopping, to market, to place of 
worship. [Insert other examples if needed] 
Do you walk or use a bicycle (pedal cycle) for at least 10 
minutes continuously to get to and from places? 
Yes 1 
P7 
No 2      If No, go to P 10 
In a typical week, on how many days do you walk or bicycle for 
at least 10 minutes continuously to get to and from places? Number of days 
└─┘ 
P8 
How much time do you spend walking or bicycling for travel on a 
typical day?  Hours : minutes └─┴─┘: └─┴─┘ 
     hrs               mins 
P9 
(a-b) 
 
 
Continued on next page 
GPAQ Analysis Guide 5
2 The questionnaire, Continued 
 
Physical Activity, Continued 
Question Response Code 
Recreational activities 
The next questions exclude the work and transport activities that you have already mentioned. 
Now I would like to ask you about sports, fitness and recreational activities (leisure), [Insert relevant terms]. 
Do you do any vigorous-intensity sports, fitness or recreational 
(leisure) activities that cause large increases in breathing or 
heart rate like [running or football]  for at least 10 minutes 
continuously?  
[INSERT EXAMPLES]   (USE SHOWCARD) 
Yes   1 
P10 
No 2      If No, go  to P 13 
In a typical week, on how many days do you do vigorous-
intensity sports, fitness or recreational (leisure) activities? Number of days 
└─┘ 
P11 
How much time do you spend doing  vigorous-intensity sports, 
fitness or recreational activities on a typical day? Hours : minutes 
└─┴─┘: └─┴─┘ 
    hrs                mins 
P12 
(a-b) 
Do you do any moderate-intensity sports, fitness or recreational 
(leisure) activities that cause a small increase in breathing or 
heart rate such as brisk walking, [cycling, swimming, volleyball] 
for at least 10 minutes continuously? 
 [INSERT EXAMPLES]   (USE SHOWCARD) 
Yes   1 
P13 
No 2      If No, go to P16 
In a typical week, on how many days do you do moderate-
intensity sports, fitness or recreational (leisure) activities?  Number of days  
└─┘ 
P14 
How much time do you spend doing moderate-intensity sports, 
fitness or recreational (leisure) activities on a typical day? Hours : minutes 
└─┴─┘: └─┴─┘ 
    hrs                mins 
P15 
(a-b) 
Sedentary behaviour 
The following question is about sitting or reclining at work, at home, getting to and from places, or with friends including time spent sitting at a 
desk, sitting with friends, traveling in car, bus, train, reading, playing cards or watching television, but do not include time spent sleeping. 
[INSERT EXAMPLES]   (USE SHOWCARD) 
How much time do you usually spend sitting or reclining on a 
typical day? Hours : minutes └─┴─┘: └─┴─┘ 
    hrs                mins 
P16  
(a-b) 
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Abstract Non-alcoholic fatty liver disease (NAFLD) is
rapidly increasing in the Asia-Pacific and affects up to
30 % of the general population. In younger children,
prevalence has been reported to be between 2.1 and 4.5 %.
The prevalence of NAFLD increases with increasing age.
NAFLD is more prevalent in men than women, but this
trend fades in older age group. NAFLD is one of the most
common causes of raised serum ALT levels and the latter is
closely related to the presence of features of metabolic
syndrome. NAFLD may contribute to metabolic syndrome
in a similar way as visceral adiposity and can be an early
predictor of metabolic disorders. NAFLD increases the risk
of developing diabetes mellitus and is closely related to
degree of glucose intolerance. A significant proportion of
patients with NAFLD have impaired glucose tolerance or
diabetes mellitus but with normal fasting blood glucose,
highlighting the importance of oral glucose tolerance test
in NAFLD patients with normal fasting blood glucose.
Besides liver-related complications, NAFLD has been
associated with cardiovascular complications, hyperurice-
mia, gout, chronic kidney disease, gallstone disease,
colorectal adenomatous polyp, and polycystic ovarian
syndrome. NAFLD seems to be related to host metabolic
factors rather than viral factors and does not seem to affect
severity of the liver disease in patients with chronic hep-
atitis B. On the other hand, hepatic steatosis may be related
to both host metabolic and viral factors in patients with
chronic hepatitis C and seems to adversely impact on the
severity of liver disease and possibly response to antiviral
therapy.
Keywords Asia-Pacific  Epidemiology  NAFLD
Introduction
Non-alcoholic fatty liver disease (NAFLD) encompasses a
spectrum of liver conditions that occur in individuals who
do not consume alcohol or who consume alcohol but in
amounts regarded as insufficient to cause liver damage. At
one end of this spectrum is steatosis or accumulation of fat
in the liver. This is followed by steatohepatitis, the more
severe form of the disease which may in time result in
fibrosis and eventually cirrhosis. Individuals with cirrhosis
due to NAFLD are at risk of developing hepatocellular
carcinoma. The purpose of this paper is to review the lit-
erature and provide a current overview of the epidemiology
of NAFLD in the Asia-Pacific region.
Methods
The authors searched via PubMed using MeSH terms
‘‘non-alcoholic fatty liver disease’’ or ‘‘fatty liver’’ and
‘‘epidemiology’’ or ‘‘prevalence’’ in November 2011. The
search yielded 495 articles. Out of these, 139 articles were
from the Asia-Pacific region. The abstracts of the articles
were examined and where doubt existed as to the relevance
of an article to the review, the full paper was examined. In
total, 63 articles were deemed relevant and were included
in the review.
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Abstract
Background and Aim: There is currently no published study comparing prevalence of
non-alcoholic fatty liver disease (NAFLD) and associated factors among diabetics of
different ethnicity in the Asia-Pacific region.
Methods: Cross-sectional study of consecutive patients in the Diabetic Clinic in Univer-
sity of Malaya Medical Centre. The Global Physical Activity Questionnaire and a semi-
quantitative food-frequency questionnaire were used to assess physical activity and dietary
intake, respectively. Diagnosis of NAFLD was ultrasound-based and following exclusion
of significant alcohol intake.
Results: Data for 399 patients were analyzed (mean age 62.3  10.5 years, 43.1% men).
The racial distribution was Chinese 43.6%, Indian 33.1%, Malay 22.3%, and others 1.0%.
The prevalence of NAFLD was 49.6%. On univariate analysis, factors associated with
NAFLD were age < 65 years, race, obesity, central obesity, glycated hemoglobin  7.0%,
and elevated serum alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase
levels. Patients with low physical activity were more likely to have NAFLD (odds ratio
[OR] = 1.67, 95% confidence interval [CI] = 1.06–2.63, P = 0.020). The prevalence of
NAFLD was highest among Malays (60.7%), followed by Indians (51.5%), and lowest
among Chinese (42.0%) consistent with higher prevalence of central obesity and higher
percentage calorie intake from fat in the former groups of patients. On multivariate
analysis, independent factors associated with NAFLD were central obesity (OR = 2.20,
95% CI = 1.29–3.75, P = 0.004) and elevated serum ALT level (OR = 1.98, 95%
CI = 1.21–3.25, P = 0.007).
Conclusions: NAFLD was seen in half of a cohort of diabetic patients and was indepen-
dently associated with central obesity and elevated serum ALT level. Prevalence of
NAFLD was different and paralleled the difference in prevalence of central obesity and in
percentage calorie intake from fat among the different ethnic groups.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is rapidly increasing in
the Asia-Pacific region and is estimated to affect up to 30% of the
general population.1 In the only published study on prevalence of
NAFLD in the general population from Malaysia, Goh et al.
reported a prevalence of 22.7% among individuals attending a
health check in a suburban medical facility.2 The study also
reported an inordinately high prevalence of NAFLD among the
Malays and Indians compared with the Chinese.
NAFLD is closely associated with diabetes mellitus (DM) and
obesity. The prevalence of NAFLD is higher in patients with DM
and has been estimated to be between 55% and 70% in previous
studies from other parts of the world.3–5 The prevalence of NAFLD
is even higher among the morbidly obese and has been reported to
be over 90%.6
In Malaysia, the prevalence of DM and obesity has reached
epidemic proportions over the years. The Third National Health
and Morbidity Survey (NHMS III) estimated the prevalence of
DM among adults aged 30 years old and above to have almost
doubled from 8.3% in 1996 to 14.9% in 2006.7 Yet to be published,
the Fourth NHMS found that this figure has increased to 20% in
2011. The NHMS III also reported that 43.1% of adult Malaysians
were overweight or obese in 2006, almost double that reported 10
doi:10.1111/jgh.12204
bs_bs_banner
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Abstract
Purpose Previous studies on multiracial Malaysian pop-
ulations found inordinately high prevalence of NAFLD
among Malays and Indians. Whether the prevalence of
NAFLD is different among young adults of different ethnic
origins is not known. We aimed to determine racial dif-
ferences in NAFLD in a young multiracial Malaysian
population and associated factors.
Methods This was a cross-sectional study on medical
students from the University of Malaya. Diagnosis of
NAFLD was by transabdominal ultrasonography and fol-
lowing exclusion of significant alcohol intake and other
causes of chronic liver disease.
Results Data of 469 subjects were analyzed (mean age
23.2 ± 2.4 years, 40.3 % male). The racial distribution
was: Chinese 53.9 %, Malay 30.5 % and Indian 15.6 %.
The overall prevalence of NAFLD was 7.9 %. Subjects
with NAFLD were older, had greater BMI and WC, higher
SBP and DBP, higher FBS, serum TG and LDL levels, and
lower serum HDL level. The prevalence of NAFLD was
higher among males compared to females (17.9 % vs.
3.3 %, p \ 0.001). The highest prevalence of NAFLD was
seen among Indian and Malay males at 33.3 and 25.5 %,
respectively, compared to Chinese males at 6.8 %
(p \ 0.001). No significant difference was seen among
females of different races. Independent factors associated
with NAFLD were male gender, obesity and hypertriglyc-
eridemia.
Conclusions The difference in prevalence of NAFLD
among the different ethnic groups can be observed as early
as young adulthood. An inordinately high prevalence of
NAFLD was observed among Malay and Indian males
consistent with the higher prevalence of obesity in these
groups.
Keywords Non-alcoholic fatty liver disease 
Epidemiology  Young adults  Ethnicity  Asian
Introduction
Non-alcoholic fatty liver disease (NAFLD) is rapidly
increasing in the Asia-Pacific region and has been esti-
mated to affect up to 30 % of the general population [1]. In
a study on a suburban population in Malaysia, the preva-
lence of NAFLD was found to be 22.7 % [2]. The preva-
lence of NAFLD among diabetics has been estimated to be
49.6 % based on a separate study on a hospital clinic
population [3]. Both studies found an inordinately high
prevalence of NAFLD among the Malays and Indians
compared to the Chinese. In a study on the etiology of liver
cirrhosis in Malaysia, a cryptogenic cause, believed to be
due to NAFLD, was identified as the cause of liver cir-
rhosis in a significantly larger proportion of Malay and
Indian patients compared to Chinese patients [4]. Besides
being one of the most common causes of chronic liver
disease, NAFLD has been closely associated with risk
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Abstract
Background and Aim: Controlled attenuation parameter (CAP) has been suggested as a
noninvasive method for detection and quantification of hepatic steatosis. We aim to study
the diagnostic performance of CAP in nonalcoholic fatty liver disease (NAFLD) patients.
Methods: Transient elastography was performed in consecutive NAFLD patients under-
going liver biopsy and non-NAFLD controls. The accuracy of CAP for the detection and
quantification of hepatic steatosis was assessed based on histological findings according to
the Nonalcoholic Steatohepatitis Clinical Research Network Scoring System.
Results: Data for 101 NAFLD patients (mean age 50.3 ± 11.3 years old, 51.5% male) and
60 non-NAFLD controls were analyzed. CAP was associated with steatosis grade (odds
ratio [OR] = 29.16, P < 0.001), body mass index (BMI; OR = 4.34, P < 0.001) and serum
triglyceride (OR = 13.59, P = 0.037) on multivariate analysis. The median CAP for ste-
atosis grades S0, S1, S2, and S3 were 184 dB/m, 305 dB/m, 320 dB/m, and 324 dB/m,
respectively. The areas under receiver operating characteristics curves (AUROC) for esti-
mation of steatosis grades ≥ S1, S2, and S3 were 0.97, 0.86, and 0.75, respectively. The
optimal CAP cutoffs for estimation of steatosis grades ≥ S1, S2, and S3 were 263 dB/m,
281 dB/m, and 283 dB/m, respectively. Among non-obese patients, the AUROC for esti-
mation of steatosis grades ≥ S1 and S2 were 0.99 and 0.99, respectively. Among obese
patients, the AUROC for estimation of steatosis grades ≥ S1, S2, and S3 were 0.92, 0.64,
and 0.58, respectively.
Conclusions: CAP is excellent for the detection of significant hepatic steatosis. However,
its accuracy is impaired by an increased BMI, and it is less accurate to distinguish between
the different grades of hepatic steatosis.
Introduction
Nonalcoholic fatty liver disease (NAFLD) encompasses a spec-
trum of liver conditions, ranging from benign steatosis to nonal-
coholic steatohepatitis (NASH) to fibrosis and cirrhosis.1 NASH
has been recognized as an important cause of cryptogenic cirrho-
sis2 and is associated with an increased risk of hepatocellular
carcinoma, even in patients without cirrhosis.3 In a study on etiol-
ogy of cirrhosis and association with hepatocellular carcinoma in
our center, cryptogenic cause, which is believed to be due to
NASH, contributed to 15.4% of cases of cirrhosis and was an
independent predictor of hepatocellular carcinoma.4 The preva-
lence of NAFLD has increased rapidly over the years parallel to
the increase in metabolic syndrome, and it is recognized as one of
the most common causes of chronic liver disease worldwide.5
Ultrasonography is by far the most common method used to
diagnose fatty liver in clinical practice and in epidemiological
studies. However, ultrasonography is accurate only when fatty
liver is moderate to severe.6 Moreover, ultrasonography is not able
to distinguish NASH from simple steatosis and to assess the sever-
ity of fibrosis. Both factors carry important prognostic implica-
tions in NAFLD patients. Histopathological examination of a liver
biopsy specimen is the current best standard for assessment of
NAFLD. It confirms the diagnosis and helps exclude other causes
of liver disease in some cases. It also distinguishes NASH from
simple steatosis and allows assessment of the severity of fibrosis.
However, liver biopsy is invasive and associated with a small risk
of complications. It may also be limited by sampling variability7
and intra- and interobserver variability.8
Recently, a novel technology called transient elastography has
been used to estimate liver stiffness, which has shown to correlate
well with histopathological fibrosis stage. This has allowed non-
invasive and accurate estimation of fibrosis stage in NAFLD
patients.9 The decrease in amplitude of ultrasound as it is
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Summary
Background:  Non-alcoholic  fatty  liver  disease  (NAFLD)  and  cardiovascular  diseases  are  both
common among  patients  with  diabetes  mellitus.
Objective:  The  aim  of  this  study  is  to  determine  if  ultrasonography-diagnosed  NAFLD  is  associ-
ated with  prevalent  ischemic  heart  disease  (IHD)  among  patients  with  diabetes  mellitus.
Methods: This  is  a  cross-sectional  study  on  consecutive  patients  seen  at  the  Diabetic  Clinic,
University  of  Malaya  Medical  Centre.  The  medical  record  for  each  patient  was  reviewed  for  doc-
umented IHD.  Patients  without  documented  IHD  but  had  symptoms  and/or  electrocardiographic
changes  suggestive  of  IHD  were  referred  for  cardiac  evaluation.
Results:  Data  for  399  patients  were  analyzed.  Mean  age  was  62.8  ±  10.5  years  with  43.1%  male.
NAFLD and  IHD  were  present  in  49.6  and  26.6%,  respectively.  The  prevalence  of  IHD  among
patients with  and  without  NAFLD  was  24.7  and  28.4%,  respectively  (P  =  0.414).  The  prevalence
 This study was funded in full by University of Malaya Research Grant (UMRG), Project No.: RG375-11HTM.
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Progression of liver disease in non-alcoholic fatty liver
disease: A prospective clinicopathological follow-up study
Wah-Kheong CHAN,* Normiha Hilmi IDA,* Phaik-Leng CHEAH† & Khean-Lee GOH*
*Gastroenterology and Hepatology Unit, Gastrointestinal Endoscopy Unit, Department of Medicine, and
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OBJECTIVE: To perform a follow-up study on non-
alcoholic fatty liver disease (NAFLD) patients in our
previous study using paired liver biopsy.
METHODS: Patients who were included in our pre-
vious study on NAFLD and agreed to receive a repeat
liver biopsy were included in the study. Their clinical
characteristics, laboratory examination results and his-
tological analysis on the repeat liver biopsied speci-
mens were prospectively collected and compared with
those in the previous study.
RESULTS: Data from 35 patients (mean age
47.5 ± 10.9 years, male 40.0%) were analyzed. The
mean interval between the liver biopsies was 6.4 ± 0.8
years. NAFLD activity score (NAS) worsened in 13,
remained unchanged in 9 and ameliorated in 13.
Fibrosis worsened in 18 and remained unchanged in
17. Two patients who were confirmed with cirrhosis
at baseline developed decompensated cirrhosis. On
multivariate analysis, elevated serum aspartate
aminotransferase (AST) (odds ratio [OR] 10.74, 95%
confidence interval [CI] 1.00–115.86, P = 0.050) and
γ-glutamyl transpeptidase (γ-GT) (OR 16.10, 95% CI
1.30–198.90, P = 0.030) at follow-up were associated
with worsened NAS. Patients with borderline NASH at
baseline were more likely to have worsened NAS at
follow-up than those with definite NASH (OR 12.67,
95% CI 2.29–70.02, P = 0.004). However, both
groups had a similar likelihood of having worsened
fibrosis at follow-up. No plausible factors were found
to be associated with worsened fibrosis.
CONCLUSIONS: NAFLD patients with persistently
elevated serum AST and γ-GT levels during follow-up
should be suspected of having worsened NAS. NASH
patients can have significant disease progression over a
relatively short period of time and fibrosis might be
irreversible without specific interventions.
KEY WORDS: disease progression, histology, NAFLD, NASH, non-alcoholic fatty liver disease, non-alcoholic
steatohepatitis.
INTRODUCTION
The prevalence of non-alcoholic fatty liver disease
(NAFLD) has rapidly increased over the decades and
the disease is estimated to affect up to 30% of the
general population in the Asia–Pacific region.1 In
Malaysia Goh et al.2 reported a prevalence of NAFLD
of 22.7% based on a group of suburban individuals
who attended health check. We found that the
prevalence of NAFLD (49.6%) among patients with
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Limited Utility of Plasma M30 in Discriminating
Non-Alcoholic Steatohepatitis from Steatosis – A
Comparison with Routine Biochemical Markers
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Abstract
Introduction: The utility of Cytokeratin-18 fragment, namely CK18Asp396 (M30), for the diagnosis of non-alcoholic
steatohepatitis (NASH) is currently uncertain. We aimed to provide further data in this area among multi-ethnic Asian
subjects with NAFLD.
Materials and Methods: The accuracy of M30 for detecting NASH was compared with serum alanine aminotransferase
(ALT), aspartate aminotransferase (AST) and gamma glutamyl transpeptidase (GGT) levels in consecutive adult subjects with
biopsy-proven non-alcoholic fatty liver disease (NAFLD).
Results: Data for 93 NAFLD subjects (mean age 51.0611.1 years old and 51.6% males) and 20 healthy controls (mean age
50.2616.4 years old and 33.3% males) were analyzed. There were 39 NASH subjects (41.9%) and 54 non-NASH subjects
(58.1%) among the NAFLD subjects. Plasma M30 (349 U/L vs. 162 U/L), and serum ALT (70 IU/L vs. 26 IU/L), AST (41 IU/L vs.
20 IU/L) and GGT (75 IU/L vs. 33 IU/L) were significantly higher in NAFLD subjects than in healthy controls. Serum ALT
(86 IU/L vs. 61 IU/L), AST (58 IU/L vs. 34 IU/L) and GGT (97 IU/L vs. 56 IU/L) were significantly higher in NASH subjects
compared to non-NASH subjects, but no significant difference was observed with plasma M30 (435 U/L vs. 331 U/L). The
accuracy of plasma M30, and serum ALT, AST and GGT was good for predicting NAFLD (AUROC 0.91, 0.95, 0.87 and 0.85,
respectively) but less so for NASH (AUROC 0.59, 0.64, 0.75 and 0.68, respectively). Serum ALT and AST, but not plasma M30
showed a significant trend with increasing grades of ballooning and lobular inflammation.
Conclusion: The utility of M30 in the detection of NASH in clinical practice appears limited, in comparison to routine
biochemical markers.
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Introduction
The prevalence of non-alcoholic fatty liver disease (NAFLD) has
increased rapidly over the years, parallel to the increase in
metabolic syndrome, and it is recognized as one of the most
common causes of chronic liver disease worldwide [1]. NAFLD
encompasses a spectrum of liver conditions, ranging from simple
steatosis to non-alcoholic steatohepatitis (NASH) to fibrosis and
cirrhosis. While simple steatosis is generally considered benign,
NASH may lead to fibrosis and eventually cirrhosis, with an
increased risk of morbidity and mortality [2,3].
The diagnosis of NASH is made by histopathological exami-
nation of a liver biopsy specimen. However, liver biopsy is invasive
and it is associated with a small risk of serious complications [4]. It
is not practical to subject all subjects with NAFLD to a liver biopsy
to diagnose NASH. Furthermore, repeated liver biopsies to
monitor disease progression in clinical practice is not acceptable
either. A simple and reliable non-invasive test is needed for the
diagnosis and follow-up of NASH.
Cytokeratin 18 (CK-18) is the major intermediate filament
protein in liver cells and it is cleaved by caspases that are activated
during apoptosis of liver cells, a process which plays an important
role in NASH [5]. CK-18 fragment, namely CK18Asp396 (M30),
has been studied for the diagnosis of NASH with varying results
[6–13]. Whilst some studies have suggested that specific cut-off
levels of CK-18 can reliably detect NASH in a cohort of NAFLD
subjects [6–10], others have not shown such promising results [11–
13]. These contrasting data may have been due to studies with a
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Abstract
Background The non-alcoholic fatty liver disease (NA-
FLD) fibrosis score (NFS) is indeterminate in a proportion
of NAFLD patients. Combining the NFS with liver stiff-
ness measurement (LSM) may improve prediction of
advanced fibrosis. We aim to evaluate the NFS and LSM in
predicting advanced fibrosis in NAFLD patients.
Methods The NFS was calculated and LSM obtained for
consecutive adult NAFLD patients scheduled for liver
biopsy. The accuracy of predicting advanced fibrosis using
either modality and in combination were assessed. An
algorithm combining the NFS and LSM was developed
from a training cohort and subsequently tested in a vali-
dation cohort.
Results There were 101 and 46 patients in the training
and validation cohort, respectively. In the training cohort,
the percentages of misclassifications using the NFS alone,
LSM alone, LSM alone (with grey zone), both tests for all
patients and a 2-step approach using LSM only for patients
with indeterminate and high NFS were 5.0, 28.7, 2.0, 2.0
and 4.0 %, respectively. The percentages of patients
requiring liver biopsy were 30.7, 0, 36.6, 36.6 and 18.8 %,
respectively. In the validation cohort, the percentages of
misclassifications were 8.7, 28.3, 2.2, 2.2 and 8.7 %,
respectively. The percentages of patients requiring liver
biopsy were 28.3, 0, 41.3, 43.5 and 19.6 %, respectively.
Conclusions The novel 2-step approach further reduced
the number of patients requiring a liver biopsy whilst
maintaining the accuracy to predict advanced fibrosis. The
combination of NFS and LSM for all patients provided no
apparent advantage over using either of the tests alone.
Keywords Non-alcoholic fatty liver disease (NAFLD) 
Liver fibrosis  Non-invasive test  NAFLD fibrosis score 
Liver stiffness measurement  Fibroscan
Introduction
Non-alcoholic fatty liver disease (NAFLD) encompasses a
spectrum of liver conditions, ranging from benign steatosis
to non-alcoholic steatohepatitis (NASH) to fibrosis and
cirrhosis [1]. The degree of liver fibrosis provides infor-
mation on prognosis and helps identify patients for inter-
vention. For example, NASH patients with advanced
fibrosis have a much higher liver-related mortality com-
pared to those without advanced fibrosis [2]. On the other
hand, the US multi-society practice guideline on diagnosis
and management of NAFLD recommends that patients
with NASH-related cirrhosis be screened for gastro-
esophageal varices and hepatocellular carcinoma [3].
Histopathological examination of a liver biopsy speci-
men is the best standard for assessment of liver fibrosis.
However, liver biopsy is invasive and associated with a
small risk of complications [4]. Technical expertise is also
required, from obtaining a good specimen to processing
and accurately interpreting the result. It is not practical to
subject all NAFLD patients to a liver biopsy to assess liver
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